

CITATION REPORT

List of articles citing

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

DOI: 10.1161/01.cir.0000437738.63853.7a
Circulation, 2014, 129, S1-45.

Source: <https://exaly.com/paper-pdf/59535271/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2352	Cerebral Amyloid Angiopathy. 534-544		3
2351	Pathophysiology and management of hypertension in acute ischemic stroke. 1994 , 23, 131-6		64
2350	Regulation of poly(ADP-ribose) metabolism by poly(ADP-ribose) glycohydrolase: where and when?. 2005 , 62, 739-50		105
2349	Can cholesterol be defined as just <u>good</u> or <u>bad</u> ? 2014 , 9, 515-516		
2348	Holistic approach to prevention and management of type 2 diabetes mellitus in a family setting. 2014 , 7, 159-68		12
2347	Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review. 2014 , 20, 12182-201		40
2346	Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis. 2014 , 9, e111247		32
2345	Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the framingham risk score: the suita study. 2014 , 21, 784-98		110
2344	Dyslipidemia in women: etiology and management. 2014 , 6, 185-94		35
2343	Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach. 2014 , 7, 489-501		16
2342	Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US. 2014 , 10, 237-46		9
2341	Health outcomes in diabetics measured with Minnesota Community Measurement quality metrics. 2015 , 8, 1-8		5
2340	Adding multiple risk factors improves Framingham coronary heart disease risk scores. 2014 , 10, 557-62		3
2339	Optimal management of infrainguinal arterial occlusive disease. 2014 , 10, 599-608		14
2338	Current Treatment of Familial Hypercholesterolaemia. 2014 , 9, 76-81		9
2337	Are the new guidelines for the use of lipid-lowering agents sound, and should their adoption be encouraged?. 2014 , 67, 246-9		3
2336	Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus. 2014 , 7, 355-64		8

2335	Antioxidant effects of statins in the management of cardiometabolic disorders. 2014 , 21, 997-1010		28
2334	Can I get a guideline to help me interpret treatment guidelines?. 2014 , 67, 181-2		
2333	Prevalence and concordance of high cardiovascular disease scores in HIV/AIDS patients from Croatia and Serbia with four international algorithms. 2014 , 17, 19549		1
2332	Eight challenges faced by general practitioners caring for patients after an acute coronary syndrome. 2014 , 201, S110-4		1
2331	Statins: definitive translational research. 2014 , 20 Suppl 1, S20-3		5
2330	International Congress of Drug Therapy in HIV Infection 2-6 November 2014, Glasgow, UK. 2014 , 17, 19856		
2329	Carotid atherosclerotic plaque stenosis: the stabilizing role of statins. 2014 , 44, 1122-34		31
2328	Comparative accuracy of different risk scores in assessing cardiovascular risk in Indians: a study in patients with first myocardial infarction. 2014 , 66, 580-6		34
2327	Prevention of cardiovascular disease: new guidelines, new tools, but challenges remain. 2014 , 100, 675-7		4
2326	Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. <i>Circulation</i> , 2014 , 129, 1048-78	16.7	272
2325	Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis. 2014 , 7, 276-84		75
2324	Statinopause. 2014 , 29, 1702-6		5
2323	Practical Implementation of the 2013 AHA/ACC Blood Cholesterol Guidelines. 2014 , 16, 347		
2322	Reprint: 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk. <i>Circulation</i> , 2013 , e2	16.7	829
2321	Chinese herbal medicine on dyslipidemia: progress and perspective. 2014 , 2014, 163036		25
2320	Risk prediction with triglycerides in patients with stable coronary disease on statin treatment. 2014 , 103, 984-97		9
2319	Validation of the pooled cohort risk score in an Asian population - a retrospective cohort study. 2014 , 14, 163		45
2318	Sekundärprävention nach Schlaganfall [mehr als nur Pillen schlucken. 2014 , 15, 13-13		1

2317	Perspektiven zu cholesterinwirksamer Behandlung 2014. 2014 , 14, 50-60	1
2316	Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study. 2014 , 37, 2622-31	76
2315	Preemptive Cardioprotective Strategies in Patients Receiving Chemotherapy. 2014 , 8, 1	4
2314	Does use of pooled cohort risk score overestimate the use of statin?: a retrospective cohort study in a primary care setting. 2014 , 15, 172	6
2313	Laboratory monitoring for pharmaceuticals: familiarity does not breed contempt. 2014 , 29, 1574-6	0
2312	Managing the information boundary of an organization: key aspect of translating research into practice. 2014 , 7, 805-6	
2311	Variations in statin prescribing for primary cardiovascular disease prevention: cross-sectional analysis. 2014 , 14, 414	21
2310	A dysglycaemic effect of statins in diabetes: relevance to clinical practice?. 2014 , 57, 2433-5	16
2309	Consensus statement on management of dyslipidemia in Indian subjects. 2014 , 66 Suppl 3, S1-51	35
2308	Dyslipidemias and chronic kidney disease: a focus on pathogenesis and treatment. 2014 , 9, 673-681	3
2307	Identifying pseudohypertriglyceridemia in clinical practice. 2014 , 9, 625-641	8
2306	Statins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins. 2014 , 15, 250-8	30
2305	Fibrates and niacin: is there a place for them in clinical practice?. 2014 , 15, 2673-80	8
2304	Krill oil for cardiovascular risk prevention: is it for real?. 2014 , 49, 907-12	11
2303	Endovascular versus medical therapy for atherosclerotic renovascular disease. 2014 , 16, 459	6
2302	Cholesterol-lowering statin therapy to prevent atherosclerotic cardiovascular disease - is the new guideline based on best evidence?. 2014 , 69, 317-8	
2301	The use of expensive technologies instead of simple, sound and effective lifestyle interventions: a perpetual delusion. 2014 , 68, 897-904	12
2300	Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial. 2014 , 2014, 459165	46

2299	What is it about very low density lipoproteins (VLDL) and cardiovascular disease in patients with type 2 diabetes mellitus: is it the triglycerides or the cholesterol?. 2014 , 237, 138-9		4
2298	New cholesterol guidelines and the secondary prevention of cardiovascular disease - a commentary on epistemic aspects. 2014 , 69, 314-6		4
2297	Sex differences in lifetime risk and first manifestation of cardiovascular disease: prospective population based cohort study. 2014 , 349, g5992		142
2296	Medical decision making and the counting of uncertainty. <i>Circulation</i> , 2014 , 129, 2500-2	16.7	4
2295	Moneyball, gambling, and the new cholesterol guidelines. 2014 , 7, 311-4		7
2294	Fixed-dose statins with no lipid targets: a new paradigm of dosing?. 2014 , 44, 64-65		
2293	Phenotype standardization for statin-induced myotoxicity. 2014 , 96, 470-6		130
2292	Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study. 2014 , 30, 1957-65		4
2291	Reaching low density lipoprotein cholesterol targets. 2014 , 30, 1967-9		10
2290	Real-life evaluation of European and American high-risk strategies for primary prevention of cardiovascular disease in patients with first myocardial infarction. 2014 , 4, e005991		20
2289	Are we moving towards concordance on the principle that lipid discordance matters?. <i>Circulation</i> , 2014 , 129, 539-41	16.7	18
2288	Statin use and pain in older people with cancer: a cross-sectional study. 2014 , 62, 1900-5		13
2287	High-dose simvastatin exhibits enhanced lipid-lowering effects relative to simvastatin/ezetimibe combination therapy. 2014 , 7, 955-964		8
2286	Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review. 2014 , 55, 2007-21		62
2285	New therapies for reducing low-density lipoprotein cholesterol. 2014 , 43, 1007-33		31
2284	Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. 2014 , 12, 1137-44		11
2283	Cholesterol treatment patterns and cardiovascular clinical outcomes associated with colesevelam HCl and ezetimibe. 2014 , 31, 683-94		3
2282	Reducing the burden of disease and death from familial hypercholesterolemia: a call to action. 2014 , 168, 807-11		34

2281	KHA-CARI commentary on the KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. 2014 , 19, 663-6		7
2280	Prevention of cardiovascular disease: highlights for the clinician of the 2013 American College of Cardiology/American Heart Association guidelines. 2014 , 37, 239-51		34
2279	Cholesterol end points predict outcome in patients with coronary disease: quality improvement metrics from the enhancing secondary prevention in coronary artery disease (ESP-CAD) trial. 2014 , 30, 1627-32		1
2278	The doctor's dilemma: challenges in the diagnosis and care of homozygous familial hypercholesterolemia. 2014 , 8, 542-549		14
2277	Cholesterol management in older persons. 2014 , 127, 1140-1		6
2276	The effect of simvastatin and pravastatin on arterial blood pressure, baroreflex, vasoconstrictor, and hypertensive effects of angiotensin II in Sprague-Dawley rats. 2014 , 8, 863-71		6
2275	Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study. 2014 , 8, 568-575		39
2274	Racial and ethnic disparities among enrollees in Medicare Advantage plans. 2014 , 371, 2288-97		82
2273	Letters to the Editor. 2014 , 44, 60-66		
2272	2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , 2014 , 130, e344-426	16.7	754
2271	Reducing the risk of heart attack and stroke: the American Heart Association/American College of Cardiology prevention guidelines. <i>Circulation</i> , 2014 , 130, e48-50	16.7	
2270	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. 2014 , 168, 682-9		303
2269	Glycated hemoglobin measurement and prediction of cardiovascular disease. 2014 , 311, 1225-33		136
2268	2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , 2014 , 130, e278-333	16.7	272
2267	The clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term management. 2014 , 11, 395-409		11
2266	The macrophage LBP gene is an LXR target that promotes macrophage survival and atherosclerosis. 2014 , 55, 1120-30		20
2265	Targeting low-density lipoprotein and dysmetabolism in type 2 diabetes mellitus. 2014 , 34, 477-8		4
2264	[Comments on the 2013 ESC/EASD guidelines on diabetes, prediabetes and cardiovascular diseases]. 2014 , 39, 971-84		

2263	Comparing a marginal structural model with a Cox proportional hazard model to estimate the effect of time-dependent drug use in observational studies: statin use for primary prevention of cardiovascular disease as an example from the Rotterdam Study. 2014 , 29, 841-50		8
2262	Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. 2014 , 14, 121		40
2261	Synergistic effects of atorvastatin and rosiglitazone on endothelium protection in rats with dyslipidemia. 2014 , 13, 168		6
2260	Diversity of apolipoprotein E genetic polymorphism significance on cardiovascular risk is determined by the presence of metabolic syndrome among hypertensive patients. 2014 , 13, 174		13
2259	Adult moyamoya disease in an urban center in the United States is associated with a high burden of watershed ischemia. 2014 , 3,		5
2258	The role of worksite health screening: a policy statement from the American Heart Association. <i>Circulation</i> , 2014 , 130, 719-34	16.7	22
2257	Efficacy and safety of ezetimibe plus atorvastatin therapy. 2014 , 9, 441-470		5
2256	Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients. 2014 , 28, 2627-2631		19
2255	Evidence of sample use among new users of statins: implications for pharmacoepidemiology. 2014 , 52, 773-80		30
2254	Editorial introduction. 2014 , 25, 159-60		
2253	Guidelines in the USA, a viewpoint contrary to those guidelines in Europe, Canada, Britain and the International Atherosclerosis Society. 2014 , 25, 413-7		2
2252	HIV and metabolic, body, and bone disorders: what we know from low- and middle-income countries. 2014 , 67 Suppl 1, S27-39		42
2251	Effect of peer education on stroke prevention: the prevent recurrence of all inner-city strokes through education randomized controlled trial. 2014 , 45, 3330-6		48
2250	Atherosclerotic cardiovascular disease prevention: a comparison between the third adult treatment panel and the new 2013 Treatment of Blood Cholesterol Guidelines. 2014 , 7, 778-9		18
2249	The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome. 2014 , 3, e000784		9
2248	2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , 2014 , 130, 2354-94	16.7	696
2247	Low-density lipoprotein cholesterol levels in adults with type 2 diabetes: an alternative equation for accurate estimation and improved cardiovascular risk classification. 2014 , 11, 431-9		6
2246	Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis. 2014 , 9, e104521		35

2245	Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study. 2014 , 174, 1964-71		123
2244	Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. 2014 , 311, 1406-15		340
2243	Familial hypercholesterolemia: developments in diagnosis and treatment. 2014 , 111, 523-9		38
2242	Lipids in high-risk patients presenting with ischemic stroke or transient ischemic attack: are we missing the target?. 2014 , 45, 3180-1		2
2241	2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. <i>Circulation</i> , 2014 , 129, S102-38	16.7	1586
2240	Atherosclerotic Cardiovascular Disease Risk and Evidence-based Management of Cholesterol. 2014 , 6, 191-8		18
2239	Comparison of low-dose rosuvastatin with atorvastatin in lipid-lowering efficacy and safety in a high-risk pakistani cohort: an open-label randomized trial. 2014 , 2014, 875907		8
2238	Documenting Lifestyle Medicine Activities. 2014 , 8, 242-243		
2237	Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound. 2014 , 14, 60		26
2236	2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. <i>Circulation</i> , 2014 , 130, e199-267	16.7	1016
2235	Prediction of asymptomatic carotid artery stenosis in the general population: identification of high-risk groups. 2014 , 45, 2366-71		51
2234	Association between statin use and serum cholesterol concentrations is modified by whole-grain consumption: NHANES 2003-2006. 2014 , 100, 1149-57		11
2233	The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for cholesterol management and for cardiovascular risk stratification: a reappraisal. 2014 , 66, 1-4		3
2232	Strategies for vascular disease prevention: the role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA ₂) and lipoprotein(a) (Lp(a)). 2014 , 28, 281-94		19
2231	Is plant-based cardioprotection evidence-based?. 2014 , 30, 1142-4		
2230	Patterns and predictors of intensive statin therapy among patients with diabetes mellitus after acute myocardial infarction. 2014 , 113, 1267-72		9
2229	Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. 2014 , 23, 700-13		950
2228	Lipid, blood pressure and kidney update 2013. 2014 , 46, 947-61		47

2227	Stellungnahme der Deutschen Gesellschaft für Kardiologie zu den neuen US-Leitlinien zur Verminderung des Atheroskleroserisikos mittels lipidsenkender Therapie. 2014 , 8, 120-124		
2226	New guidelines for metabolic targets in diabetes: clinician's opinion does matter. 2014 , 46, 431-4		4
2225	A Latin American perspective on the new ACC/AHA clinical guidelines for managing atherosclerotic cardiovascular disease. 2014 , 16, 400		7
2224	Beyond Framingham and coronary calcium: predicted lifetime risk identifies unfavorable risk trajectories. 2014 , 21, 42-5		
2223	Trends in statin therapy initiation during the period 2000-2010 in Israel. 2014 , 70, 557-64		3
2222	New American College of Cardiology and American Heart Association cholesterol treatment guidelines: subjects with Type 2 diabetes are under treated with high-intensity statins. 2014 , 31, 879-80		2
2221	New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk. 2014 , 126, 169-75		14
2220	Long-term atorvastatin treatment leads to alterations in behavior, cognition, and hippocampal biochemistry. 2014 , 267, 6-11		21
2219	Screening strategies for cardiovascular disease in asymptomatic adults. 2014 , 41, 371-97		26
2218	Lipids and lipid management in diabetes. 2014 , 28, 325-38		45
2217	Lipid-lowering guidelines and statin use in CKD: a time for change. 2014 , 63, 736-8		1
2216	Dyslipidemia in Diabetes Mellitus and Chronic Kidney Disease. 2014 , 141-152		
2215	Critical limb ischemia: current approach and future directions. 2014 , 7, 437-45		8
2214	Therapeutic approaches to diabetic nephropathy--beyond the RAS. 2014 , 10, 325-46		131
2213	Closing the gap in hypertension control between younger and older adults: National Health and Nutrition Examination Survey (NHANES) 1988 to 2010. <i>Circulation</i> , 2014 , 129, 2052-61	16.7	26
2212	Current recommendations: what is the clinician to do?. 2014 , 101, 916-21		26
2211	Cardiovascular complications of diabetic kidney disease. 2014 , 21, 273-80		111
2210	2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. <i>Circulation</i> , 2014 , 130, 2071-104	16.7	1447

2209	Effect of change in systolic blood pressure between clinic visits on estimated 10-year cardiovascular disease risk. 2014 , 8, 159-65	6
2208	Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics. 2014 , 11, 72-4	13
2207	[Assessing the cardiovascular risk in patients with systemic lupus erythematosus]. 2014 , 35, 723-9	4
2206	Sudden cardiac death from the perspective of coronary artery disease. 2014 , 89, 1685-98	26
2205	Peeking into a cool future: genome editing to delete PCSK9 and control hypercholesterolemia in a single shot. 2014 , 115, 472-4	2
2204	Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. 2014 , 45, 3754-832	921
2203	Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. 2014 , 237, 829-37	19
2202	Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. 2014 , 57, 2444-52	69
2201	Statins, mood, sleep, and physical function: a systematic review. 2014 , 70, 1413-22	8
2200	Rationale and design of the Henry Ford Exercise Testing Project (the FIT project). 2014 , 37, 456-61	71
2199	A look at statin cost-effectiveness in view of the 2013 ACC/AHA cholesterol management guidelines. 2014 , 16, 438	13
2198	Lifestyle strategies for cardiovascular risk reduction. 2014 , 16, 444	17
2197	Long-term effects of an intensive intervention in HIV-infected patients with moderate-high atherosclerotic cardiovascular risk. 2014 , 69, 3051-6	6
2196	Laboratory validation of a low density lipoprotein apolipoprotein-B assay. 2014 , 47, 211-5	2
2195	Guideline-directed low-density lipoprotein management in high-risk patients with ischemic stroke: findings from Get with the Guidelines-Stroke 2003 to 2012. 2014 , 45, 3343-51	24
2194	Aspirin Use for Primary and Secondary Prevention in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Patients. 2014 , 1, ofu076	23
2193	Impact of the new American and British guidelines on the management and treatment of dyslipidemia in a Spanish working population. 2014 , 67, 906-11	1
2192	2013 American Heart Association/American College of Cardiology Guideline on Lifestyle Management to Reduce Cardiovascular Risk: practice opportunities for registered dietitian nutritionists. 2014 , 114, 1723-9	18

2191	Statin medications are associated with a lower probability of having an abnormal screening prostate-specific antigen result. 2014 , 84, 1058-65		10
2190	Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology position statement on dyslipidemia management. Differences between the European and American guidelines. 2014 , 67, 913-9		1
2189	Association of coronary artery calcium and coronary heart disease events in young and elderly participants in the multi-ethnic study of atherosclerosis: a secondary analysis of a prospective, population-based cohort. 2014 , 89, 1350-9		69
2188	Fabricating millimeter-scale polymeric structures for biomedical applications via a combination of UV-activated materials and daily-use tools. 2014 , 4, 12538-12544		1
2187	HDL cholesterol efflux capacity and incident cardiovascular events. 2014 , 371, 2383-93		869
2186	Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: a case-control study of the 20-year Familial Atherosclerosis Treatment - Observational Study (FATS-OS). 2014 , 8, 489-93		7
2185	LDL cholesterol as a predictor of mortality, and beyond: to fast or not to fast, that is the question?. <i>Circulation</i> , 2014 , 130, 528-9	16.7	5
2184	Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction. <i>Circulation</i> , 2014 , 129, 1303-9	16.7	50
2183	The effects of statin medications on aerobic exercise capacity and training adaptations. 2014 , 44, 1519-30		22
2182	10-year risk for atherosclerotic cardiovascular disease and coronary heart disease among Korean adults: findings from the Korean National Health and Nutrition Examination Survey 2009-2010. 2014 , 176, 418-22		8
2181	Secondary prevention of stroke in the elderly: focus on drug therapy. 2014 , 31, 721-30		12
2180	Tratamiento médico y criterios de seguimiento de la angina estable. 2014 , 21, 479-484		
2179	Posicionamiento del Comité Español Interdisciplinario de Prevención Cardiovascular y la Sociedad Española de Cardiología en el tratamiento de las dislipemias. Divergencia entre las guías europea y estadounidense. 2014 , 67, 913-919		19
2178	Impacto de las nuevas guías estadounidense y británica en el manejo y el tratamiento de las dislipemias en una población laboral española. 2014 , 67, 906-911		3
2177	Cardiac imaging in the geriatric population: what do we think we know, and what do we need to learn?. 2014 , 57, 204-14		6
2176	Risk stratification in very old adults: how to best gauge risk as the basis of management choices for patients aged over 80. 2014 , 57, 197-203		20
2175	Binswanger's disease: toward a diagnosis agreement and therapeutic approach. 2014 , 14, 1203-13		19
2174	Global perspective on acute coronary syndrome: a burden on the young and poor. 2014 , 114, 1959-75		136

2173	From the editor: The art of prevention. 2014 , 8, 359-62	1
2172	Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. 2014 , 8, 390-400	105
2171	Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. 2014 , 384, 591-598	376
2170	Adverse reactions to biologic agents and their medical management. 2014 , 10, 612-27	63
2169	2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , 2014 , 129, S49-73	167 2093
2168	Evidence-based prescribing: combining network meta-analysis with multicriteria decision analysis to choose among multiple drugs. 2014 , 7, 787-92	23
2167	¿Es necesario reducir aún más el colesterol-LDL en prevención secundaria?. 2014 , 21, 471-474	
2166	Increased Hs-CRP/adiponectin ratio is associated with increase carotid intima-media thickness. 2014 , 13, 120	13
2165	Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. 2014 , 59, e96-138	209
2164	Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (. 2014 , 114, 1682-9	44
2163	A summary and critical assessment of the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: filling the gaps. 2014 , 89, 1257-78	29
2162	[Lipid therapy for patients with coronary heart disease and diabetes. Current state and perspectives]. 2014 , 39, 299-305	1
2161	[New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk : Statement of the DAACH Society for Prevention of Cardiovascular Diseases, the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society for Cardiology]. 2014 , 55, 601-6	5
2160	Dietary supplementation with essential amino acids boosts the beneficial effects of rosuvastatin on mouse kidney. 2014 , 46, 2189-203	11
2159	Older statin initiators in Finland - cardiovascular risk profiles and persistence of use. 2014 , 28, 263-72	7
2158	Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. 2014 , 28, 281-9	78
2157	Impact of diet and exercise on lipid management in the modern era. 2014 , 28, 405-21	33
2156	[Significance of cardiovascular risk factors in persons of very advanced age: evidence, paradoxes and objectives]. 2014 , 49, 49-50	2

2155 Lipid-lowering therapy and mortality post-MI: is it just about the LDL?. **2014**, 100, 825-6

2154 Chasing Mendel: five questions for personalized medicine. **2014**, 592, 2381-8

21

2153 Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). *Circulation*, **2014**, 130, 546-53

16.7 94

2152 Combined effect of plant sterols and dietary fiber for the treatment of hypercholesterolemia. **2014**, 69, 93-100

14

2151 Adiposopathy, "sick fat," Ockham's razor, and resolution of the obesity paradox. **2014**, 16, 409

56

2150 2013 ACC/AHA cholesterol guideline for reducing cardiovascular risk: what is so controversial?. **2014**, 16, 413

9

2149 Primary prevention of cardiovascular disease with statins in the elderly. **2014**, 16, 420

20

2148 Emerging therapeutic approaches to treat dyslipidemia. **2014**, 16, 506

4

2147 Risks and benefits of statin use in young people with type 1 diabetes. **2014**, 14, 499

10

2146 Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases. **2014**, 37, 481-500

4

2145 Safety and efficacy of colesvelam HCl in the treatment of elderly patients. **2014**, 31, 461-70

5

2144 Clinical factors associated with statins prescription in acute ischemic stroke patients: findings from the Lombardia Stroke Registry. **2014**, 14, 53

11

2143 Claims-based algorithms for identifying Medicare beneficiaries at high estimated risk for coronary heart disease events: a cross-sectional study. **2014**, 14, 195

4

2142 Cardiovascular guidelines: separate career may help attenuate controversy. **2014**, 13, 66

1

2141 Nutrici3n y enfermedades metab3licas en el anciano. Estrategias alimentarias. **2014**, 11, 3691-3704

2140 An overview of the identification and management of the metabolic syndrome in chiropractic practice. **2014**, 13, 210-9

4

2139 Top 10 cardiovascular therapies and interventions for the next decade. **2014**, 11, 671-83

29

2138 Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China). **2014**, 237, 99-105

20

2137	Management of outpatients in France with stable coronary artery disease. Findings from the prospective observational Longitudinal Registry of patients with stable coronary artery disease (CLARIFY) registry. 2014 , 107, 452-61	9
2136	A Statin a Day to Keep the Doctor Away? Comparing Aspirin and Statins for Primary Prevention of Cardiovascular Disease. 2014 , 48, 1238-1241	5
2135	Strategies for treating lipids for prevention: risk stratification models with and without imaging. 2014 , 28, 295-307	2
2134	2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 63, 2935-2959	1625
2133	Has the adult treatment panel III guideline been updated?. 2014 , 114, 660	
2132	Overcoming toxicity and side-effects of lipid-lowering therapies. 2014 , 28, 439-52	31
2131	British and American prevention guidelines: different committees, same science, considerable agreement. 2014 , 100, 678-9	3
2130	Fixed-dose combination therapy for the prevention of cardiovascular disease. 2014 , CD009868	37
2129	[Management of vascular risk factors in patients older than 80]. 2014 , 143, 134.e1-11	8
2128	Coronary artery disease and diabetes mellitus. 2014 , 32, 439-55	92
2127	Meta-analysis of the effect of statins on renal function. 2014 , 114, 562-70	41
2126	The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. 2014 , 15, 1-15	62
2125	Diabetes and age-related demographic differences in risk factor control. 2014 , 8, 394-404	9
2124	Comparison of lipid management in patients with coronary versus peripheral arterial disease. 2014 , 113, 1320-5	18
2123	Recent AHA/ACC cholesterol guidelines: vice or virtue?. 2014 , 63, 605-6	1
2122	Lipid lowering in liver and chronic kidney disease. 2014 , 28, 339-52	7
2121	Looking back, looking forward. 2014 , 3, 3	1
2120	Effect of high-dose statin loading on biomarkers related to inflammation and renal injury in patients hospitalized with acute heart failure. Randomized, controlled, open-label, prospective pilot study. 2014 , 78, 2447-54	6

2119	Statins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular disease. 2014 , 78, 281-7	30
2118	Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study. 2014 , 78, 1073-82	87
2117	Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabetes patients (LISTEN) study 2014 , 78, 2512-5	17
2116	Do statins have a specific drug effect beyond low-density lipoprotein-cholesterol-lowering in the secondary prevention of coronary artery disease?. 2015 , 79, 49-50	
2115	Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. 2014 , 37, 597-604	36
2114	Understanding the new atherosclerotic cardiovascular disease prevention guidelines: going beyond the headlines. 2014 , 9, 121-123	
2113	POINT: should patients receiving statins prior to ICU admission be continued on statin therapy? Yes. 2014 , 146, 1431-1433	2
2112	Treating dyslipidemia in patients with type 2 diabetes mellitus. 2015 , 40, 22-23	
2111	Nutrition attributes and health effects of pistachio nuts. 2015 , 113 Suppl 2, S79-93	69
2110	Lipid-modifying Therapy: The Clinician's Perspective. 2015 , 37, 2712-5	
2109	Clinical lipidology: A subspecialty whose time has come. 2015 , 9, 634-9	2
2108	Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target. 2015 , 145, 67-69	
2107	Statin prescribing for primary prevention of cardiovascular disease: a cross-sectional, observational study. 2015 , 65, e538-44	14
2106	Challenges and Opportunities in the Management of Cardiovascular Risk Factors in Youth With Type 1 Diabetes: Lifestyle and Beyond. 2015 , 15, 119	18
2105	Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. 2015 , 13, 229	126
2104	Reduction in saturated fat intake for cardiovascular disease. 2015 , CD011737	197
2103	Posicionamiento del Comité Español Interdisciplinario de Prevención Cardiovascular y la Sociedad Española de Cardiología en el tratamiento de las dislipemias. Divergencia entre las guías europea y estadounidense. 2015 , 67, 488-496	
2102	Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study. 2015 , 67, 1995-2003	86

2101	Do we need a disease-specific cardiovascular risk calculator for patients with rheumatoid arthritis?. 2015 , 67, 1990-4	8
2100	Burden of First and Recurrent Cardiovascular Events Among Patients With Hyperlipidemia. 2015 , 38, 483-91	26
2099	US adults recommended for weight reduction by 1998 and 2013 obesity guidelines, NHANES 2007-2012. 2015 , 23, 527-31	22
2098	Implications of incretin-based therapies on cardiovascular disease. 2015 , 69, 531-49	10
2097	Cholesterol, statins, and dementia: what the cardiologist should know. 2015 , 38, 243-50	36
2096	Remnant Lipoprotein Cholesterol and Mortality After Acute Myocardial Infarction: Further Evidence for a Hypercholesterolemia Paradox From the TRIUMPH Registry. 2015 , 38, 660-7	16
2095	Genetic variants of SLC17A1 are associated with cholesterol homeostasis and hyperhomocysteinaemia in Japanese men. 2015 , 5, 15888	5
2094	Life-Time Risk, Screening and The Cost of Cardiovascular Comorbidities in CKD Patients. 2015 , 36, 85-90	
2093	Statin Adverse Events in Primary Prevention: Between Randomized Trials and Observational Studies. 2015 , 350, 330-7	15
2092	Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. 2015 , 125, 2771-8	68
2091	Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. 2015 , 126, 2739-46	92
2090	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan 2015. 2015 , 21, 1-87	390
2089	Risk scoring for the primary prevention of cardiovascular disease. 2015 ,	3
2088	The value of aspartate aminotransferase and alanine aminotransferase in cardiovascular disease risk assessment. 2015 , 2, e000272	33
2087	Effectiveness of Liraglutide in Type II Diabetes Mellitus Management: Experience in Emirati Patients. 2015 , 8, 67-72	2
2086	A review of the clinical evidence related to early treatment of elevated LDL for cardiovascular primary prevention. 2015 , 20, 162-9	3
2085	Autoimmune statin-induced myopathy: a case report. 2015 , 5, 28374	7
2084	Lipid paradox in acute myocardial infarction-the association with 30-day in-hospital mortality. 2015 , 43, 1255-64	47

2083	Quality markers in cardiology: measures of outcomes and clinical practice from perspective of the Spanish Society of Cardiology and of Thoracic and Cardiovascular Surgery1. 2015 , 22, 315-324	
2082	Temporal trends in lipid screening and therapy among youth from 2002 to 2012. 2015 , 9, S77-87	15
2081	Indicadores de calidad en cardiología. Principales indicadores para medir la calidad de los resultados (indicadores de resultados) y parámetros de calidad relacionados con mejores resultados en la práctica clínica (indicadores de práctica asistencial). INCARDIO (Indicadores de Calidad en Unidades Asistenciales del Área del Corazón): Declaración de posicionamiento de consenso de SEC/SECTCV. 2015 , 22, 314 e1-314 e30	
2080	Transitions of care and long-term surveillance after vascular surgery. 2015 , 28, 134-40	4
2079	Prevention und Management kardiovaskulärer Erkrankungen mit Nilotinib. 2015 , 21, 724-731	1
2078	The apoB100/apoA1 ratio is independently associated with the severity of coronary heart disease: a cross sectional study in patients undergoing coronary angiography. 2015 , 14, 150	14
2077	Assessment of dipyridamole stress echocardiography for risk stratification of diabetic patients. 2015 , 13, 35	3
2076	How low should we target the LDL goal to improve survival for acute coronary syndrome patients in Hong Kong?. 2015 , 15, 117	8
2075	Improving the odds: ezetimibe and cardiovascular disease. 2015 , 69, 390-5	2
2074	Identifying Individuals at Risk for Cardiovascular Events Across the Spectrum of Blood Pressure Levels. 2015 , 4, e002126	17
2073	Improvements in Cardiometabolic Risk Factors Among Overweight and Obese Employees Participating in a University Worksite Wellness Program. 2015 , 16, 805-13	6
2072	Interventions to improve adherence to cardiovascular disease guidelines: a systematic review. 2015 , 16, 147	32
2071	Management of hyperlipidemia among patients with rheumatoid arthritis in the primary care setting. 2015 , 16, 237	16
2070	Longitudinal study on the association between three dietary indices, anthropometric parameters and blood lipids. 2015 , 12, 47	14
2069	Study protocol for "Study of Practices Enabling Implementation and Adaptation in the Safety Net (SPREAD-NET)": a pragmatic trial comparing implementation strategies. 2015 , 10, 144	9
2068	Increased Risk of Acute Coronary Syndrome in Patients With Diverticular Disease: A Nationwide Population-Based Study. 2015 , 94, e2020	9
2067	High dose statins prior to PCI--change our modus operandis and start guideline therapy earlier?. 2015 , 85, 61-2	1
2066	Interaction analysis of the new pooled cohort equations for 10-year atherosclerotic cardiovascular disease risk estimation: a simulation analysis. 2015 , 5, e006468	4

2065	Association of Treatment for Hyperlipidemia with Decreased Total Mortality in Japanese Individuals: the Yamagata (Takahata) Study. 2015 , 22, 1030-9	8
2064	Statin therapy and gastrointestinal hemorrhage: a retrospective cohort study with propensity score-matching. 2015 , 24, 849-57	15
2063	Human Performance Optimization Metrics: Consensus Findings, Gaps, and Recommendations for Future Research. 2015 , 29 Suppl 11, S221-45	22
2062	Risk of new-onset diabetes associated with statin use. 2015 , 3, 2050312115605518	23
2061	Statin intolerance. 2015 , 26, 492-501	25
2060	The hinterland of familial hypercholesterolaemia: what do we not know?. 2015 , 26, 475-83	4
2059	Preoperative statin therapy for patients undergoing cardiac surgery. 2015 , CD008493	15
2058	Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population. 2015 , 45, 1017-24	23
2057	A Student-Led Health Education Initiative Addressing Health Disparities in a Chinatown Community. 2015 , 79, 132	8
2056	Can we treat to target in osteoporosis?. 2015 , 10, 1-4	3
2055	Statin Use Is Associated With Incident Diabetes Mellitus Among Patients in the HIV Outpatient Study. 2015 , 69, 306-11	20
2054	Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies. 2015 , 35, 1189-203	14
2053	A Cluster-Randomized Trial of a Centralized Clinical Pharmacy Cardiovascular Risk Service to Improve Guideline Adherence. 2015 , 35, 653-62	10
2052	Excessive range of statin dose in Western Australian primary care. 2015 , 45, 860-3	2
2051	Update on perioperative care of the cardiac patient for noncardiac surgery. 2015 , 28, 342-8	7
2050	Prioritizing health outcomes in a limited world: writing lipid guidelines. 2015 , 26, 188-94	1
2049	Did we abandon probucol too soon?. 2015 , 26, 304-16	33
2048	Recent developments in modulating atherogenic lipoproteins. 2015 , 26, 369-75	6

2047	Non-high-density lipoprotein cholesterol: current status as cardiovascular marker. 2015 , 26, 502-10	50
2046	Application of New Cholesterol Guidelines to the Korean Adult Diabetic Patients. 2015 , 30, 1612-7	5
2045	Is carotid artery evaluation necessary for primary prevention in asymptomatic high-risk patients without atherosclerotic cardiovascular disease?. 2015 , 10, 1111-9	5
2044	Statin Use, Incident Dementia and Alzheimer Disease in Elderly African Americans. 2015 , 25, 345-54	33
2043	The genetics of familial hypercholesterolemia and emerging therapies. 2015 , 8, 27-36	28
2042	HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. 2015 , 133, 541-2	7
2041	Reducing Medication Costs to Prevent Cardiovascular Disease: A Community Guide Systematic Review. 2015 , 12, E208	18
2040	2015 Korean Guidelines for Management of Dyslipidemia. 2015 , 4, 61	33
2039	Adherence to guideline-recommended therapies among patients with diverse manifestations of vascular disease. 2015 , 11, 185-92	26
2038	Benefit-risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients. 2015 , 10, 733-40	6
2037	Combination pharmacotherapy in lipid management. 2015 , 58, 745	
2036	Study of the Use of Lipid Panels as a Marker of Insulin Resistance to Determine Cardiovascular Risk. 2015 , 19, 4-10	7
2035	Prevention, Detection and Management of Coronary Artery Disease in Minority Females. 2015 , 25, 499-506	9
2034	Internal Iliac Artery Stenosis: Diagnosis and How to Manage it in 2015. 2015 , 2, 33	21
2033	Association of Chest Pain and Risk of Cardiovascular Disease with Coronary Atherosclerosis in Patients with Inflammatory Joint Diseases. 2015 , 2, 80	7
2032	New developments in atherosclerosis: clinical potential of PCSK9 inhibition. 2015 , 11, 493-501	16
2031	Transforming cardiovascular disease prevention in women: time for the Pygmalion construct to end. 2015 , 130, 62-8	6
2030	Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trials. 2015 , 7, 555-65	6

2029	Type of dyslipidemia and achievement of the LDL-cholesterol goal in chronic kidney disease patients at the University Hospital. 2015 , 11, 563-7	2
2028	Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection. 2015 , 10, e0118228	18
2027	Predicting Stroke Risk Based on Health Behaviours: Development of the Stroke Population Risk Tool (SPoRT). 2015 , 10, e0143342	18
2026	The Polypill: From Promise to Pragmatism. 2015 , 12, e1001862	18
2025	Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. 2015 , 10, e0132970	62
2024	Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins. 2015 , 10, e0138332	16
2023	Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. 2015 , 6, 1246-58	437
2022	Relationship between hyperuricemia and lipid profiles in US adults. 2015 , 2015, 127596	97
2021	Cardiovascular Complications of HIV-Associated Immune Dysfunction. 2015 , 2015, 302638	12
2020	Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. 2015 , 11, 1-23	252
2019	The Effect of Elevated Triglycerides on the Onset and Progression of Coronary Artery Disease: A Retrospective Chart Review. 2015 , 2015, 292935	3
2018	The association of metabolic syndrome and urolithiasis. 2015 , 2015, 570674	32
2017	A Whole-Food Plant-Based Diet Reversed Angina without Medications or Procedures. 2015 , 2015, 978906	10
2016	Impact of predictors upon the reduction of lipid parameters in family medicine practice. 2015 , 133, 428-34	
2015	Application of new guidelines for the primary prevention of atherosclerotic cardiovascular disease in a Korean population. 2015 , 22, 293-303	8
2014	Coronary atherosclerosis is already ongoing in pre-diabetic status: Insight from intravascular imaging modalities. 2015 , 6, 184-91	6
2013	Atherosclerosis and CAD. 2015 , 36, 457-9	3
2012	The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. 2015 , 36, 2110-2118	44

2011	Strokes in young adults: epidemiology and prevention. 2015 , 11, 157-64	158
2010	Statin therapy in patients with cirrhosis. 2015 , 6, 255-261	8
2009	Discordance between Risk Factors and Coronary Artery Calcium: Implications for Guiding Treatment Strategies in Primary Prevention Settings. 2015 , 58, 10-8	8
2008	Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy. 2015 , 12, 406-14	66
2007	Metabolic syndrome, dyslipidemia and prostate cancer recurrence after primary surgery or radiation in a veterans cohort. 2015 , 18, 190-5	15
2006	Proof That Lower Is Better--LDL Cholesterol and IMPROVE-IT. 2015 , 372, 2448-50	82
2005	Aortic Atherosclerosis as an Embolic Source. 2015 , 1-64	
2004	Conflicts of interest: part 1: Reconnecting the dots--reinterpreting industry-physician relations. 2015 , 372, 1860-4	68
2003	Primary and secondary prevention of ischemic heart disease in women. 2015 , 17, 38	1
2002	Dyslipidemia and cardiovascular disease in women. 2015 , 17, 609	46
2001	PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials. 2015 , 38, 519-26	50
2000	Relation of black race between high density lipoprotein cholesterol content, high density lipoprotein particles and coronary events (from the Dallas Heart Study). 2015 , 115, 890-4	29
1999	PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia. 2015 , 763, 38-47	26
1998	Effects of rosuvastatin combined with fasudil therapy on rabbits with dyslipidemia. 2015 , 14, 52	1
1997	Twenty-five years of statins: where do we go from here?. 2015 , 10, 33-45	2
1996	From Durban to Boston, a "modest proposal" to improve perioperative cardiovascular risk stratification. 2015 , 120, 515-518	1
1995	Pharmacological treatment and current management of peripheral artery disease. 2015 , 116, 1579-98	66
1994	Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. 2015 , 241, 169-75	114

1993	Insulin Resistance and Risk of Cardiovascular Disease in Postmenopausal Women: A Cohort Study From the Women's Health Initiative. 2015 , 8, 309-16		15
1992	Precision medicine--personalized, problematic, and promising. 2015 , 372, 2229-34		571
1991	Improving clinical practice guidelines for practicing cardiologists. 2015 , 115, 1773-6		19
1990	Perioperative Care of the Surgical Patient. 2015 , 155-180		
1989	Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events. 2015 , 8, 457-79		16
1988	We don't prescribe statins to lower cholesterol: we prescribe statins to reduce vascular risk. 2015 , 26, 1001-3		4
1987	Hypertension in african americans aged 60 to 79 years: statement from the international society of hypertension in blacks. 2015 , 17, 252-9		9
1986	Development of a Risk Index for Serious Prescription Opioid-Induced Respiratory Depression or Overdose in Veterans' Health Administration Patients. 2015 , 16, 1566-79		94
1985	Cognitive and Physical Function by Statin Exposure in Elderly Individuals Following Acute Myocardial Infarction. 2015 , 38, 455-61		3
1984	Replacing the hypertension control paradigm with a strategy of cardiovascular risk reduction. 2015 , 1, 17-22		6
1983	Cholesterol production, accumulation, reverse transport, and excretion: opportunities for statins, PPAR- α agonists, and PCSK9 inhibitors. 2015 , 36, 2965-7		1
1982	Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2015 , 132, 2424-47	16.7	168
1981	The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2015 , 132, 2167-92	16.7	377
1980	Risk factor burden in midlife: is it water under the bridge?. 2015 , 101, 1859-60		
1979	Comparing Guidelines for Statin Treatment in Canada and the United States. 2015 , 4,		7
1978	High Cholesterol Awareness, Treatment, and Control Among Hispanic/Latinos: Results From the Hispanic Community Health Study/Study of Latinos. 2015 , 4,		29
1977	Implications of the US cholesterol guidelines on eligibility for statin therapy in the community: comparison of observed and predicted risks in the Framingham Heart Study Offspring Cohort. 2015 , 4,		28
1976	Distribution of Short-Term and Lifetime Predicted Risks of Cardiovascular Diseases in Peruvian Adults. 2015 , 4, e002112		5

1975	Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes. 2015 , 37, 2751-69	21
1974	Follow the guideline for reducing cardiovascular risk with statins. 2015 , 45, 40-6; quiz 46-7	
1973	Coronary artery calcium in hypertension: a review. 2015 , 9, 993-1000	7
1972	Indicadores de calidad en cardiología. Principales indicadores para medir la calidad de los resultados (indicadores de resultados) y parámetros de calidad relacionados con mejores resultados en la práctica clínica (indicadores de práctica asistencial). INCARDIO (Indicadores de Calidad en Unidades Asistenciales del Rea del Corazón): Declaración de posicionamiento de consenso de SEC/SECTCV. 2015 , 68, 276-1005	33
1971	Screening asymptomatic patients with type 2 diabetes is recommended-Con. 2015 , 22, 1229-32	4
1970	Treating dyslipidemia in patients with type 2 diabetes mellitus. 2015 , 40, 18-22; quiz 22-3	2
1969	IMPROVE-IT-Studie. 2015 , 9, 329-331	
1968	Considering gender in prescribing statins: what do physicians need to know?. 2015 , 10, 499-512	11
1967	Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4-Year Follow-Up. 2015 , 4,	15
1966	Individualized Risk Communication and Outreach for Primary Cardiovascular Disease Prevention in Community Health Centers: Randomized Trial. 2015 , 8, 560-6	13
1965	Competing Dyslipidemia Guidelines for Adolescents. 2015 , 34, 1-1	
1964	Statin Selection in Qatar Based on Multi-indication Pharmacotherapeutic Multi-criteria Scoring Model, and Clinician Preference. 2015 , 37, 2798-810	4
1963	Discordance between apolipoprotein B and low-density lipoprotein particle number is associated with insulin resistance in clinical practice. 2015 , 9, 247-55	16
1962	Disparities in lipid control and statin drug use among diabetics with noncoronary atherosclerotic vascular disease vs those with coronary artery disease. 2015 , 9, 241-6	4
1961	Is HPS2-THRIVE the death knell for niacin?. 2015 , 9, 343-50	8
1960	Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease. 2015 , 4, e001675	17
1959	How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. 2015 , 31, 221-8	16
1958	Why are anti-obesity drugs stigmatized?. 2015 , 14, 185-9	13

1957	Ischemic heart disease in women: a focus on risk factors. 2015 , 25, 140-51	101
1956	The year in cardiology 2014: prevention. 2015 , 36, 214-8	4
1955	[Position of Interdisciplinary Spanish Committee for Cardiovascular Prevention about dyslipemia treatment guidelines]. 2015 , 27, 34-5	
1954	Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy. 2015 , 15, 287-98	6
1953	Use of cardiac CT and calcium scoring for detecting coronary plaque: implications on prognosis and patient management. 2015 , 88, 20140594	19
1952	Significant interactions between traditional risk factors affect cardiovascular risk prediction in healthy general population. 2015 , 47, 53-60	1
1951	Rheumatoid arthritis, a new focus on cardiovascular risk. 2015 , 11, 129-30	
1950	New cholesterol guidelines and primary prevention in women. 2015 , 25, 84-94	12
1949	Cardiovascular news 2013/2014. 2015 , 215, 33-42	
1948	The Cholesterol Lowering Atherosclerosis Study (CLAS): what it tells us about niacin/colestipol therapy. 2015 , 9, 11-3	2
1947	Is it Time to Enhance Assessment of Alcohol Intake in Patients Slated for Statin Therapy?. 2015 , 4, 1-5	2
1946	Statins and cognitive function: an updated review. 2015 , 17, 4	15
1945	Association between use of statins and outcomes in heart failure with reduced ejection fraction: prospective propensity score matched cohort study of 21 864 patients in the Swedish Heart Failure Registry. 2015 , 8, 252-60	30
1944	Incremental prognostic value of kidney function decline over coronary artery disease for cardiovascular event prediction after coronary computed tomography. 2015 , 88, 152-9	13
1943	How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease. 2015 , 8, 201-10	37
1942	ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. 2015 , 11, 27-37	45
1941	Availability and utilization of cardiovascular fixed-dose combination drugs in the United States. 2015 , 169, 379-386.e1	18
1940	Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. 2015 , 35, 211-9	45

1939	Evolution of intracranial atherosclerotic disease under modern medical therapy. 2015 , 77, 478-86		30
1938	Ezetimibe use remains common among medical inpatients. 2015 , 128, 193-5		2
1937	Management of diabetes in the elderly. 2015 , 99, 351-77		27
1936	What if the FDA had launched its action plan to close the health disparities gap for women two decades earlier?. 2015 , 25, 95-7		2
1935	Puesta al día en estatinas. Nuevas recomendaciones. 2015 , 67, 304-311		1
1934	Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. <i>Circulation</i> , 2015 , 131, 927-64	16.7	226
1933	Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience. 2015 , 239, 93-100		54
1932	Cardiovascular news 2013/2014. 2015 , 215, 33-42		
1931	Cost-effectiveness of statin treatment for primary prevention in conditions of real-world adherence—estimates from the Finnish prescription register. 2015 , 239, 240-7		14
1930	The highs and lows of cardiovascular risk prediction: time for paradigm shift?. 2015 , 239, 436-8		1
1929	Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. 2015 , 61, 25-41S		420
1928	The association of statin use and gonado-sexual function in women: a retrospective cohort analysis. 2015 , 12, 83-92		6
1927	Overview. 2015 , 1-19		
1926	Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom. 2015 , 37, 804-15		2
1925	Harnessing the Therapeutic Potential of MicroRNAs for Cardiovascular Disease. 2015 , 20, 131-43		12
1924	Statin treatment for older adults: the impact of the 2013 ACC/AHA cholesterol guidelines. 2015 , 32, 87-93		5
1923	Current drug treatment of hyperlipidemia in older adults. 2015 , 32, 127-38		10
1922	Early investigational drugs targeting PPAR- β for the treatment of metabolic disease. 2015 , 24, 611-21		34

1921	Leptin and incident cardiovascular disease: the Multi-ethnic Study of Atherosclerosis (MESA). 2015 , 239, 67-72		35
1920	Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. 2015 , 90, 24-34		139
1919	Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. 2015 , 385, 1397-405		756
1918	Heart disease and stroke statistics--2015 update: a report from the American Heart Association. <i>Circulation</i> , 2015 , 131, e29-322	16.7	5259
1917	Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. 2015 , 30, 348-58		133
1916	Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. <i>Circulation</i> , 2015 , 131, 774-85	16.7	367
1915	Primary prevention with statins in cardiovascular diseases: A Saudi Arabian perspective. 2015 , 27, 179-91		13
1914	Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. 2015 , 36, 1186-94		289
1913	Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). 2015 , 17, 395-402		33
1912	The recent national lipid association recommendations: how do they compare to other established dyslipidemia guidelines?. 2015 , 17, 494		7
1911	Present status of statin therapy. 2015 , 25, 216-25		13
1910	Statins and Incident Diabetes: Can Risk Outweigh Benefit?. 2015 , 9, 1		1
1909	State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus. 2015 , 9, 4		11
1908	Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin. 2015 , 35, 45-51		9
1907	[Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain]. 2015 , 27, 228-38		3
1906	SCCT curriculum guidelines for general (level 1) cardiovascular CT training. 2015 , 9, 81-8		10
1905	The new ACCF/AHA guidelines on the treatment of dyslipidemia: pros. 2015 , 10, 115-7		1
1904	The new ACC/AHA guidelines on the treatment of dyslipidemia: cons. 2015 , 10, 119-22		1

1903	Comparing cardiovascular risk prediction scores. 2015 , 162, 313-4	19
1902	Should non-cardiovascular mortality be considered in the SCORE model? Findings from the Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort. 2015 , 30, 47-56	3
1901	Statin-Therapie bei KHK-Patienten mit Herzinsuffizienz. 2015 , 15, 35-38	
1900	Primary prevention of atherosclerotic cardiovascular disease: controversies and clinical considerations. 2015 , 49, 484-93	8
1899	Renin-angiotensin system inhibitor and statins combination therapeutics - what have we learnt?. 2015 , 16, 949-53	11
1898	Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients. 2015 , 240, 482-9	17
1897	Interaction between periodontal disease and atherosclerotic vascular disease--Fact or fiction?. 2015 , 241, 555-60	43
1896	The world and lipidology as it relates to cardiology. 2015 , 33, xiii-xiv	
1895	Management of patients with familial hypercholesterolaemia. 2015 , 12, 565-75	79
1894	Adverse pregnancy outcomes and cardiovascular risk factor management. 2015 , 39, 268-75	20
1893	The new lipid guidelines: what do primary care clinicians think?. 2015 , 128, 914.e5-914.e10	13
1892	The Burden of Cardiovascular Disease in Low- and Middle-Income Countries: Epidemiology and Management. 2015 , 31, 1151-9	98
1891	Association Between Use of Statins and Mortality in Patients With Heart Failure and Ejection Fraction of ≤ 0 . 2015 , 8, 862-70	64
1890	Clinical Effectiveness of Statin Therapy After Ischemic Stroke: Primary Results From the Statin Therapeutic Area of the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. <i>Circulation</i> , 2015 , 132, 1404-13	16.7 35
1889	A centralized cardiovascular risk service to improve guideline adherence in private primary care offices. 2015 , 43, 25-32	13
1888	The low-density lipoprotein hypothesis: Proven again with the Improved Reduction of Outcomes: Vytorin Efficacy International Trial. 2015 , 9, 496-7	1
1887	[Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target]. 2015 , 145, 67-9	2
1886	Update in preoperative risk assessment in vascular surgery patients. 2015 , 62, 499-509	12

1885	Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines. <i>Circulation</i> , 2015 , 132, 916-22	16.7	60
1884	Cardiovascular risk assessment in rheumatoid arthritis: What goals should be achieved?. 2015 , 44, e20-1		
1883	Cardiovascular Disease in South Asian Migrants. 2015 , 31, 1139-50		52
1882	Impact of combination therapy with statin and ezetimibe on secondary prevention for post-acute myocardial infarction patients in the statin era. 2015 , 8, 154-160		2
1881	Nonalcoholic fatty liver disease and statins. 2015 , 64, 1215-23		47
1880	Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9. 2015 , 129, 63-79		19
1879	Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol: The Very Large Database of Lipids Study (VLDL-2B). <i>Circulation</i> , 2015 , 132, 667-76	16.7	28
1878	State-of-the-Art Updates on Cardiac Computed Tomographic Angiography for Assessing Coronary Artery Disease. 2015 , 17, 398		3
1877	Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. 2015 , 35, 1880-8		51
1876	Effects of daily almond consumption on cardiometabolic risk and abdominal adiposity in healthy adults with elevated LDL-cholesterol: a randomized controlled trial. 2015 , 4, e000993		66
1875	The new pooled cohort equations risk calculator. 2015 , 31, 613-9		52
1874	Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy. 2015 , 56, 14-23		18
1873	Risk of major cardiovascular events among incident dialysis patients: A Korean national population-based study. 2015 , 198, 95-101		34
1872	Preeclampsia and future cardiovascular disease in women: How good are the data and how can we manage our patients?. 2015 , 39, 276-83		44
1871	Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes. 2015 , 5, 7706		18
1870	Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic. 2015 , 66, 346-53		20
1869	A Randomized Double-blind Controlled Trial of Lactobacillus acidophilus Plus Bifidobacterium bifidum versus Placebo in Patients with Hypercholesterolemia. 2015 , 9, KC01-4		20
1868	Mapping hyperlipidemia in young adulthood to coronary risk: importance of cumulative exposure and how to stay young. <i>Circulation</i> , 2015 , 131, 445-7	16.7	6

1867	Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. 2015 , 4, e001937	57
1866	SALTIRE-RAAVE: targeting calcific aortic valve disease LDL-density-radius theory. 2015 , 13, 355-67	6
1865	Deprescripci3 de medicamentos. 2015 , 22, 9-33	
1864	Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs. 2015 , 75, 1201-28	15
1863	Rationale and design of the Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial. 2015 , 170, 430-7.e9	6
1862	High-density lipoprotein cholesterol efflux capacity as a relevant predictor of atherosclerotic coronary disease. 2015 , 242, 318-22	28
1861	Cholesterol biosensor based on inkjet-printed Prussian blue nanoparticle-modified screen-printed electrodes. 2015 , 221, 187-190	43
1860	Ethnicity and coronary artery disease: the role of high-density lipoprotein - a change in paradigm. 2015 , 13, 923-31	1
1859	The role of apoB measurement in Type 2 diabetic patients. 2015 , 10, 137-144	2
1858	Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. 2015 , 314, 142-50	138
1857	The role of statins in the setting of HIV infection. 2015 , 12, 305-12	20
1856	Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish Longitudinal Study on Ageing (TILDA). 2015 , 5, e008017	18
1855	Cardiovascular risk assessment in rheumatoid arthritis and other inflammatory arthritides. 2015 , 44, e19	
1854	Persistent lipid abnormalities in patients with hypertension and dyslipidemia treated with statins: results of the Portuguese hypertensive subpopulation of the Dyslipidemia International Study (DYSIS). 2015 , 37, 116-21	5
1853	PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a). 2015 , 29, 295-308	14
1852	Hypercholesterolemia and Hypertension: Two Sides of the Same Coin. 2015 , 15, 403-14	36
1851	Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. 2015 , 241, 409-18	63
1850	Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian Randomization Analysis. 2015 , 8, 618-27	41

1849	Sweetless'n low LDL-C targets for PCSK9 treatment. 2015 , 36, 1146-8	8
1848	Current Treatment of Dyslipidemia: A New Paradigm for Statin Drug Use and the Need for Additional Therapies. 2015 , 75, 1187-99	20
1847	Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. 2015 , 17, 434-41	29
1846	Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. 2015 , 170, 117-22	25
1845	Risk factor burden and control at the time of admission in patients with acute myocardial infarction: Results from the NCDR. 2015 , 170, 173-9, 179.e1	3
1844	Dyslipidemia testing: Why, for whom and when. 2015 , 81, 442-5	3
1843	Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View. 2015 , 10, 1089-93	32
1842	Trends in myocardial infarction secondary prevention: The National Health and Nutrition Examination Surveys (NHANES), 1999-2012. 2015 , 4,	31
1841	Primary prevention: do the very elderly require a different approach?. 2015 , 25, 228-39	15
1840	Updated cholesterol guidelines and intensity of statin therapy. 2015 , 9, 357-9	8
1839	Congenital heart disease in the older adult: a scientific statement from the American Heart Association. <i>Circulation</i> , 2015 , 131, 1884-931	16.7 140
1838	Las guías de práctica clínica de manejo de la dislipemia. Una visión transatlántica. 2015 , 15, 1	
1837	Escalas de cálculo del riesgo cardiovascular para pacientes con diabetes. ¿Qué son y de qué nos sirven?. 2015 , 31, 102-112	1
1836	Del concepto de estatinas de alta potencia a los efectos extralipídicos de las estatinas. 2015 , 15, 22-27	1
1835	Real time atherosclerosis assessment in outpatient cardiology practice along with cardiovascular risk assessment and physician patient communication: a three-pronged approach for patient risk evaluation, education, and treatment. 2015 , 28, A16-7	2
1834	[Update of planning tables of cholesterol-lowering therapy orientated to achieve LDL therapeutic targets]. 2015 , 27, 138-43	6
1833	Risk identification and possible countermeasures for muscle adverse effects during statin therapy. 2015 , 26, 82-8	56
1832	Implementation and evaluation of evidence-based patient care application during a primary care advanced practice experience. 2015 , 7, 324-331	2

1831	[Evidence-based medicine and clinical practice in octogenarians: the management of hypercholesterolemia]. 2015 , 50, 49-50		2
1830	Using age- and sex-specific risk thresholds to guide statin therapy: one size may not fit all. 2015 , 65, 1633-1639	41	
1829	Update in venous thromboembolism pathophysiology, diagnosis, and treatment for surgical patients. 2015 , 52, 233-59		5
1828	Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. <i>Circulation</i> , 2015 , 131, 1715-36	16.7	32
1827	Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study. 2015 , 190, 20-5		19
1826	Genetic and immunologic susceptibility to statin-related myopathy. 2015 , 240, 260-71		26
1825	[Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology Position Statement on Dyslipidemia Management. Differences Between the European and American Guidelines]. 2015 , 32, 83-91		1
1824	Guidelines and guidance in lipid modification. 2015 , 25, 348-50		2
1823	Optimizing statin treatment. 2015 , 25, 226-7		
1822	Participation in the Vascular Quality Initiative is associated with improved perioperative medication use, which is associated with longer patient survival. 2015 , 61, 1010-9		41
1821	[Spanish interdisciplinary committee for cardiovascular disease prevention and the spanish society of cardiology position statement on dyslipidemia management. Differences between the European and american guidelines]. 2015 , 41, 149-57		0
1820	Soluble ST2 testing in the general population. 2015 , 115, 22B-5B		11
1819	Race-sex differences in the management of hyperlipidemia: the REasons for Geographic and Racial Differences in Stroke study. 2015 , 48, 520-7		22
1818	Statin therapy and bone marrow CD34+ cell frequency in type 2 diabetes mellitus: Dose and form. 2015 , 187, 75-7		1
1817	Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients. 2015 , 67, 2004-10		38
1816	Polypharmacy Among Adults Aged 65 Years and Older in the United States: 1988-2010. 2015 , 70, 989-95		281
1815	Evolocumab (AMG 145) for primary hypercholesterolemia. 2015 , 13, 477-88		40
1814	Cardiovascular mortality in chronic kidney disease patients: potential mechanisms and possibilities of inhibition by resin-based phosphate binders. 2015 , 13, 489-99		2

1813	Role for combination therapy in diabetic dyslipidemia. 2015 , 17, 32		21
1812	Secondary Prevention of Heart Disease in Women: Gaps in Care/Gaps in Knowledge—Where Do We Need to Focus Our Attention. 2015 , 9, 1		
1811	Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia. 2015 , 9, 360-7		19
1810	Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. 2015 , 14, 935-55		94
1809	Evaluation of aspirin use for primary prevention in diabetic patients. 2015 , 49, 150-1		1
1808	Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. 2015 , 372, 1500-9		1081
1807	Statins can increase the risk of herpes zoster infection in Asia. 2015 , 34, 1451-8		15
1806	Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study. <i>Circulation</i> , 2015 , 131, 2104-13	16.7	239
1805	Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 2015 , 9, 453-98		39
1804	Chronic kidney disease: Statins in chronic kidney disease: time to move on?. 2015 , 11, 262-3		4
1803	Heart failure risk prediction in childhood cancer survivors: where is our crystal ball?. 2015 , 33, 379-80		
1802	High-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity. 2015 , 58, 32-40		58
1801	Statins and congenital malformations: cohort study. 2015 , 350, h1035		126
1800	Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats. 2015 , 14, 41		8
1799	A joint model of persistent human papillomavirus infection and cervical cancer risk: Implications for cervical cancer screening. 2015 , 178, 903-923		4
1798	Comparison of equations for the calculation of LDL-cholesterol in hospitalized patients. 2015 , 444, 137-42		27
1797	"Add-on" effect of phytosterols-enriched fermented milk on lipids and markers of cholesterol metabolism in statin-treated elderly patients. 2015 , 99, 293-8		8
1796	Targeting lipoprotein (a): an evolving therapeutic landscape. 2015 , 17, 502		7

1795	Statins, cognition, and dementia. Systematic review and methodological commentary. 2015 , 11, 220-9	73
1794	Understanding the Importance of Race/Ethnicity in the Care of the Hypertensive Patient. 2015 , 17, 15	14
1793	Women-specific factors to consider in risk, diagnosis and treatment of cardiovascular disease. 2015 , 11, 239-257	67
1792	Pathophysiology and Lifetime Risk Factors for Atherosclerosis and Coronary Artery Disease in Women and in the Elderly. 2015 , 425-441	1
1791	Pediatric guidelines for dyslipidemia. 2015 , 9, S5-S10	14
1790	Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials. 2015 , 191, 138-48	33
1789	Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States. 2015 , 162, 533-41	74
1788	Ezetimibe plus simvastatin for the treatment of hypercholesterolemia. 2015 , 16, 1255-62	11
1787	Prevention and Treatment of Atherosclerotic Vascular Disease: Hypolipidemic Agents. 2015 , 589-611	
1786	Managing residual risk after myocardial infarction among individuals with low cholesterol levels. 2015 , 33, 299-308	3
1785	Management of hypertriglyceridemia for prevention of atherosclerotic cardiovascular disease. 2015 , 33, 309-23	11
1784	Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis. 2015 , 10, 732-9	41
1783	Statins and New-Onset Diabetes Mellitus and Diabetic Complications: A Retrospective Cohort Study of US Healthy Adults. 2015 , 30, 1599-610	52
1782	Dyslipidemia in special ethnic populations. 2015 , 33, 325-33	27
1781	New cholesterol guidelines for the management of atherosclerotic cardiovascular disease risk: a comparison of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines with the 2014 National Lipid Association recommendations for patient-centered management of dyslipidemia. 2015 , 33, 181-96	20
1780	Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Non-ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry). 2015 , 115, 1655-60	7
1779	Cardiovascular risk factors and disease in women. 2015 , 99, 535-52	12
1778	Statin use after acute myocardial infarction by patient complexity: are the rates right?. 2015 , 53, 324-31	8

1777	Lipids, blood pressure and kidney update 2014. 2015 , 95-96, 111-25	70
1776	PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9. 2015 , 22, 126-32	21
1775	Management of dyslipidaemia in statin-intolerant patients in light of AHA and NPA guidelines of 2013-2014. 2015 , 5, 119-122	1
1774	Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients. 2015 , 67, 23-6	19
1773	Deciphering cholesterol treatment guidelines: a clinician's perspective. 2015 , 313, 1009-10	7
1772	Mechanisms of action for arsenic in cardiovascular toxicity and implications for risk assessment. 2015 , 331, 78-99	33
1771	Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge. 2015 , 47, 805-13	10
1770	Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. 2015 , 17, 541	15
1769	The 2015 standards for diabetes care: maintaining a patient-centered approach. 2015 , 162, 785-6	8
1768	An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. 2015 , 162, 266-75	312
1767	In the clinic. Type 2 diabetes. 2015 , 162, ITC1-16	22
1766	Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial. 2015 , 66, 353-8	9
1765	Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 2015 , 65, 1372-407	76
1764	Rosuvastatin Enhances the Catabolism of LDL apoB-100 in Subjects with Combined Hyperlipidemia in a Dose Dependent Manner. 2015 , 50, 447-58	4
1763	Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management. 2015 , 4, 25-38	43
1762	Statins and aspirin: do they really work in women?. 2015 , 15, 151-62	1
1761	The screening value of baPWV and hs-crp to ASCVD in middle and elderly community population in Shanghai. 2015 , 186, 289-90	1
1760	Risk of Intracranial Hemorrhage From Statin Use in Asians: A Nationwide Cohort Study. <i>Circulation</i> , 2015 , 131, 2070-8	16.7 27

1759	Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>Circulation</i> , 2015 , 131, e435-70	16.7	80
1758	Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention. 2015 , 20, 299-312		4
1757	The epidemiology of blood pressure and its worldwide management. 2015 , 116, 925-36		118
1756	Statin eligibility and cardiovascular risk burden assessed by coronary artery calcium score: comparing the two guidelines in a large Korean cohort. 2015 , 240, 242-9		10
1755	The relationship between coronary artery calcium score and the long-term mortality among patients with minimal or absent coronary artery risk factors. 2015 , 185, 275-81		19
1754	Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence. 2015 , 72, 1623-9		10
1753	Coronary Plaque Burden at Coronary CT Angiography in Asymptomatic Men and Women. 2015 , 277, 73-80		36
1752	Conflicts of Interest. 2015 , 373, 779-80		1
1751	[LDL-Cholesterol--Is there an "LDL hypothesis"?]. 2015 , 140, 761-4		2
1750	Quality Markers in Cardiology. Main Markers to Measure Quality of Results (Outcomes) and Quality Measures Related to Better Results in Clinical Practice (Performance Metrics). INCARDIO (Indicadores de Calidad en Unidades Asistenciales del Rea del Coraz3n): A SEC/SECTCV Consensus Position Paper. 2015 , 68, 976-995.e10		1
1749	The Role of Omega-3 Fatty Acids in Dyslipidemias. 2015 , 45-64		1
1748	Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk. 2015 , 3, e000132		8
1747	Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy. 2015 , 61, 1566-72		27
1746	Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. <i>Circulation</i> , 2015 , 132, 1648-66	16.7	124
1745	Dyslipidemia in Obesity. 2015 , 1-18		
1744	Additive effects of plant sterols supplementation in addition to different lipid-lowering regimens. 2015 , 9, 542-52		16
1743	Risk Stratification for Primary Prevention of Coronary Artery Disease: Roles of C-Reactive Protein and Coronary Artery Calcium. 2015 , 17, 110		15
1742	Optimal treatment of extracranial carotid artery disease: carotid endarterectomy, carotid stenting, or optimal medical therapy. 2015 , 17, 84		3

1741	Cardiac Rehabilitation: Underrecognized/Underutilized. 2015 , 17, 62		14
1740	Genetic considerations in the treatment of familial hypercholesterolemia. 2015 , 10, 387-403		1
1739	Realizing the Potential of Clinical Risk Prediction Models: Where Are We Now and What Needs to Change to Better Personalize Delivery of Care?. 2015 , 8, 332-4		10
1738	Assessment of serum 25-hydroxy vitamin D improves coronary heart disease risk stratification in patients with type 2 diabetes. 2015 , 170, 573-9.e5		22
1737	Cardiac screening with electrocardiography, stress echocardiography, or myocardial perfusion imaging: advice for high-value care from the American College of Physicians. 2015 , 162, 438-47		28
1736	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. <i>Circulation</i> , 2015 , 132, 691-718	16.7	239
1735	Statins for people at low risk. 2015 , 351, h3908		14
1734	[Is the antibiotic prophylaxis necessary for the prevention of infective endocarditis?]. 2015 , 41, 446-7		
1733	Levels of atherogenic lipoproteins are unexpectedly reduced in interstitial fluid from type 2 diabetes patients. 2015 , 56, 1633-9		3
1732	Sociodemographic and diagnostic characteristics of prescribing a second-line lipid-lowering medication: ezetimibe used as initial medication, switch from statins, or add-on medication. 2015 , 71, 1245-54		6
1731	Use of statins is associated with lower serum total and non-sex hormone-binding globulin-bound testosterone levels in male participants of the Rotterdam Study. 2015 , 173, 155-65		23
1730	Statin use and risk of haemorrhagic stroke in a community-based cohort of postmenopausal women: an observational study from the Women's Health Initiative. 2015 , 5, e007075		4
1729	Statins and their increased risk of inducing diabetes. 2015 , 14, 1835-44		20
1728	Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study. 2015 , 351, h4984		33
1727	Usefulness of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as Predictors of Cardiovascular Disease in Chinese. 2015 , 116, 1063-70		22
1726	A cholesterol-lowering VLP vaccine that targets PCSK9. 2015 , 33, 5747-5755		85
1725	Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab. 2015 , 49, 1327-35		19
1724	Emergency Neurological Life Support: Acute Ischemic Stroke. 2015 , 23 Suppl 2, S94-102		6

1723	Impact of Statins on Physical Activity and Fitness: Ally or Adversary?. 2015 , 90, 1314-9	17
1722	Desiderata for computable representations of electronic health records-driven phenotype algorithms. 2015 , 22, 1220-30	75
1721	Keys to long-term care of the liver transplant recipient. 2015 , 12, 639-48	35
1720	Evaluating the Heart Through the Breasts: A Feasible Strategy?. 2015 , 24, 787-8	
1719	Prevalence and incidence of dyslipidaemia among adults in Africa: a systematic review and meta-analysis protocol. 2015 , 5, e007404	9
1718	Applicability and potential clinical effects of 2013 cholesterol guidelines on major cardiovascular events. 2015 , 170, 598-605.e7	7
1717	Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry). 2015 , 116, 547-53	19
1716	Cardiovascular comorbidity in rheumatic diseases. 2015 , 11, 693-704	185
1715	Primary Care of the Human Immunodeficiency Virus Patient. 2015 , 99, 1105-22	8
1714	Prevalence and Implications of Subclinical Coronary Artery Disease in Patients With Atrial Fibrillation. 2015 , 116, 1219-23	18
1713	Perspectives on Cholesterol Guidelines. 2015 , 313-327	
1712	ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study. 2015 , 16, 803-15	23
1711	Are Statins out in the COLD? The STATCOPE Trial. 2015 , 31, 970-3	4
1710	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. 2015 , 38, 1777-803	271
1709	Safety and efficacy of ezetimibe: A meta-analysis. 2015 , 201, 247-52	54
1708	What to Expect From the Evolving Field of Geriatric Cardiology. 2015 , 66, 1286-1299	72
1707	Reverse Epidemiology of Traditional Cardiovascular Risk Factors in the Geriatric Population. 2015 , 16, 933-9	78
1706	Estimating The Potential Impact Of Insurance Expansion On Undiagnosed And Uncontrolled Chronic Conditions. 2015 , 34, 1554-62	19

1705	Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates. 2015 , 88, 1411-1418		15
1704	Current Science on Consumer Use of Mobile Health for Cardiovascular Disease Prevention: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2015 , 132, 1157-213	16.7	333
1703	Detection and treatment of at-risk mental state for developing a first psychosis: making up the balance. 2015 , 2, 825-34		32
1702	Overhauling Cardiovascular Risk Prediction in Primary Prevention: Difficult Journey Worth the Destination. 2015 , 8, 466-8		5
1701	Relationship between different cardiovascular risk scores and measures of subclinical atherosclerosis in an Indian population. 2015 , 67, 332-40		22
1700	Validity of self-report of lipid medication use: the Atherosclerosis Risk in Communities (ARIC) Study. 2015 , 242, 625-9		2
1699	The Atherogenicity of Plant Sterols: The Evidence from Genetics to Clinical Trials. 2015 , 98, 742-749		23
1698	Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities: Task Force 8: Coronary Artery Disease: A Scientific Statement from the American Heart Association and American College of Cardiology. <i>Circulation</i> , 2015 , 132, e310-4	16.7	23
1697	The effect of a low-fat spread with added plant sterols on vascular function markers: results of the Investigating Vascular Function Effects of Plant Sterols (INVEST) study. 2015 , 101, 733-41		38
1696	Markers of chronic kidney disease add predictive value for further cardiovascular events. 2015 , 9, 825-826		
1695	Preventive Cardiology Update: Controversy, Consensus, and Future Promise. 2015 , 58, 1-2		2
1694	Association between higher rates of cardioprotective drug use and survival in patients on dialysis. 2015 , 11, 824-43		6
1693	An evaluation of alirocumab for the treatment of hypercholesterolemia. 2015 , 13, 1307-23		15
1692	LDL cholesterol levels and thin cap fibroatheromas: A dynamic and complex puzzle. 2015 , 243, 179-80		
1691	Validation of the Pooled Cohort equations in a long-term cohort study of Hong Kong Chinese. 2015 , 9, 640-6.e2		27
1690	Statin allergy: Clinical experience and structural relation as a framework for evaluation. 2015 , 3, 993-5		3
1689	Patient-reported outcomes to initiate a provider-patient dialog for the management of hip and knee osteoarthritis. 2015 , 45, 123-31		9
1688	[Benefits and risks for primary prevention with statins in the elderly]. 2015 , 44, 1219-25		2

1687	Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy. 2015 , 4,	30
1686	Sex-specific differential in risk of diabetes-related macrovascular outcomes. 2015 , 15, 85	12
1685	The effect of rosuvastatin on low-density lipoprotein subfractions in patients with impaired fasting glucose. 2015 , 20, 276-83	7
1684	Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial. 2015 , 278, 59-67	35
1683	Statins in the elderly: a patient-focused approach. 2015 , 38, 56-61	32
1682	[Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology position statement on dyslipidemia management. Differences between the European and American guidelines]. 2015 , 27, 36-44	2
1681	Rheumatoid Arthritis, a New Focus on Cardiovascular Risk. 2015 , 11, 129-130	
1680	Treatment options for symptomatic carotid stenosis: timing and approach. 2015 , 13, 44-51	6
1679	KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD. 2015 , 65, 354-66	73
1678	Effects of cardiac medications for patients with obstructive coronary artery disease by coronary computed tomographic angiography: results from the multicenter CONFIRM registry. 2015 , 238, 119-25	8
1677	Heterogeneity in statin indications within the 2013 american college of cardiology/american heart association guidelines. 2015 , 115, 27-33	1
1676	The significance of circulating endothelin-1 as a predictor of coronary artery disease status and clinical outcomes following coronary artery catheterization. 2015 , 24, 19-25	21
1675	Pharmacists role in cholesterol management: addressing challenges and barriers. 2015 , 28, 35-43	1
1674	Stroke: LDL and stroke risk—clinical practice or target practice?. 2015 , 11, 8-9	4
1673	Critical limb ischemia. 2015 , 33, 37-47	26
1672	Renal artery stenosis. 2015 , 33, 59-73	16
1671	Understanding Medical Literature. 2015 , 4, 106-127	
1670	Non-traditional dosing of statins in statin-intolerant patients—is it worth a try?. 2015 , 17, 475	12

1669	Statins and male sexual health: a retrospective cohort analysis. 2015 , 12, 158-67	14
1668	Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10?. 2015 , 17, 472	25
1667	Screening and treatment by the primary care provider of common diabetes complications. 2015 , 99, 201-19	13
1666	Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database. 2015 , 15, 27-34	12
1665	Contrasting Cholesterol Management Guidelines for Adults with CKD. 2015 , 26, 1173-80	46
1664	Statins and delirium: is there a role?. 2015 , 17, 470	4
1663	The Role of Statins in Preventing Contrast-Induced Acute Kidney Injury: A Narrative Review. 2015 , 66, 701-7	13
1662	Uric acid promotes chemokine and adhesion molecule production in vascular endothelium via nuclear factor-kappa B signaling. 2015 , 25, 187-94	40
1661	Do clinicians recommend aspirin to patients for primary prevention of cardiovascular disease?. 2015 , 30, 155-60	9
1660	What Is the Appropriate Duration of High-Dose Atorvastatin Therapy Post-Acute Coronary Syndrome?. 2015 , 28, 555-60	1
1659	Adverse effects of androgen deprivation therapy and strategies to mitigate them. 2015 , 67, 825-36	394
1658	Defining cardiovascular risk in diabetes: the emerging role of troponin assays. 2016 , 2, 37-37	1
1657	Drug treatment of dyslipidemia. 2016 , 59, 366	6
1656	Therapeutic Strategies and Health Costs of Patients Admitted for a Cardiovascular Event in Italy. 2016 , 3, GRHTA.5000221	3
1655	Eligibility for Statin Treatment in Korean Subjects with Reduced Renal Function: An Observational Study. 2016 , 31, 402-409	4
1654	Chancen und Risiken von e-Health in der Labormedizin. 2016 , 40,	4
1653	Cardiovascular risk assessment in rheumatoid arthritis - controversies and the new approach. 2016 , 54, 128-35	12
1652	New concept of treatment guideline of dyslipidemia. 2016 , 59, 349	

1651	In Search of an Optimal Target Level of Low Density Lipoprotein Cholesterol for Secondary Prevention Among the Japanese Population. 2016 , 23, 397-8	1
1650	Maintenance of Clinical Endpoints After Discharge from a Pharmacist-Managed Risk Reduction Clinic at a Veterans Affairs Medical Center. 2016 , 22, 14-20	1
1649	Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention. 2016 , 8, 45-50	2
1648	Vascular Pathobiology. 2016 , 85-124	6
1647	Clinical Inertia in the Management of Hypercholesterolemia: What Clinicians Need to do. 2016 , 23, 552-3	3
1646	PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. 2016 , 12, 185-97	11
1645	Relationship between Non-High-Density Lipoprotein Cholesterol and Low-Density Lipoprotein Cholesterol in the General Population. 2016 , 23, 477-90	21
1644	Overview of guidelines for the management of dyslipidemia: EU perspectives. 2016 , 12, 357-369	11
1643	Economic Evaluation of Rosuvastatin and Atorvastatin for the Treatment of Dyslipidemia from a Korean Health System Perspective. 2016 , 5, 61	1
1642	Treatment of Homozygous Familial Hypercholesterolemia: Challenges and Latest Development. 2016 ,	
1641	Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. 2016 , 15, 8-14	21
1640	Absolute risk of cardiovascular disease events, and blood pressure- and lipid-lowering therapy in Australia. 2016 , 204, 320	50
1639	Stabilization of high-risk plaques. 2016 , 6, 304-21	8
1638	Multiprofessional Treatment of High Blood Pressure in Very Elderly Patients. 2017 , 108, 53-59	3
1637	Impact of the 2013 Cholesterol Guideline on Patterns of Lipid-Lowering Treatment in Patients with Atherosclerotic Cardiovascular Disease or Diabetes After 1 Year. 2016 , 22, 901-8	22
1636	Comparing the Trend of Physical Activity and Caloric Intake between Lipid-Lowering Drug Users and Nonusers among Adults with Dyslipidemia: Korean National Health and Nutrition Examination Surveys (2010-2013). 2016 , 37, 105-10	1
1635	Rationale and Design of the PROSPECTIVE Trial: Probuocol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease. 2016 , 23, 746-56	12
1634	Large Artery Occlusive Disease. 2016 ,	

1633	2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation). 2016 , 46, 275-306	79
1632	Statin Therapy Alters Lipid Storage in Diabetic Skeletal Muscle. 2016 , 7, 95	3
1631	Statin prescription initiation and lifestyle behaviour: a primary care cohort study. 2016 , 17, 77	6
1630	Clinician time used for decision making: a best case workflow study using cardiovascular risk assessments and Ask Mayo Expert algorithmic care process models. 2016 , 16, 96	6
1629	Beneficial Effects of Exercise-Based Cardiac Rehabilitation on High-Density Lipoprotein-Mediated Cholesterol Efflux Capacity in Patients with Acute Coronary Syndrome. 2016 , 23, 865-77	15
1628	[Programs for Continuing Medical Education: B session; 1. Pathogenesis of atherosclerosis and an approach to reduce cardiovascular events]. 2016 , 105, 471-6	
1627	Disentangling the Association between Statins, Cholesterol, and Colorectal Cancer: A Nested Case-Control Study. 2016 , 13, e1002007	35
1626	A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy. 2016 , 11, e0146222	7
1625	Diabetic Cardiovascular Autonomic Neuropathy Predicts Recurrent Cardiovascular Diseases in Patients with Type 2 Diabetes. 2016 , 11, e0164807	25
1624	Survival Benefits of Statins for Primary Prevention: A Cohort Study. 2016 , 11, e0166847	4
1623	Relationship between Statin Utilization and Socioeconomic Deprivation in Hungary. 2016 , 7, 66	16
1622	Wide Variation in Absolute Cardiovascular Risk Assessment in Aboriginal and Torres Strait Islander People with Type 2 Diabetes. 2016 , 4, 37	7
1621	Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study). 2016 , 9, 347-353	6
1620	Management of intracerebral hemorrhage--use of statins. 2016 , 12, 153-61	11
1619	A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab. 2016 , 22, 641-653q	30
1618	The Relationships Between the Arterial Stiffness Index Measured at the Radial Artery and Left Ventricular Diastolic Dysfunction in Asymptomatic High Risk Patients Without Atherosclerotic Cardiovascular Disease. 2016 , 57, 73-9	4
1617	Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies. 2016 , 8, 201-10	31
1616	Do statins really cause diabetes? A meta-analysis of major randomized controlled clinical trials. 2016 , 37, 1051-60	9

1615	Diabetes Mellitus and Intestinal Niemann-Pick C1Like 1 Gene Expression. 2016 , 277-290	1
1614	Appropriate Level of Low-Density Lipoprotein Cholesterol for Secondary Prevention of Coronary Artery Disease. 2016 , 23, 413-21	6
1613	Editorial: collecting new external evidence for cholesterol management. 2016 , 23, 121-3	
1612	Statins to improve cardiovascular outcomes in treated HIV infection. 2016 , 29, 1-9	22
1611	Statin myopathy: over-rated and under-treated?. 2016 , 31, 417-25	6
1610	Statins accelerate disease progression and shorten survival in SOD1(G93A) mice. 2016 , 54, 284-91	16
1609	Should apolipoprotein B replace LDL cholesterol as therapeutic targets are lowered?. 2016 , 27, 359-66	10
1608	Effect of Statin Therapy on Mortality in Older Adults Hospitalized with Coronary Artery Disease: A Propensity-Adjusted Analysis. 2016 , 64, 1475-9	18
1607	Algorithms to Identify Statin Intolerance in Medicare Administrative Claim Data. 2016 , 30, 525-533	21
1606	Personalized Prediction of Psychosis: External Validation of the NAPLS-2 Psychosis Risk Calculator With the EDIPPP Project. 2016 , 173, 989-996	112
1605	High-dose statin therapy and risk of intracerebral hemorrhage: a meta-analysis. 2016 , 134, 22-8	34
1604	Risk prediction of major complications in individuals with diabetes: the Atherosclerosis Risk in Communities Study. 2016 , 18, 899-906	8
1603	Plasma cholesterol is related to menstrual status in adolescent girls with eating disorders and weight loss. 2016 , 105, 317-23	1
1602	Quality of care in patients with diabetic kidney disease in Asia: The Joint Asia Diabetes Evaluation (JADE) Registry. 2016 , 33, 1230-9	23
1601	Open-label randomized non-inferiority trial of a fixed-dose combination of glimepiride and atorvastatin for the treatment of people whose Type 2 diabetes is uncontrolled on metformin. 2016 , 33, 1084-93	1
1600	WITHDRAWN: Preoperative statin therapy for patients undergoing cardiac surgery. 2016 , CD008493	1
1599	Should we reconsider the role of age in treatment allocation for primary prevention of cardiovascular disease?. 2017 , 38, 1542-1547	14
1598	Enough Evidence, Time to Act!. <i>Circulation</i> , 2016 , 134, 20-3	16.7 1

1597	The role of neuropeptide Y in the pathophysiology of atherosclerotic cardiovascular disease. 2016 , 220, 235-41	26
1596	Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use. 2016 , 25, 827-35	26
1595	Moving the goalposts - towards cardiovascular prevention. 2016 , 70, 429-31	
1594	Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight. 2016 , 26, 767-72	9
1593	Lipoprotein subfraction cholesterol distribution is more atherogenic in insulin resistant adolescents with type 1 diabetes. 2016 , 17, 257-65	20
1592	The metabolic syndrome and ED. 2016 , 109-119	1
1591	Stable Coronary Artery Disease. 2016 , 138-147	
1590	Global Risk Assessment and Coronary Artery Calcium Scoring in Low-Intermediate Risk Women: What Is a Picture Really Worth?. 2016 , 9, e004817	
1589	Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. 2016 , 7, 13457	161
1588	Serum cholesterol levels, HMG-CoA reductase inhibitors and the risk of intracerebral haemorrhage. The Multicenter Study on Cerebral Haemorrhage in Italy (MUCH-Italy). 2016 , 87, 924-9	22
1587	[Statins Use in Elderly Patients]. 2015 ,	1
1586	Secondary prevention after coronary artery bypass graft surgery: a primer. 2016 , 31, 635-643	19
1585	2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. 2016 , 34, 1887-920	582
1584	Statin adherence and risk of acute cardiovascular events among women: a cohort study accounting for time-dependent confounding affected by previous adherence. 2016 , 6, e011306	15
1583	The Prevalence of Atherosclerosis in Those with Inflammatory Connective Tissue Disease by Race, Age, and Traditional Risk Factors. 2016 , 6, 20303	30
1582	Short-term Changes in Gal 3 Circulating Levels After Acute Myocardial Infarction. 2016 , 47, 521-525	32
1581	IMPROVEMENTS IN METABOLIC CONTROL IN ADULTS WITH TYPE 2 DIABETES FOLLOWING REFERRAL TO A DIABETES CENTER, 2005-2010. 2016 , 22, 689-98	
1580	Looking Beyond Statins: Will the Dollars Make Sense?. <i>Circulation</i> , 2016 , 134, 1944-1947	16.7 1

1579	Effectiveness of a Multicomponent Quality Improvement Strategy to Improve Achievement of Diabetes Care Goals: A Randomized, Controlled Trial. 2016 , 165, 399-408	59
1578	Interventions to improve adherence to lipid-lowering medication. 2016 , 12, CD004371	34
1577	Diabetic Dyslipidemia and Risk of Cardiovascular Disease. 2016 , 643-652	
1576	Remission of pre-diabetes to normal glucose tolerance in obese adults with high protein versus high carbohydrate diet: randomized control trial. 2016 , 4, e000258	24
1575	Statins Improve Long Term Patency of Arteriovenous Fistula for Hemodialysis. 2016 , 6, 22197	22
1574	Cardiovascular risk prediction in people with chronic kidney disease. 2016 , 25, 518-523	21
1573	The future of lipid guidelines. 2016 , 27, 585-591	2
1572	Evaluation of statin prescriptions in type 2 diabetes: India Heart Watch-2. 2016 , 4, e000275	15
1571	Prevention and screening. 2016 , 46-57	
1570	Diabetes mellitus in the older adult. 2016 , 421-435	
1569	Lipid management in older patients. 2016 , 436-445	
1568	Socioeconomic Inequalities in Statin Adherence Under Universal Coverage: Does Sex Matter?. 2016 , 9, 704-713	18
1567	Access to Evidence-Based Statins in Low-Cost Generic Drug Programs. 2016 , 9, 785-787	1
1566	Cardiovascular risk in systemic lupus erythematosus. 2016 , 23, 242-249	
1565	Can cardiovascular disease guidelines that advise treatment decisions based on absolute risk be improved?. 2016 , 16, 221	2
1564	Principles of Transgender Medicine and Surgery. 2016 ,	33
1563	Delphi consensus on the diagnosis and management of dyslipidaemia in chronic kidney disease patients: A post hoc analysis of the DIANA study. 2016 , 36, 679-686	
1562	Efficacy and safety of Yirui capsule in patients with hyperlipidemia: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial. 2016 , 17, 291	2

1561	Preventing and Experiencing Ischemic Heart Disease as a Woman: State of the Science: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2016 , 133, 1302-31	16.7	151
1560	Metabolic Profiles Based on the 2013 Prevention Guidelines. 2016 , 83-88		
1559	More HOPE for Prevention with Statins. 2016 , 374, 2085-7		11
1558	Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2015. 2016 , 129, 879.e13-8		1
1557	Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. 2016 , 67, 2578-89		458
1556	Increases in plasma plant sterols stabilize within four weeks of plant sterol intake and are independent of cholesterol metabolism. 2016 , 26, 302-9		15
1555	Nonutilization of Statins in a Community-based Population with a History of Coronary Revascularization. 2016 , 38, 288-296.e2		4
1554	Maximum Low-density Lipoprotein Cholesterol Lowering Capacity Achievable With Drug Combinations. When 50 Plus 20 Equals 60. 2016 , 69, 342-3		3
1553	[PCSK9 inhibitors : New treatment option in clinical practice]. 2016 , 41, 290-5		2
1552	A non-hypocholesterolemic atorvastatin treatment improves vessel elasticity by acting on elastin composition in WHHL rabbits. 2016 , 251, 70-77		9
1551	A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. 2016 , 10, 472-89		154
1550	Cardiovascular Disease in Women: Primary and Secondary Cardiovascular Disease Prevention. 2016 , 43, 265-85		3
1549	HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. 2016 , 39, 1424-30		25
1548	Discontinuation of Statins: What Are the Risks?. 2016 , 18, 41		8
1547	Modulating cholesterol efflux capacity to improve cardiovascular disease. 2016 , 27, 398-407		31
1546	Un paso más allén la prevención secundaria del riesgo cardiovascular. Documento de consenso del uso clínico del policomprimido. 2016 , 69, 547-550		14
1545	Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk. 2016 , 18, 65		12
1544	A Step Ahead in Secondary Prevention of Cardiovascular Risk. Consensus Document on Clinical Use of the Polypill. 2016 , 69, 547-50		1

1543	Does statin use cause memory decline in the elderly?. 2016 , 26, 550-65	18
1542	Prevention: HOPE-3 trial - targeting BP and LDL-C in at-risk patients. 2016 , 13, 315-6	2
1541	Three-dimensional morphological response of lipid-rich coronary plaques to statin therapy: a serial optical coherence tomography study. 2016 , 27, 350-6	8
1540	Impact of incident diabetes on atherosclerotic cardiovascular disease according to statin use history among postmenopausal women. 2016 , 31, 747-61	4
1539	Coronary-Artery Bypass Grafting. 2016 , 374, 1954-64	101
1538	Statin-centered treatment of dyslipidemia. New evidence-based paradigm, or only part of the evidence?. 2016 , 63, 1-3	2
1537	Viejos y nuevos hipolipemiantes. 2016 , 23, 172-184	
1536	Consensus between the American College of Cardiology and the National Lipid Association on the use of non-statin therapy for atherosclerotic cardiovascular disease prevention. 2016 , 10, 458-61	1
1535	The Pooled Cohort Equations for Predicting Risk of Myocardial Infarction and Stroke: Validated in Representative Natural History Populations. 2016 , 91, 692-4	2
1534	Diabetic microvascular complications as simple indicators of risk for cardiovascular outcomes and heart failure. 2016 , 4, 555-6	3
1533	Statin intolerance in a referral lipid clinic. 2016 , 10, 870-879.e3	10
1532	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. 2016 , 12, 467-84	22
1531	Statin use prior to first myocardial infarction in contemporary patients: Inefficient and not gender equitable. 2016 , 83, 63-9	9
1530	Predictors of cholesterol treatment discussions and statin prescribing for primary cardiovascular disease prevention in community health centers. 2016 , 88, 176-81	5
1529	Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. 2016 , 4, 588-97	118
1528	Screening for Asymptomatic Carotid Plaques with Ultrasound. 2016 , 52, 309-12	11
1527	Association of Blood Glucose Control and Lipids With Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT). 2016 , 39, 816-22	8
1526	Seguir la gu de reducci del riesgo cardiovascular con estatinas. 2016 , 33, 38-43	

1525	An Update on the Utility of Coronary Artery Calcium Scoring for Coronary Heart Disease and Cardiovascular Disease Risk Prediction. 2016 , 18, 13	12
1524	Recent Insights Into Cardiovascular Disease (CVD) Risk Among HIV-Infected Adults. 2016 , 13, 44-52	33
1523	Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. 2016 , 244, 138-46	150
1522	Máxima reducción de colesterol unido a lipoproteínas de baja densidad alcanzable con combinaciones farmacológicas. Cuando 50 mg + 20 suma 60. 2016 , 69, 342-343	16
1521	Global cardiovascular protection in chronic kidney disease. 2016 , 13, 603-8	24
1520	Applicability of the 2013 ACC/AHA Risk Assessment and Cholesterol Treatment Guidelines in the real world: results from a multiethnic case-control study. 2016 , 48, 282-92	2
1519	Diabetes Dyslipidemia. 2016 , 7, 203-19	171
1518	Coronary CT Angiography Versus Standard Emergency Department Evaluation for Acute Chest Pain and Diabetic Patients: Is There Benefit With Early Coronary CT Angiography? Results of the Randomized Comparative Effectiveness ROMICAT II Trial. 2016 , 5, e003137	15
1517	Statin and Aspirin Use Among Hispanic and Latino Adults at High Cardiovascular Risk: Findings From the Hispanic Community Health Study/Study of Latinos. 2016 , 5, e002905	11
1516	Biochemistry of Statins. 2016 , 73, 127-68	16
1515	Statin combination therapy and cardiovascular risk reduction. 2016 , 12, 289-315	9
1514	Cardiovascular Disease in Women: Clinical Perspectives. 2016 , 118, 1273-93	435
1513	Stroke Symptoms as a Predictor of Future Hospitalization. 2016 , 25, 702-9	6
1512	Moving Toward the Next Paradigm for Cardiovascular Prevention. <i>Circulation</i> , 2016 , 133, 1533-6	16.7 18
1511	Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA]). 2016 , 117, 1921-7	31
1510	Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements. 2016 , 12, 261-8	5
1509	Statin prescribing among hypertensive patients in southwest Nigeria: findings and implications for the future. 2016 , 5, 281-8	8
1508	Primary Prevention of Cardiovascular Disease in Older Adults. 2016 , 32, 1074-81	14

1507	LDL-cholesterol targets: perspectives for the use of PCSK9 inhibitors. 2016 , 37, 1337-40		2
1506	Developing and evaluating polygenic risk prediction models for stratified disease prevention. 2016 , 17, 392-406		338
1505	Recent Update to the US Cholesterol Treatment Guidelines: A Comparison With International Guidelines. <i>Circulation</i> , 2016 , 133, 1795-806	16.7	69
1504	Antiplatelet Management for Coronary Heart Disease: Advances and Challenges. 2016 , 18, 35		12
1503	Evidence-Based Policy Making: Assessment of the American Heart Association's Strategic Policy Portfolio: A Policy Statement From the American Heart Association. <i>Circulation</i> , 2016 , 133, e615-53	16.7	24
1502	DISLIPIDEMIA DIABETICA. 2016 , 27, 152-159		4
1501	Diagnostic testing to evaluate ischemic symptoms in women. 2016 , 12, 267-70		
1500	Predicting the Benefit of Statins in Patients With Diabetes Mellitus: A Case of Perfect Being the Enemy of Good?. 2016 , 9, 191-3		1
1499	2013 ACC/AHA Cholesterol Guideline Versus 2004 NCEP ATP III Guideline in the Prediction of Coronary Artery Calcification Progression in a Korean Population. 2016 , 5,		11
1498	Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke. 2016 , 181, 130-136		15
1497	Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. 2016 , 37, 3588-3595		135
1496	Cardiovascular Outcomes Associated with Lowering Low-density Lipoprotein Cholesterol in Rheumatoid Arthritis and Matched Nonrheumatoid Arthritis. 2016 , 43, 1989-1996		20
1495	Statins for aortic valve stenosis. 2016 , 9, CD009571		10
1494	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). 2016 , 253, 281-344		519
1493	Relation of Statin Use and Mortality in Community-Dwelling Frail Older Patients With Coronary Artery Disease. 2016 , 118, 1624-1630		37
1492	Exploring cardiovascular disease risk evaluation in patients with inflammatory joint diseases. 2016 , 223, 331-336		22
1491	Employing an optimized spray-drying process to produce ezetimibe tablets with an improved dissolution profile. 2016 , 46, 583-592		13
1490	Clinical considerations of lipid target and goal in dyslipidemia control. 2016 , 2, 3-6		1

1489	The 2013 cholesterol guideline controversy: Would better evidence prevent pharmaceuticalization?. 2016 , 120, 797-808	8
1488	Impact of statin therapy on long-term clinical outcomes of vasospastic angina without significant stenosis: A propensity-score matched analysis. 2016 , 223, 791-796	8
1487	Comment on Modifying Effect of Body Mass Index on Survival in Elderly Type 2 Diabetic Patients: Hong Kong Diabetes Registry and Reverse Epidemiology of Traditional Cardiovascular Risk Factors in the Geriatric Population. 2016 , 17, 561-2	
1486	New lipid therapies: PCSK9 inhibitors. 2016 , 2, 23-26	
1485	Comparison of serum lipid management between elderly and non-elderly patients with and without coronary heart disease (CHD). 2016 , 4, 192-8	3
1484	Age-Dependent Predictive Value of Endothelial Dysfunction for Arrhythmia Recurrence Following Pulmonary Vein Isolation. 2016 , 5,	7
1483	Re: 'Long-term Mortality in Patients with Asymptomatic Carotid Stenosis: Implications for Statin Therapy'. 2016 , 52, 395	1
1482	Delphi consensus on the diagnosis and management of dyslipidaemia in chronic kidney disease patients: A post hoc analysis of the DIANA study. 2016 , 36, 679-686	0
1481	Riesgo cardiovascular en lupus eritematoso sistémico. 2016 , 23, 242-249	2
1480	Assessing Level of Agreement for Atherosclerotic Cardiovascular Disease Risk Categorization Between Coronary Artery Calcium Score and the American College of Cardiology/American Heart Association Cardiovascular Prevention Guidelines and the Potential Impact on Treatment Recommendations. 2016 , 118, 1480-1485	4
1479	The effect of the intensity of lipid-lowering medications on the LDL cholesterol treatment goals of Asian patients with dyslipidaemia in primary care. 2016 , 41, 677-683	4
1478	Fibromyalgia is associated to receiving chronic medications beyond appropriateness: a cross-sectional study. 2016 , 36, 1691-1699	5
1477	The Risk of Achilles or Biceps Tendon Rupture in New Statin Users: A Propensity Score-Matched Sequential Cohort Study. 2016 , 39, 1229-1237	11
1476	Statins in Primary Prevention: Uncertainties and Gaps in Randomized Trial Data. 2016 , 16, 407-418	3
1475	Pharmacist prescribing practices in a clinical pharmacy cardiac risk service. 2016 , 73, 1442-50	7
1474	Statin Adherence: Does Gender Matter?. 2016 , 18, 63	26
1473	Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome. 2016 , 18, 76	33
1472	Validation of the european SCORE risk chart in the healthy middle-aged Japanese. 2016 , 252, 116-121	6

1471	Are We Ready for Routine 'Subclinical' Atherosclerosis Screening? Not Yet [2016, 52, 313-6	2
1470	[Not Available]. 2016, 48 Suppl 1, 4-26	5
1469	Retinal Vessel Calibers in Predicting Long-Term Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study. <i>Circulation</i> , 2016, 134, 1328-1338	16.7 121
1468	[Introduction of PCSK9 inhibitors : New perspectives in treatment and practical implementation]. 2016, 41, 307-12	2
1467	Genomic prediction of coronary heart disease. 2016, 37, 3267-3278	184
1466	Blood-Pressure and Cholesterol Lowering in the HOPE-3 Trial. 2016, 375, 1193-4	5
1465	Rationale and design of the Study of a Tele-pharmacy Intervention for Chronic diseases to Improve Treatment adherence (STIC2IT): A cluster-randomized pragmatic trial. 2016, 180, 90-7	16
1464	Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease. 2016, 6, 8-14	23
1463	Impact of Replacing the Pooled Cohort Equation With Other Cardiovascular Disease Risk Scores on Atherosclerotic Cardiovascular Disease Risk Assessment (from the Multi-Ethnic Study of Atherosclerosis [MESA]). 2016, 118, 691-6	13
1462	Advances in Lipid Therapy: The Role of Lipid Treatment in Women in Primary Prevention. 2016, 59, 178-189	4
1461	Statin Intolerance: A Literature Review and Management Strategies. 2016, 59, 153-164	49
1460	Relation of longitudinal changes in body mass index with atherosclerotic cardiovascular disease risk scores in middle-aged black and white adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. 2016, 26, 521-526	4
1459	Stenting versus Surgery for Carotid Stenosis. 2016, 375, 603-4	
1458	Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resin. 2016, 252, 82-87	7
1457	Statin Use and Its Facility-Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database. 2016, 39, 185-91	31
1456	Implications of the New US Cholesterol Guidelines in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). 2016, 39, 215-22	4
1455	Initiation patterns of statin therapy among adult patients undergoing intermediate to high-risk non-cardiac surgery. 2016, 25, 64-72	3
1454	Analysis and comparison of statin prescription patterns and outcomes according to clinical department. 2016, 41, 70-7	15

1453	Statin-related aminotransferase elevation according to baseline aminotransferases level in real practice in Korea. 2016 , 41, 266-72	13
1452	Effect of Vascular Risk Factors and Diseases on Mortality in Individuals with Dementia: A Systematic Review and Meta-Analysis. 2016 , 64, 37-46	23
1451	Lipoprotein(a) and Increased Cardiovascular Risk in Women. 2016 , 39, 96-102	9
1450	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. 2016 , 37, 2999-3058	1781
1449	Preventing Atherosclerotic Cardiovascular Disease Using American College of Cardiology and American Heart Association Prevention Guidelines: Some Good News, But Caveats Remain. 2016 , 5,	5
1448	Diagnosis and treatment of high density lipoprotein deficiency. 2016 , 59, 97-106	45
1447	Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. 2016 , 23, 217-30	18
1446	Effect of visit-to-visit blood pressure variability on cardiovascular events in patients with coronary artery disease and well-controlled blood pressure. 2016 , 10, 799-810	9
1445	Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. 2016 , 180, 22-8	23
1444	The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in Coronary Artery Disease Patients with Type 2 Diabetes Mellitus: Rationale and Design of RosCal Study. 2016 , 36, 1023-1029	4
1443	The Influence of Statin Therapy on Restenosis in Patients Who Underwent Nitinol Stent Implantation for de Novo Femoropopliteal Artery Disease: Two-Year Follow-up at a Single Center. 2016 , 27, 1494-501	10
1442	2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals. 2016 , 5,	19
1441	Synthetic High-Density Lipoprotein (sHDL) Inhibits Steroid Production in HAC15 Adrenal Cells. 2016 , 157, 3122-9	3
1440	What the Latest Evidence Tells Us About Fat and Cardiovascular Health. 2016 , 29, 171-5	3
1439	Effect of Tai Chi exercise on blood lipid profiles: a meta-analysis of randomized controlled trials. 2016 , 17, 640-8	14
1438	Primary Prevention of Stroke. 2016 , 316, 658-9	11
1437	Hypolipidemic drugs in elderly subjects: Indications and limits. 2016 , 26, 1064-1070	4
1436	Effect of inter-individual blood pressure variability on the progression of atherosclerosis in carotid and coronary arteries: a post hoc analysis of the NORMALISE and PREVENT studies. 2017 , 3, 82-89	15

1435	HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015). 2016 , 26, 1257-1272	16
1434	Caution is Needed in Designing Pharmacy Coverage. 2016 , 5,	
1433	Efficacy and safety of different doses of evolocumab in reducing low-density lipoprotein cholesterol levels: A meta-analysis. 2016 , 5, 541-547	4
1432	Introduction: What Have We Learned Since the 2013 ACC/AHA Guidelines?. 2016 , 118, 1A-3A	2
1431	ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study. 2017 , 38, 586-594	36
1430	Non-High-Density Lipoprotein Cholesterol Levels on the Risk of Asymptomatic Intracranial Arterial Stenosis: A Result from the APAC Study. 2016 , 6, 37410	8
1429	[ECS guidelines 2016 - dyslipidaemias]. 2016 , 41, 671-676	2
1428	Statin Adherence After Ischemic Stroke or Transient Ischemic Attack Is Associated With Clinical Outcome. 2016 , 80, 731-7	26
1427	Systemic Inflammation Is Associated With Coronary Artery Calcification and All-Cause Mortality in Chronic Kidney Disease. 2016 , 80, 1644-52	18
1426	Effects of 4 Statins on Regression of Coronary Plaque in Acute Coronary Syndrome. 2016 , 80, 1634-43	12
1425	Patient Perceptions About Prediabetes and Preferences for Diabetes Prevention. 2016 , 42, 667-677	23
1424	Coronary atheroma progression rates in men and women following high-intensity statin therapy: A pooled analysis of REVERSAL, ASTEROID and SATURN. 2016 , 254, 78-84	16
1423	New Eyes on Lipids and Lipoproteins. 2016 , 59, 95-96	1
1422	Risk factors for lack of statin therapy in patients with diabetes and coronary artery disease. 2016 , 10, 1406-1413	6
1421	A Contemporary Estimate of Total Mortality and Cardiovascular Disease Risk in Young Adults With Type 1 Diabetes: The Pittsburgh Epidemiology of Diabetes Complications Study. 2016 , 39, 2296-2303	60
1420	Personalizing Treatment: Between Primary and Secondary Prevention. 2016 , 118, 4A-12A	10
1419	Interpretation of the evidence for the efficacy and safety of statin therapy. 2016 , 388, 2532-2561	961
1418	Practice-Level Variation in Statin Use Among Patients With Diabetes: Insights From the PINNACLE Registry. 2016 , 68, 1368-9	34

1417	Enhanced P-selectin expression on platelet—a marker of platelet activation, in young patients with angiographically proven coronary artery disease. 2016 , 419, 125-33	20
1416	'Should we reconsider the role of age in treatment allocation for primary prevention of cardiovascular disease?' No, but we can improve risk communication metrics. 2017 , 38, 1548-1552	9
1415	Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice. 2016 , 128 Suppl 1, 31-9	4
1414	Nuts and their co-products: The impact of processing (roasting) on phenolics, bioavailability, and health benefits [A comprehensive review. 2016 , 26, 88-122	95
1413	Oxidized Low-Density Lipoprotein-β-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease. 2016 , 118, 673-8	9
1412	Efficacy of high intensity atorvastatin versus moderate intensity atorvastatin for acute coronary syndrome patients with diabetes mellitus. 2016 , 222, 22-26	11
1411	Impact of Statin Use After Heart Transplantation: A Meta-Analysis. 2016 , 9,	32
1410	Effects of a Health-Partner Intervention on Cardiovascular Risk. 2016 , 5,	13
1409	Complicaciones macrovasculares de la diabetes. Evaluación del riesgo cardiovascular y objetivos terapéuticos. Estrategias de prevención y tratamiento. 2016 , 12, 947-957	1
1408	Estratificación del riesgo cardiovascular en el paciente con diabetes. Utilidad de los marcadores de aterosclerosis subclínica. 2016 , 12, 991-994	
1407	Cardiovascular risk prevention and all-cause mortality in primary care patients with an abdominal aortic aneurysm. 2016 , 103, 1626-1633	34
1406	Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date. 2016 , 70, 886-897	14
1405	Using human genetics to discover new therapeutic targets for plasma lipids. 2016 , 280, 487-495	3
1404	Prevalence and Prognostic Implications of Coronary Artery Calcification in Low-Risk Women: A Meta-analysis. 2016 , 316, 2126-2134	79
1403	Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2016 , 134, e535-e578	16.7 164
1402	Effect of selected clinical trial publication on adjunctive nonstatin medication prescribing in the Veterans Health Administration system. 2016 , 73, S141-S147	
1401	Trends in Nonlipid Cardiovascular Disease Risk Factor Management in the Women's Interagency HIV Study and Association with Adherence to Antiretroviral Therapy. 2016 , 30, 445-454	13
1400	Statins for Primary Prevention: The Debate Is Intense, but the Data Are Weak. 2016 , 316, 1979-1981	34

1399	Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence. 2016 , 316, 1971-1972	50
1398	Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. 2016 , 316, 1997-2007	343
1397	Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease. 2016 , 18, 69	9
1396	The effect of a nurse-led telephone-based care coordination program on the follow-up and control of cardiovascular risk factors in patients with coronary artery disease. 2016 , 28, 758-763	4
1395	Risk stratification of atherosclerotic cardiovascular disease in Chinese adults. 2016 , 2, 102-109	8
1394	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRs). 2017 , 19, 190-225	44
1393	Inflammatory markers and cardiovascular risks among overweight-obese Emirati women. 2016 , 9, 355	3
1392	Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs. 2016 , 9, 348-54	3
1391	Transitions in Metabolic Risk and Long-Term Cardiovascular Health: Coronary Artery Risk Development in Young Adults (CARDIA) Study. 2016 , 5,	21
1390	Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2016 , 134, e468-e495	16.7 129
1389	Prognostic Value of Coronary Artery Calcium Score in Acute Chest Pain Patients Without Known Coronary Artery Disease: Systematic Review and Meta-analysis. 2016 , 68, 659-670	20
1388	Effects of plant stanol or sterol-enriched diets on lipid profiles in patients treated with statins: systematic review and meta-analysis. 2016 , 6, 31337	24
1387	Clinical Utility of Multimarker Genetic Risk Scores for Prediction of Incident Coronary Heart Disease: A Cohort Study Among Over 51 000 Individuals of European Ancestry. 2016 , 9, 531-540	34
1386	Assessment of antioxidant activity, lipid profile, general biochemical and immune system responses of Wistar rats fed with dairy dessert containing <i>Lactobacillus acidophilus</i> La-5. 2016 , 90, 275-280	41
1385	Role of Statins in Glucose Homeostasis and Insulin Resistance. 2016 , 10, 1	1
1384	Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. 2016 , 353, i3283	130
1383	Current and Emerging Uses of Statins in Clinical Therapeutics: A Review. 2016 , 9, 13-29	78
1382	Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. A systematic review and meta-analysis of randomised controlled trials. 2016 , 116, 162-71	24

1381	Using a multiplier of 10-year cardiovascular mortality underestimates cardiovascular risk in younger individuals and women. 2016 , 21, 150	1
1380	Die Verbreitung von Risikofaktoren für Herz-Kreislauf-Erkrankungen in der Bevölkerung. 2016 , 24, 91-94	
1379	Die 2016 ESC/EAS-Leitlinien zur Behandlung von Dyslipidämien. 2016 , 16, 47-49	
1378	Impact of clinical input variable uncertainties on ten-year atherosclerotic cardiovascular disease risk using new pooled cohort equations. 2016 , 16, 165	1
1377	Low use of statins for secondary prevention in primary care: a survey in a northern Swedish population. 2016 , 17, 110	11
1376	Accuracy of Pooled-Cohort Equation and SCORE cardiovascular risk calculators to identify individuals with high coronary atherosclerotic burden - implications for statin treatment. 2016 , 27, 573-9	5
1375	Diagnosis and treatment of familial hypercholesterolemia: The impact of recent guidelines. 2016 , 41, 36-43	1
1374	Altered lipoproteins in patients with systemic lupus erythematosus are associated with augmented oxidative stress: a potential role in atherosclerosis. 2016 , 18, 306	21
1373	Statins and risk for new-onset diabetes mellitus: A real-world cohort study using a clinical research database. 2016 , 95, e5429	16
1372	Management of hypertension and diabetes mellitus by cardiovascular and endocrine physicians: a China registry. 2016 , 34, 1648-53	16
1371	International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK. 2016 , 19, 21487	15
1370	Cardiovascular disease risk by assigned treatment using the 2013 and 1998 obesity guidelines. 2016 , 24, 1554-60	
1369	Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes. 2016 , 39, 1408-15	94
1368	Current State of Value-Based Purchasing Programs. <i>Circulation</i> , 2016 , 133, 2197-205	16.7 94
1367	Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: a retrospective cohort study. 2016 , 16, 13	25
1366	Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications: A joint position statement issued by eight medical societies. 2016 update. 2016 , 128 Suppl 2, S216-28	4
1365	Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature. 2016 , 17, 1041-1053	5
1364	The impact of multiple single day blood pressure readings on cardiovascular risk estimation: The Atherosclerosis Risk in Communities study. 2016 , 23, 1529-36	2

1363	Effect of rosuvastatin on plasma coenzyme Q10 in HIV-infected individuals on antiretroviral therapy. 2016 , 17, 140-6	5
1362	[PCSK9 inhibitors : Recommendations for patient selection]. 2016 , 41, 296-306	2
1361	The Impact of Cardiorespiratory Fitness Levels on the Risk of Developing Atherogenic Dyslipidemia. 2016 , 129, 1060-6	16
1360	Sick Populations and Sick Subpopulations: Reducing Disparities in Cardiovascular Disease Between Blacks and Whites in the United States. <i>Circulation</i> , 2016 , 134, 472-85	16.7 12
1359	What's next for dyslipidemia management? The 2013 ACC/AHA Guidelines, the NLA recommendations, and beyond. 2016 , 56, 284-92	4
1358	Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients. 2016 , 5, 355-64	3
1357	Imaging Atherosclerotic Plaque Calcification: Translating Biology. 2016 , 18, 51	20
1356	Uptake of evidence-based statin therapy among atrial fibrillation patients in China: A report from the CAFR (Chinese Atrial Fibrillation Registry) Study. 2016 , 220, 284-9	3
1355	[In Process Citation]. 2016 , 28 Suppl 1, 1-49	0
1354	Estimated glomerular filtration rate and albuminuria in Korean population evaluated for cardiovascular risk. 2016 , 48, 759-64	1
1353	Circulating Thrombotic Risk Factors in Young Patients with Coronary Artery Disease Who Are on Statins and Anti-platelet Drugs. 2016 , 31, 302-9	4
1352	Indicadores de calidad en patologĳa vascular: estudio piloto multicĳtrico nacional. 2016 , 68, 285-291	
1351	Novel Biomarkers to Improve the Prediction of Cardiovascular Event Risk in Type 2 Diabetes Mellitus. 2016 , 5,	44
1350	Lipid Management Guidelines from the Departments of Veteran Affairs and Defense: A Critique. 2016 , 129, 906-12	5
1349	Consensus statement on the management of dyslipidemia in Indian subjects: Our perspective. 2016 , 68, 238-41	
1348	Subclinical Cardiovascular Disease in Lymphoma Survivors by Sex. 2016 , 45, 438-53	2
1347	Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. 2016 , 30, 305-13	27
1346	Communicating statin evidence to support shared decision-making. 2016 , 17, 41	16

1345	Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate. 2016 , 14, 4		51
1344	Expert opinion: the therapeutic challenges faced by statin intolerance. 2016 , 17, 1497-507		40
1343	Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. <i>Circulation</i> , 2016 , 133, 2459-502	16.7	520
1342	Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions. 2016 , 3, ofw097		24
1341	Identifying familial hypercholesterolemia in acute coronary syndrome. 2016 , 27, 375-81		14
1340	Drug allergies documented in electronic health records of a large healthcare system. 2016 , 71, 1305-13		113
1339	No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy. 2016 , 17, 631-3		7
1338	Rosuvastatin Decreases Mean Platelet Volume in Patients With Diabetes Mellitus. 2016 , 67, 116-20		17
1337	C-reactive protein and serum creatinine, but not haemoglobin A1c, are independent predictors of coronary heart disease risk in non-diabetic Chinese. 2016 , 23, 1339-49		9
1336	Attainment of low-density lipoprotein cholesterol goal after endovascular treatment is associated with reduced cardiovascular events in patients with peripheral arterial disease. 2016 , 63, 756-63		9
1335	Quality markers in cardiology: measures of outcomes and clinical practice--a perspective of the Spanish Society of Cardiology and of Thoracic and Cardiovascular Surgery. 2016 , 37, 12-23		10
1334	Role of Coronary Artery Calcium Score of Zero and Other Negative Risk Markers for Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA). <i>Circulation</i> , 2016 , 133, 849-58	16.7	234
1333	Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey. 2016 , 246, 243-50		121
1332	Update on PCSK9 therapies for the treatment of dyslipidemia. 2016 , 11, 87-95		2
1331	Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. <i>Circulation</i> , 2016 , 133, e38-360	16.7	4504
1330	Statins and myocardial infarction: Type, dose, and administration time: Does it matter?. 2016 , 26, 433-41		4
1329	Healthy lifestyle factors and incident heart disease and mortality in candidates for primary prevention with statin therapy. 2016 , 207, 196-202		35
1328	Cardiovascular risk profile and use of statins at the age of 70 years: a comparison of two Finnish birth cohorts born 20 years apart. 2016 , 45, 84-90		5

1327	A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever. 2016 , 44, 9-20	1
1326	Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists. 2016 , 18, 7	2
1325	Red Raspberries and Their Bioactive Polyphenols: Cardiometabolic and Neuronal Health Links. 2016 , 7, 44-65	89
1324	Prevalence, awareness, treatment, and control of high low-density lipoprotein cholesterol in Brazil: Baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). 2016 , 10, 568-76	19
1323	Prognosis after Stroke. 2016 , 234-252.e10	1
1322	2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?. 2016 , 129, 384-91	26
1321	A retrospective evaluation of the NHS Health Check Programme in a multi-ethnic population. 2016 , 38, 534-542	5
1320	Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?. 2016 , 17, 275-81	8
1319	Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes. 2016 , 37, 37-61	148
1318	Statin Use and the Risk of Kidney Disease With Long-Term Follow-Up (8.4-Year Study). 2016 , 117, 647-655	25
1317	2015 ACC/AHA Focused Update of Secondary Prevention Lipid Performance Measures: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. 2016 , 9, 68-95	16
1316	Effects of an evidence-based computerized virtual clinician on low-density lipoprotein and non-high-density lipoprotein cholesterol in adults without cardiovascular disease: The Interactive Cholesterol Advisory Tool. 2016 , 22, 897-910	2
1315	Current Management of Hyperlipidemia in Patients Discharged With a Diagnosis of Acute Coronary Syndrome. 2016 , 69, 83-4	
1314	Improving Cardiovascular Disease Risk Prediction With Albuminuria and Glomerular Filtration Rate. 2016 , 67, 179-81	
1313	Changing Cholesterol Levels and Coronary Heart Disease Risk. <i>Circulation</i> , 2016 , 133, 239-41	16.7 3
1312	Evolocumab: A Review in Hyperlipidemia. 2016 , 16, 67-78	6
1311	Testosterone: a hormone preventing cardiovascular disease or a therapy increasing cardiovascular events?. 2016 , 37, 3569-3575	23
1310	Subclinical Vascular Brain Injury. 2016 , 265-275	

1309	Cardiovascular Pharmacogenomics--Implications for Patients With CKD. 2016 , 23, 82-90	11
1308	Guidelines for the Reduction of Cardiovascular Disease in Women. 2016 , 45, 402-12	5
1307	Lifetime Perspectives on Primary Prevention of Atherosclerotic Cardiovascular Disease. 2016 , 315, 1449-50	19
1306	Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011. 2016 , 176, 473-82	320
1305	Knowing the Prevalence of Familial Hypercholesterolemia Matters. <i>Circulation</i> , 2016 , 133, 1054-7	16.7 27
1304	Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease. 2016 , 50, 119-35	2
1303	The Problem and Promise of Prognosis Research. 2016 , 170, 411-2	12
1302	Long-Term Outcomes of Short-Term Statin Use in Healthy Adults: A Retrospective Cohort Study. 2016 , 39, 543-59	11
1301	Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines. 2016 , 36, 586-90	14
1300	Absolute or relative effects? Arm-based synthesis of trial data. 2016 , 7, 23-8	52
1299	Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. 2016 , 9, 240-9	126
1298	Burden of Coronary Heart Disease Rehospitalizations Following Acute Myocardial Infarction in Older Adults. 2016 , 30, 323-31	15
1297	Juggling Multiple Guidelines: A Woman's Heart in the Balance. 2016 , 25, 213-21	7
1296	Rationale and design of the Further cardiovascular Outcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. 2016 , 173, 94-101	124
1295	Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels. 2016 , 45, 171-84	1
1294	Dyslipidemia in Special Ethnic Populations. 2016 , 45, 205-16	6
1293	Comparison of the Effect of Rosuvastatin 2.5 mg vs 20 mg on Coronary Plaque Determined by Angioscopy and Intravascular Ultrasound in Japanese With Stable Angina Pectoris (from the Aggressive Lipid-Lowering Treatment Approach Using Intensive Rosuvastatin for Vulnerable Coronary Artery Plaque [ALTAIR] Randomized Trial). 2016 , 117, 1206-12	12
1292	Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study. <i>Circulation</i> , 2016 , 133, 1073-80	16.7 143

1291	Implementation of the American Diabetes Association's Standards of Medical Care post-Medicare Part D: The case of statin utilization in the elderly with diabetes. 2016 , 12, 419-27		
1290	Imbalanced insulin action in chronic over nutrition: Clinical harm, molecular mechanisms, and a way forward. 2016 , 247, 225-82		51
1289	New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk: A Comparison of the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines with the 2014 National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia. 2016 , 45, 17-37		18
1288	Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease. 2016 , 45, 185-204		17
1287	Alterations of carotid arterial mechanics preceding the wall thickening in patients with hypertension. 2016 , 248, 84-90		6
1286	CKD and Diabetes: What Can We Learn From Their Similarities and Differences?. 2016 , 67, 360-3		7
1285	The Prediction of Atherosclerotic Cardiovascular Disease in Type 1 Diabetes Mellitus: Do We Just Stop Here?. <i>Circulation</i> , 2016 , 133, 1051-3	16.7	4
1284	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). 2016 , 67, 576-84		16
1283	OpenFDA: an innovative platform providing access to a wealth of FDA's publicly available data. 2016 , 23, 596-600		28
1282	The pharmacokinetic characters of simvastatin after co-administration with Shexiang Baoxin Pill in healthy volunteers' plasma. 2016 , 1026, 162-167		3
1281	[To improve cardiovascular health: we are forced for not losing impulse]. 2016 , 28, 43-6		
1280	Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. 2016 , 246, 115-20		14
1279	ESSENS dyslipidemia: A placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia. 2016 , 32, 767-76		13
1278	Inflammation, High-sensitivity C-reactive Protein, and Persistent Patent Ductus Arteriosus in Preterm Infants. 2016 , 69, 84-5		4
1277	Manejo actual de la hiperlipemia en pacientes dados de alta con el diagnóstico de síndrome coronario agudo. 2016 , 69, 83-84		2
1276	New Therapeutic Approaches to the Treatment of Dyslipidemia. 2016 , 23, 405-12		53
1275	Statins: the Panacea of Cirrhosis?. 2016 , 15, 1-7		5
1274	Z-Scan Analysis: a New Method to Determine the Oxidative State of Low-Density Lipoprotein and Its Association with Multiple Cardiometabolic Biomarkers. 2016 , 46, 163-169		3

1273	Dyslipidemia in Obesity. 2016 , 525-540		1
1272	Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. 2016 , 30, 1044-54		497
1271	Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia. 2016 , 38, 603-9		7
1270	Reducing Cardiovascular Risk Using Genomic Information in the Era of Precision Medicine. <i>Circulation</i> , 2016 , 133, 1155-9	16.7	8
1269	Adherence to the 2013 Blood Cholesterol Guidelines in Patients With Diabetes at a PCMH: Comparison of Physician Only and Combination Physician/Pharmacist Visits. 2016 , 42, 228-33		4
1268	Shared Risk Factors in Cardiovascular Disease and Cancer. <i>Circulation</i> , 2016 , 133, 1104-14	16.7	536
1267	Slippery Slope of Triglycerides: They Are Associated With Risk, But in the Statin Era, Does Targeting Them Confer Benefit?. 2016 , 9, 97-9		2
1266	Lipid Control and Beyond: Current and Future Indications for Statin Therapy in Stroke. 2016 , 18, 27		6
1265	A perspective in cardiovascular risk stratification: role of vascular ultrasound. 2016 , 12, 109-14		1
1264	Gemfibrozil in Combination with Statins-Is It Really Contraindicated?. 2016 , 18, 18		8
1263	A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk. 2016 , 117, 40-7		79
1262	Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease. <i>Circulation</i> , 2016 , 133, 1574-81	16.7	54
1261	Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease. 2016 , 23, 1393-400		12
1260	Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes. 2016 , 57, 310-7		11
1259	Omega-3 supplements and cardiovascular disease. Re: Sperling LS, Nelson JR. History and future of omega-3 fatty acids in cardiovascular disease. <i>Curr Med Res Opin</i> 2015; 32(2);301-311. 2016 , 32, 583-4		1
1258	Statin therapy with or without ezetimibe and the progression to diabetes. 2016 , 10, 306-13		29
1257	Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting. 2016 , 36, 225-33		8
1256	Current Controversies With Recent Cholesterol Treatment Guidelines. 2016 , 29, 15-25		5

1255	Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence. 2016 , 72, 349-57	11
1254	Study of Cardiovascular Health Outcomes in the Era of Claims Data: The Cardiovascular Health Study. <i>Circulation</i> , 2016 , 133, 156-64	16.7 68
1253	Preoperative antiplatelet and statin treatment was not associated with reduced myocardial infarction after high-risk vascular operations in the Vascular Quality Initiative. 2016 , 63, 182-9.e2	16
1252	HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target. 2016 , 18, 2	43
1251	Association of Statin Therapy and Risks of Cholelithiasis, Biliary Tract Diseases, and Gallbladder Procedures: Retrospective Cohort Analysis of a US Population. 2016 , 50, 161-71	4
1250	Relation of statin use with non-melanoma skin cancer: prospective results from the Women's Health Initiative. 2016 , 114, 314-20	11
1249	Visit-to-visit variability in LDL- and HDL-cholesterol is associated with adverse events after ST-segment elevation myocardial infarction: A 5-year follow-up study. 2016 , 244, 86-92	41
1248	Plaque Imaging to Decide on Optimal Treatment: Medical Versus Carotid Endarterectomy Versus Carotid Artery Stenting. 2016 , 26, 165-73	6
1247	Statin-centered treatment of dyslipidemia. New evidence-based paradigm, or only part of the evidence?. 2016 , 63, 1-3	1
1246	Effect Sizes and Primary Outcomes in Large-Budget, Cardiovascular-Related Behavioral Randomized Controlled Trials Funded by NIH Since 1980. 2016 , 50, 130-46	6
1245	Metabolic Syndrome and Kidney Stone Disease: A Systematic Review of Literature. 2016 , 30, 246-53	71
1244	Diabetic Dyslipidaemia. 2016 , 549-573	2
1243	Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis. 2016 , 28, 475-82	15
1242	Evidence, Guidelines, and Gut Checks: Musings on Entering the Post-Statin Era of Lipid Management. 2016 , 32, 271-4	1
1241	Designing of the fixed-dose gastroretentive bilayer tablet for sustained release of metformin and immediate release of atorvastatin. 2016 , 42, 340-9	10
1240	Plaque Assessment in the Management of Patients with Asymptomatic Carotid Stenosis. 2016 , 26, 111-27	8
1239	Mortality benefit of statin use in traumatic spinal cord injury: a retrospective analysis. 2016 , 54, 298-302	8
1238	Integrative Medicine for Breast Cancer. 2016 ,	

1237	Evaluation of Statin Prescribing for Secondary Prevention in Primary Care Following New Guideline Recommendations. 2016 , 50, 17-21	11
1236	Statin Use With the ATP III Guidelines Compared to the 2013 ACC/AHA Guidelines in HIV Primary Care Patients. 2017 , 30, 64-69	6
1235	Statin-induced calcific Achilles tendinopathy in rats: comparison of biomechanical and histopathological effects of simvastatin, atorvastatin and rosuvastatin. 2017 , 25, 1884-1891	17
1234	Brief report of virtual clinician research tools for tobacco dependence or dyslipidemia. 2017 , 22, 1463-1468	4
1233	Retrospective Evaluation of ASCVD Risk and Statin Therapy Need in Nondiabetic Patients Based on the 2013 ACC/AHA Cholesterol Guidelines. 2017 , 30, 300-305	1
1232	Common genetic risk factors for coronary artery disease: new opportunities for prevention?. 2017 , 37, 243-254	9
1231	Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. 2017 , 20, 555-564	39
1230	The Role of Nutrition and Lifestyle in the Prevention and Treatment of Cardiovascular Disease. 2017 , 137-150	
1229	Renal Artery Stenosis: When to Revascularize in 2017. 2017 , 42, 110-135	21
1228	In-hospital statin underutilization among high-risk patients: delayed uptake of the 2013 cholesterol guidelines in a U.S. cohort. 2017 , 45, 16-20	2
1227	Transitioning from pediatric to adult health care with familial hypercholesterolemia: Listening to young adult and parent voices. 2017 , 11, 147-159	12
1226	Prevalence of potential drug interactions in Thai patients receiving simvastatin: The causality assessment of musculoskeletal adverse events induced by statin interaction. 2017 , 25, 823-829	6
1225	Evolution and degree of control of cardiovascular risk factors after 5 years of follow-up and their relationship with the incidence of peripheral arterial disease: ARTPER cohort. 2017 , 148, 107-113	3
1224	Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease. 2017 , 148, 139.e1-139.e15	6
1223	Pleiotropic Effects of Statins on the Cardiovascular System. 2017 , 120, 229-243	514
1222	Statins usage and target achievement of LDL-C level in Chinese patients with coronary artery disease impacted by 2013 ACC/AHA cholesterol guideline. 2017 , 14, 33-37	5
1221	Therapies in non-alcoholic steatohepatitis (NASH). 2017 , 37 Suppl 1, 97-103	129
1220	Later chronotype is associated with higher hemoglobin A1c in prediabetes patients. 2017 , 34, 393-402	31

1219	Management of acute ischaemic stroke in patients with dementia. 2017 , 281, 348-364	28
1218	Niacin intake and risk of skin cancer in US women and men. 2017 , 140, 2023-2031	26
1217	A systematic review to assess adherence and persistence with statins. 2017 , 33, 769-778	51
1216	[PCSK9 inhibitors : Current clinical relevance]. 2017 , 58, 196-201	
1215	A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy. 2017 , 10, 3-11	14
1214	Global Risk Assessment to Guide Blood Pressure Management in Cardiovascular Disease Prevention. 2017 , 69, e2-e9	23
1213	Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. <i>Circulation</i> , 2017 , 135, e146-e603	16.7 5568
1212	Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study. 2017 , 40, 529-537	138
1211	Dyslipidemia. 2017 , 472-478	
1210	Association Between Statin Use and Prevalence of Exercise-Related Injuries: A Cross-Sectional Survey of Amateur Runners in the Netherlands. 2017 , 47, 1885-1892	5
1209	PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges. 2017 , 26, 786-798	1
1208	Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients. 2017 , 24, 981-989	21
1207	Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting. <i>Circulation</i> , 2017 , 135, 2091-2101 ^{16.7}	244
1206	Big Data Cohort Extraction to Facilitate Machine Learning to Improve Statin Treatment. 2017 , 39, 42-62	6
1205	Pericoronary adipose tissue ratio is a stronger associated factor of plaque vulnerability than epicardial adipose tissue on coronary computed tomography angiography. 2017 , 32, 813-822	8
1204	Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses. 2017 , 69, 458-463	61
1203	Current use of guideline-based medical therapy in elderly patients admitted with acute heart failure with reduced ejection fraction and its impact on event-free survival. 2017 , 235, 162-168	27
1202	Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. 2017 , 63, 870-879	47

1201	Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II. 2017 , 19, 989-996	37
1200	The association of antidepressant and statin use with death and incident cardiovascular disease varies by depression severity. 2017 , 22, 919-931	3
1199	Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients. 2017 , 6,	13
1198	Myocardial infarction in the Wisconsin Longitudinal Study: the interaction among environmental, health, social, behavioural and genetic factors. 2017 , 7, e011529	6
1197	Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation. 2017 , 42, 198-225	13
1196	Technological advances and proteomic applications in drug discovery and target deconvolution: identification of the pleiotropic effects of statins. 2017 , 22, 848-869	19
1195	Impact of Changes in Cardiorespiratory Fitness on Hypertension, Dyslipidemia and Survival: An Overview of the Epidemiological Evidence. 2017 , 60, 56-66	31
1194	Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: protocol for an overview of systematic reviews. 2017 , 7, e014206	7
1193	Ezetimibe: an update on its clinical usefulness in specific patient groups. 2017 , 8, 4-11	26
1192	Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study. 2017 , 33, 869-876	5
1191	Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease. 2017 , 148, 139.e1-139.e15	
1190	Cardiovascular disease prevalence and insulin resistance in the Kyushu-Okinawa Population Study and the Framingham Offspring Study. 2017 , 11, 348-356	10
1189	Inhibidores de la paraproteína convertasa subtilisina/kexina tipo 9: una alternativa de manejo para las dislipidemias. 2017 , 24, 411-416	
1188	Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). <i>Circulation</i> , 2017 , 135, 1911-1921	16.7 43
1187	Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis. 2017 , 7, 39982	29
1186	Use of Moderate-Intensity Statins for Low-Density Lipoprotein Cholesterol Level above 190 mg/dL at Baseline in Koreans. 2017 , 121, 272-278	8
1185	Stroke Caused by Extracranial Disease. 2017 , 120, 496-501	20
1184	Identification of new biosignatures for clinical outcomes in stable coronary artery disease - The study protocol and initial observations of a prospective follow-up study in Taiwan. 2017 , 17, 42	13

1183	Use of lipid lowering drugs in patients at very high risk of cardiovascular events: An analysis on nearly 3,000,000 Italian subjects of the ARNO Observatory. 2017 , 246, 62-67		7
1182	Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. <i>Circulation</i> , 2017 , 135, 1819-1831	16.7	52
1181	Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea. 2017 , 42, 292-300		5
1180	Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. 2017 , 3, CD009868		31
1179	Association of Coronary Artery Calcium in Adults Aged 32 to 46 Years With Incident Coronary Heart Disease and Death. 2017 , 2, 391-399		153
1178	Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease. 2017 , 76, 1237-1244		30
1177	Cholesterol Levels Should Play a More Important Role in Identifying Statin Recipients. <i>Circulation</i> , 2017 , 135, 627-629	16.7	9
1176	Potential for Net Benefit Should Guide Preventive Therapy. <i>Circulation</i> , 2017 , 135, 630-632	16.7	2
1175	Statins and Diabetes: Wider Utilization Is Needed in Treatment and Prevention. 2017 , 130, 499-500		
1174	Impact of Gender on Satisfaction and Confidence in Cholesterol Control Among Veterans at Risk for Cardiovascular Disease. 2017 , 26, 806-814		4
1173	Sociodemographic factors are associated with utilisation of statins after ischaemic stroke/TIA. 2017 , 71, e12936		8
1172	Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia: effects of rosuvastatin. 2017 , 58, 1315-1324		27
1171	Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients. 2017 , 31, 965-971		4
1170	Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients. 2017 , 6,		36
1169	Statin Eligibility and Outpatient Care Prior to ST-Segment Elevation Myocardial Infarction. 2017 , 6,		6
1168	Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. 2017 , 4, e284-e294		52
1167	Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States. 2017 , 20, 723-731		8
1166	Does Supplementation with Omega-3 PUFAs Add to the Prevention of Cardiovascular Disease?. 2017 , 19, 47		20

1165	Targeting LDL Cholesterol: Beyond Absolute Goals Toward Personalized Risk. 2017 , 19, 52	7
1164	Should a statin be given to all hypertensive patients?. 2017 , 18, 66	
1163	Is there a role for lifestyle changes in cardiovascular prevention? What, when and how?. 2017 , 26, 2-15	22
1162	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. 2017 , 38, 2459-2472	1267
1161	Statins and Lower Gastrointestinal Conditions: A Retrospective Cohort Study. 2017 , 57, 1053-1063	0
1160	Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor β modulator (SPPARM β) in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. 2017 , 261, 144-152	69
1159	Increased maternal and fetal cholesterol efflux capacity and placental CYP27A1 expression in preeclampsia. 2017 , 58, 1186-1195	21
1158	Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines. 2017 , 317, 1563-1567	40
1157	Another statin option in HIV. 2017 , 4, e278-e279	
1156	Nontraditional Lipid Variables Predict Recurrent Brain Ischemia in Embolic Stroke of Undetermined Source. 2017 , 26, 1670-1677	8
1155	Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries. 2017 , 2, 890-895	68
1154	HDL abnormalities in familial hypercholesterolemia: Focus on biological functions. 2017 , 67, 16-26	31
1153	American College of Cardiology/American Heart Association (ACC/AHA) Class I Guidelines for the Treatment of Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Implications for US Hispanics/Latinos Based on Findings From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). 2017 , 6,	12
1152	Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves. 2017 , 37, 802-814	15
1151	[Choosing wisely recommendations in cardiology]. 2017 , 58, 556-567	1
1150	The effect of statins on renal outcomes in patients with diabetic kidney disease: A systematic review and meta-analysis. 2017 , 33, e2901	14
1149	Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study. <i>Circulation</i> , 2017 , 136, 263-276	16.7 74
1148	Influence of Baseline Psychological Health on Muscle Pain During Atorvastatin Treatment. 2017 , 32, 544-550	3

1147	Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs. 2017 , 11, 858-871.e3		80
1146	Management of Dyslipidemias in Europe and the USA: Same Evidence, Different Conclusions? Can We Find Common Ground?. 2017 , 19, 49		2
1145	Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. 2017 , 389, 2473-2481		184
1144	Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. <i>Circulation</i> , 2017 , 135, 2572-2574	16.7	37
1143	Cardiovascular risk assessment in patients with diabetes. 2017 , 9, 25		84
1142	Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2017 , 135, 2204-2206	16.7	28
1141	Implementing Cardiovascular Risk Prediction in Clinical Practice: The Future Is Now. 2017 , 6,		11
1140	Strengths and Limitations of Using the Polypill in Cardiovascular Prevention. 2017 , 19, 45		26
1139	Role of Nonstatin Therapies for Low-Density Lipoprotein Cholesterol Lowering in Management of Atherosclerotic Cardiovascular Disease Risk. 2017 , 2, 218-219		1
1138	A novel approach to screening for familial hypercholesterolemia in a large public venue. 2017 , 8, 35-44		10
1137	AMPK activation enhances the anti-atherogenic effects of high density lipoproteins in apoE mice. 2017 , 58, 1536-1547		40
1136	Niacin for primary and secondary prevention of cardiovascular events. 2017 , 6, CD009744		26
1135	Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial. 2017 , 11, 929-937		5
1134	Emerging biologic therapies for hypercholesterolaemia. 2017 , 17, 1077-1087		9
1133	Multicenter Study of Temporal Trends in the Achievement of Atherosclerotic Cardiovascular Disease Risk Factor Goals During Cardiac Rehabilitation. 2017 , 37, 11-21		3
1132	Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management. 2017 , 263, 112-118		3
1131	Intensive versus moderate atorvastatin therapy and one-year graft patency after CABG: Rationale and design of the ACTIVE (Aggressive Cholesterol Therapy to Inhibit Vein Graft Events) randomized controlled trial (NCT01528709). 2017 , 59, 98-104		8
1130	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. 2017 , 376, 1933-1942		406

1129	Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. 2017 , 28, 3034-3043	18
1128	Hypertension update, JNC8 and beyond. 2017 , 33, 41-46	18
1127	Lipoprotein(a): A Lipoprotein Whose Time Has Come. 2017 , 19, 48	9
1126	Assessing and Modifying Coronary Artery Disease Risk in Women. 2017 , 19, 51	4
1125	Dyslipidemia management update. 2017 , 33, 47-55	31
1124	Medical management of claudication. 2017 , 66, 275-280	14
1123	2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document. 2017 , 24, 313-329	7
1122	Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia. 2017 , 66, 572-578	28
1121	Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. 2017 , 19, 62	3
1120	Kommentar zu den neuen Leitlinien (2016) der Europäischen Gesellschaft für Kardiologie (ESC) zur kardiovaskulären Prävention. 2017 , 11, 21-26	4
1119	Effective low-density lipoprotein-lowering therapy: Implementation in clinical practice. 2017 , 24, 71-76	10
1118	Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland. 2017 , 71, 496-502	14
1117	Incident Cardiovascular Disease Among Adults With Blood Pressure . <i>Circulation</i> , 2017 , 136, 798-812	16.7 39
1116	High-Quality Statin Trials Support the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines After the HOPE-3 Trial (Heart Outcomes Prevention Evaluation-3): MESA (The Multiethnic Study of Atherosclerosis). <i>Circulation</i> , 2017 , 136, 1863-1865	16.7 7
1115	Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patients. 2017 , 31, 681-688	12
1114	The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL. 2017 , 16, 66	9
1113	Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study. 2017 , 7, e013851	18
1112	Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. 2017 , 102, 2950-2961	44

1111	Reduction in Cardiovascular Risk Among Latino Participants in a Community-Based Intervention Linked With Clinical Care. 2017 , 53, e71-e75	6
1110	Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet. 2017 , 7, 2169	23
1109	Mailed outreach and facilitated test ordering to promote cholesterol screening in community health centers: A randomized trial. 2017 , 23, 620-624	1
1108	Association of statins with aortic, peripheral, and visceral artery aneurysm development. 2017 , 25, 372-381	2
1107	[Changes in the prevalence of statin use in Germany - findings from national health interview and examination surveys 1997-1999 and 2008-2011]. 2017 , 122, 22-31	7
1106	Medical Management of Asymptomatic Carotid Artery Stenosis. 2017 , 59, 585-590	20
1105	Getting Out of the Phosphate Bind: Trials to Guide Treatment Targets. 2017 , 12, 868-870	2
1104	Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association. 2017 , 11, 891-900	34
1103	Statins for Primary Prevention of Cardiovascular Disease: Review of Evidence and Recommendations for Clinical Practice. 2017 , 101, 689-699	31
1102	Cardiovascular Risk Assessment. 2017 , 101, 673-688	18
1101	Type 2 diabetes specialty clinic model for the accountable care organization era. 2017 , 31, 1521-1526	1
1100	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. 2017 , 122, 105-117	16
1099	Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance. 2017 , 120, 774-781	15
1098	Invited Commentary: The Framingham Offspring Study-A Pioneering Investigation Into Familial Aggregation of Cardiovascular Risk. 2017 , 185, 1103-1108	4
1097	Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy. 2017 , 24, 1297-1307	20
1096	Investigational therapies for hypercholesterolemia. 2017 , 26, 603-617	2
1095	Progress toward newer guidelines of lipid management. 2017 , 24, 119-121	
1094	Dislipidemia en las personas de edad muy avanzada. 2017 , 21, 1-10	

1093	Reply to: "Appropriate use of cholesterol-lowering therapy". 2017 , 262, 200-201	
1092	Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain. 2017 , 39, 771-786.e3	35
1091	The association between dietary cholesterol intake and subclinical atherosclerosis in Korean adults: The Kangbuk Samsung Health Study. 2017 , 11, 432-441.e3	12
1090	From the Editor. 2017 , 11, 1-2	1
1089	Evolution and degree of control of cardiovascular risk factors after 5 years of follow-up and their relationship with the incidence of peripheral arterial disease: ARTPER cohort. 2017 , 148, 107-113	
1088	PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers. 2017 , 40, 243-254	52
1087	Current status of lipid management in acute coronary syndrome. 2017 , 70, 101-106	14
1086	Health benefits and consequences of the Eastern Orthodox fasting in monks of Mount Athos: a cross-sectional study. 2017 , 71, 743-749	23
1085	Dislipidemia nel soggetto molto anziano. 2017 , 19, 1-10	
1084	Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials. 2017 , 7, 45788	10
1083	Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention. 2017 , 15, 23-36	28
1082	Gender differences in the effects of cardiovascular drugs. 2017 , 3, 163-182	126
1081	Dyslipidemia in diabetes mellitus and cardiovascular disease. 2017 , 6, 27-32	20
1080	PPAR- α agonists are still on the rise: an update on clinical and experimental findings. 2017 , 26, 593-602	34
1079	Office Blood Pressure and Cardiovascular Disease: Pathophysiologic Implications for Diagnosis and Treatment. 2017 , 69, e14-e20	2
1078	Low-Density Lipoprotein Measurement Discordance: When 2 Wrongs Lead to the Right Answer-Elevated Lipoprotein (a). 2017 , 2, 697-698	
1077	THE IMPACT OF CARDIOVASCULAR DRUGS ON GLYCEMIC CONTROL: A REVIEW. 2017 , 23, 363-371	3
1076	Diabetes and cardiovascular events in high-risk patients: Insights from a multicenter registry in a middle-income country. 2017 , 127, 275-284	11

1075	Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. <i>Circulation</i> , 2017 , 135, e927-e999	16.7	1452
1074	Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts. <i>Circulation</i> , 2017 , 135, 2119-2132	16.7	51
1073	Clinical determinants and treatment gaps in familial hypercholesterolemia: Data from a multi-ethnic regional health service. 2017 , 24, 867-875		10
1072	Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands. 2017 , 39, 819-827.e1		34
1071	Role of Coronary Calcium for Risk Stratification and Prognostication. 2017 , 19, 8		2
1070	Presence, Characteristics, and Volumes of Coronary Plaque Determined by Computed Tomography Angiography in Young Type 2 Diabetes Mellitus. 2017 , 119, 1566-1571		17
1069	Statins for primary prevention of cardiovascular disease : Patients need better tools to navigate divergent recommendations. 2017 , 103, 477-478		5
1068	Application of Metabolic Profiling to Abdominal Aortic Aneurysm Research. 2017 , 16, 2325-2332		8
1067	Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. 2017 ,		2
1066	A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTEMI-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin. 2017 , 235, 49-55		15
1065	Effects of dyslipidaemia on monocyte production and function in cardiovascular disease. 2017 , 14, 387-400		46
1064	Prediction of Cardiovascular Disease by the Framingham-REGICOR Equation in the High-Risk PREDIMED Cohort: Impact of the Mediterranean Diet Across Different Risk Strata. 2017 , 6,		11
1063	2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack. 2017 , 12, 302-320		52
1062	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. 2017 , 376, 1713-1722		2700
1061	Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals: The Jackson Heart Study. 2017 , 2, 644-652		27
1060	Performance of the Atherosclerotic Cardiovascular Disease Pooled Cohort Risk Equations by Social Deprivation Status. 2017 , 6,		33
1059	Dyslipidemia in patients with chronic kidney disease. 2017 , 18, 29-40		75
1058	People with epilepsy receive more statins than the general population but have no higher cardiovascular risk: results from a cross-sectional study. 2017 , 24, 419-426		7

1057	Editorial: Do Not Let Gout Apathy Lead to Gouty Arthropathy. 2017 , 69, 479-482	12
1056	Cost Effectiveness of Achieving Targets of Low-Density Lipoprotein Particle Number Versus Low-Density Lipoprotein Cholesterol Level. 2017 , 119, 404-409	8
1055	Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk. 2017 , 39, 107-117	21
1054	Association of statins with diabetes mellitus and diabetic complications: role of confounders during follow-up. 2017 , 65, 32-42	8
1053	Depression contributing to dyslipidemic cardiovascular risk in the metabolic syndrome. 2017 , 40, 539-546	6
1052	Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. 2017 , 2, 370-380	98
1051	An Evidence-Based Guide to Cholesterol-Lowering Guidelines. 2017 , 33, 343-349	13
1050	Trends in Perioperative Cardiovascular Events: Mostly Sunny, With Showers. 2017 , 2, 188-189	1
1049	Cardiovascular risk and prevention in patients with head and neck cancer treated with radiotherapy. 2017 , 39, 527-532	15
1048	The Changing Face of HDL and the Best Way to Measure It. 2017 , 63, 196-210	64
1047	High-Sensitivity Cardiac Troponin T (hs-cTnT) as a Predictor of Incident Diabetes in the Atherosclerosis Risk in Communities Study. 2017 , 40, 261-269	18
1046	Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial. 2017 , 37, 350-358	24
1045	Secondary cvd prevention-Lipid modification strategies: A critical analysis. 2017 , 11 Suppl 1, S187-S193	
1044	The year in cardiology 2016: imaging. 2017 , 38, 390-399	3
1043	Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events. 2017 , 119, 565-571	10
1042	Sarcopenia is a risk factor for cardiovascular events experienced by patients with critical limb ischemia. 2017 , 65, 1390-1397	30
1041	Association of Perioperative Statin Use With Mortality and Morbidity After Major Noncardiac Surgery. 2017 , 177, 231-242	52
1040	The need for re-defining cut-off values in heart failure: From obesity to iron deficiency. 2017 , 87, 1-7	3

1039	Diabetic foot ulcer severity predicts mortality among veterans with type 2 diabetes. 2017 , 31, 556-561	73
1038	Evaluation of the Pooled Cohort Equations for Prediction of Cardiovascular Risk in a Contemporary Prospective Cohort. 2017 , 119, 881-885	18
1037	Muscle Mass and Body Fat in Relation to Cardiovascular Risk Estimation and Lipid-Lowering Eligibility. 2017 , 20, 247-255	11
1036	Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. 2017 , 48, e44-e71	178
1035	Cardiovascular Health in African Americans: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2017 , 136, e393-e423	16.7 425
1034	Sirolimus for the treatment of lymphangioleiomyomatosis. 2017 , 5, 907-921	5
1033	The challenges of proprotein convertase subtilisin-kexin-9 inhibitors for lipid guidelines and models of care. 2017 , 28, 470-476	1
1032	Electronegative Low-Density Lipoprotein L5 Induces Adipose Tissue Inflammation Associated With Metabolic Syndrome. 2017 , 102, 4615-4625	14
1031	Strategies to Prioritize Clinical Options in Primary Care. 2017 , 15, 10-13	14
1030	Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry. 2017 , 267, 19-26	36
1029	Modelling total coronary heart disease burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease. 2017 , 3, 281-288	0
1028	Changes in truncal obesity and fat distribution predict arterial health. 2017 , 11, 1354-1360.e3	14
1027	The effects of lifestyle modification and statin therapy on the circulatory markers for vascular risk in patients with epilepsy. 2017 , 76, 133-135	3
1026	Statin-associated muscle symptoms (SAMS) in primary prevention for cardiovascular disease in older adults: a protocol for a systematic review and meta-analysis of randomised controlled trials. 2017 , 7, e017587	4
1025	Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction. 2017 , 74, 1319-1327	13
1024	Underutilization of Statins When Indicated in HIV-Seropositive and Seronegative Women. 2017 , 31, 447-454	20
1023	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects. 2017 , 39, 2243-2259.e5	10
1022	Moderate to high intensity statin in dialysis patients after acute myocardial infarction: A national cohort study in Asia. 2017 , 267, 158-166	12

1021	Diagnosis and Management of Noncardiac Complications in Adults With Congenital Heart Disease: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2017 , 136, e348-e392	16.7	90
1020	Stroke Revisited: Diagnosis and Treatment of Ischemic Stroke. 2017 ,		3
1019	Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres. 2017 , 71, e13032		25
1018	Increasing prevalence of vascular risk factors in patients with stroke: A call to action. 2017 , 89, 1985-1994		29
1017	Diabetes Mellitus and Control of Cardiovascular Disease Risk Factors: A Challenge to Improve Usual Care. <i>Circulation</i> , 2017 , 136, 1204-1206	16.7	1
1016	Biochemical risk markers and 10-year incidence of atherosclerotic cardiovascular disease: independent predictors, improvement in pooled cohort equation, and risk reclassification. 2017 , 193, 95-103		13
1015	Statin Discontinuation, Reinitiation, and Persistence Patterns Among Medicare Beneficiaries After Myocardial Infarction: A Cohort Study. 2017 , 10,		26
1014	Association Between Living in Food Deserts and Cardiovascular Risk. 2017 , 10,		33
1013	Vulnerabilities to Health Disparities and Statin Use in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. 2017 , 6,		27
1012	Statins. 2017 , 22, 442-445		6
1011	Comparison of 3 risk estimators to guide initiation of statin therapy for primary prevention of cardiovascular disease. 2017 , 11, 1441-1447		4
1010	10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. 2017 , 7, e014150		24
1009	Changes in Statin Adherence Following an Acute Myocardial Infarction Among Older Adults: Patient Predictors and the Association With Follow-Up With Primary Care Providers and/or Cardiologists. 2017 , 6,		20
1008	Lipids and Lipoproteins. 2017 , 287-294		
1007	Is anti-platelet therapy always necessary in asymptomatic 30-40% carotid stenosis?. 2017 , 18 Suppl 1: Special Issue on T, e112-e116		1
1006	Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status. 2017 , 65, 1542-1550		7
1005	Using the McSweeney Acute and Prodromal Myocardial Infarction Symptom Survey to Predict the Occurrence of Short-Term Coronary Heart Disease Events in Women. 2017 , 27, 660-665		7
1004	Substantial improvement of primary cardiovascular prevention by a systematic score-based multimodal approach: A randomized trial: The PreFord-Study. 2017 , 24, 1544-1554		11

1003	Heart disease: Putative medicines that mimic mutations. 2017 , 548, 530-531	3
1002	Prognostic Value of Coronary Artery Calcium in the PROMISE Study (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). <i>Circulation</i> , 2017 , 136, 1993-2005	16.7 117
1001	Accuracy of Cardiovascular Risk Prediction Varies by Neighborhood Socioeconomic Position: A Retrospective Cohort Study. 2017 , 167, 456-464	48
1000	Potential contribution of lifestyle and socioeconomic factors to healthy user bias in antihypertensives and lipid-lowering drugs. 2017 , 4, e000417	7
999	Non-Atherosclerotic Vascular Disease in Women. 2017 , 19, 78	3
998	Effects of Statin Intensity and Adherence on the Long-Term Prognosis After Acute Ischemic Stroke. 2017 , 48, 2723-2730	47
997	Emergency Neurological Life Support: Acute Ischemic Stroke. 2017 , 27, 102-115	8
996	Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia. 2017 , 13, 1099-1104	13
995	Defining Optimal Brain Health in Adults: A Presidential Advisory From the American Heart Association/American Stroke Association. 2017 , 48, e284-e303	168
994	The renaissance of lipoprotein(a): Brave new world for preventive cardiology?. 2017 , 68, 57-82	46
993	Statins for Primary Prevention in Older Adults: An Unresolved Conundrum. 2017 , 65, 2352-2353	2
992	Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. 2017 , 5, 941-950	330
991	Preventative Cardiology. 2017 , 2, 743-758	
990	Race and Socioeconomic Differences Associated With Changes in Statin Eligibility Under the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines. 2017 , 10,	6
989	Effects of Low-density Lipoprotein Cholesterol on Coronary Artery Calcification Progression According to High-density Lipoprotein Cholesterol Levels. 2017 , 48, 284-291	4
988	2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. 2017 , 10,	43
987	Optimal Target Level of Low-density Lipoprotein Cholesterol for Vascular Function in Statin Naïve Individuals. 2017 , 7, 8422	9
986	Use of statins and adverse outcomes in patients with atrial fibrillation: An analysis from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) general registry pilot phase. 2017 , 248, 166-172	6

985	Optimal Medical Management Reduces Risk of Disease Progression and Ischemic Events in Asymptomatic Carotid Stenosis Patients: A Long-Term Follow-Up Study. 2017 , 44, 150-159		12
984	Reducing the Global Burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease. 2017 , 121, 695-710		134
983	Identification of Vascular Risk Factors. 2017 , 247-253		
982	Cholesterol Management After Stroke. 2017 , 285-294		
981	Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry. 2017 , 193, 84-92		32
980	Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 22-Year Observational Follow-Up Study. 2017 , 136, 1878-1884	16.7	92
979	Exploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study. 2017 , 7, e014427		4
978	Balancing Primary Prevention and Statin-Induced Diabetes Mellitus Prevention. 2017 , 120, 1122-1128		14
977	Point-of-care testing to promote cardiovascular disease risk assessment: A proof of concept study. 2017 , 7, 136-139		5
976	Is it time to get serious about cholesterol screening?. 2017 , 11, 1118-1121		
975	Low-density lipoprotein cholesterol variability increases the risk of cardiovascular events: the importance of keeping constant low cholesterol levels. 2017 , 18 Suppl 1, e91-e93		1
974	Cardiovascular Health During Pregnancy: Future Health Implications for Mothers. 2017 , 4, 232-238		4
973	Twenty-Year Nationwide Trends in Statin Utilization and Expenditure in Denmark. 2017 , 10,		18
972	Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia. 2017 , 37, 1172-1190		14
971	Lipoprotein(a)-apheresis in the light of new drug developments. 2017 , 30, 38-43		12
970	Risk of misclassification with a non-fasting lipid profile in secondary cardiovascular prevention. 2017 , 472, 90-95		4
969	LDL subfractions are associated with incident cardiovascular disease in the Malmö Prevention Project Study. 2017 , 263, 287-292		30
968	Intracoronary Imaging, Cholesterol Efflux, and Transcriptomics after Intensive Statin Treatment in Diabetes. 2017 , 7, 7001		8

967	The Expressed Genome in Cardiovascular Diseases and Stroke: Refinement, Diagnosis, and Prediction: A Scientific Statement From the American Heart Association. 2017 , 10,	18
966	The preference of the physicians in diagnosis and treatment of cardiovascular diseases. 2017 , 3, 11-15	1
965	Opportunities for improving cardiovascular health outcomes in adults younger than 65 years with guideline-recommended statin therapy. 2017 , 19, 850-860	1
964	Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?. 2017 , 2, 937-938	
963	Effect of Disclosing Genetic Risk for Coronary Heart Disease on Information Seeking and Sharing: The MI-GENES Study (Myocardial Infarction Genes). 2017 , 10,	15
962	Utilization of Statins Beyond the Initial Period After Stroke and 1-Year Risk of Recurrent Stroke. 2017 , 6,	21
961	Zhibitai and low-dose atorvastatin reduce blood lipids and inflammation in patients with coronary artery disease. 2017 , 96, e6104	12
960	Impact of hyperlipidemia on alloimmunity. 2017 , 22, 14-21	4
959	The Veterans Affairs Cardiac Risk Score: Recalibrating the Atherosclerotic Cardiovascular Disease Score for Applied Use. 2017 , 55, 864-870	17
958	The Benefit Model for Prevention of Cardiovascular Disease: An Opportunity to Harmonize Guidelines. 2017 , 2, 1175-1176	10
957	Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODE) using individual participant data from randomised trials. 2017 , 5, 788-798	72
956	Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments. 2017 , 13, 973-983	16
955	Cholesterol Management in the Era of PCSK9 Inhibitors. 2017 , 19, 83	4
954	Kommentar zu den neuen Leitlinien (2016) der European Society of Cardiology und European Atherosclerosis Society zur Diagnostik und Therapie der Dyslipidämien. 2017 , 11, 295-299	
953	Optimizing Diet, Weight, and Exercise in Adults With Familial Hypercholesterolemia. 2017 , 13, 603-609	1
952	The Variation of Statin Use Among Nursing Home Residents and Physicians: A Cross-Sectional Analysis. 2017 , 65, 2044-2051	18
951	Statins and Cardiovascular Health: Controversy, Consensus, and Clinical Judgment. 2017 , 32, 90-92	
950	Unique Presentations and Etiologies of Myocardial Infarction in Women. 2017 , 19, 66	9

949	Target achievement with maximal statin-based lipid-lowering therapy in Korean patients with familial hypercholesterolemia: A study supported by the Korean Society of Lipid and Atherosclerosis. 2017 , 40, 1291-1296	7
948	Use of the Coronary Artery Calcium Score in Discussion of Initiation of Statin Therapy in Primary Prevention. 2017 , 92, 1831-1841	22
947	LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China: Subgroup analysis of the dyslipidemia international study of China (DYSIS-China). 2017 , 96, e8555	9
946	The New 2017 ACC/AHA Guidelines "Up the Pressure" on Diagnosis and Treatment of Hypertension. 2017 , 318, 2083-2084	32
945	Migration and Cardiovascular Disease Risk Among Ghanaian Populations in Europe: The RODAM Study (Research on Obesity and Diabetes Among African Migrants). 2017 , 10,	18
944	Analyzing the Clinical Outcomes of a Rapid Mass Conversion From Rosuvastatin to Atorvastatin in a VA Medical Center Outpatient Setting. 2017 , 33, 189-194	1
943	Clinical risk reclassification at 10 years. 2017 , 36, 4498-4502	6
942	Risk assessment with newer statistical metrics. 2017 , 36, 4509-4510	1
941	Cardiovascular Risk Factors After Single Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy (SADI-S): a New Effective Therapeutic Approach?. 2017 , 19, 58	22
940	Effects of Guideline and Formulary Changes on Statin Prescribing in the Veterans Affairs. 2017 , 52, 1996-2017	7
939	Closing the Remaining Evidence Gap: Randomized Controlled Trial Data to Support Statin Therapy for Low-Density Lipoprotein ≥ 190 mg/dL. <i>Circulation</i> , 2017 , 136, 1892-1894	16.7
938	Identification and Characterization of Fenofibrate-Induced Liver Injury. 2017 , 62, 3596-3604	33
937	A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia. 2017 , 39, 2366-2379	11
936	Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey. <i>Circulation</i> , 2017 , 136, 1860-1862	16.7 2
935	Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. 2017 , 2, 1385-1391	62
934	Coronary Artery Calcium Score for Long-term Risk Classification in Individuals With Type 2 Diabetes and Metabolic Syndrome From the Multi-Ethnic Study of Atherosclerosis. 2017 , 2, 1332-1340	95
933	25-Year Physical Activity Trajectories and Development of Subclinical Coronary Artery Disease as Measured by Coronary Artery Calcium: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. 2017 , 92, 1660-1670	33
932	Isquemia crónica de miembros inferiores. Enfermedad arterial periférica. 2017 , 12, 2440-2447	

931	Protocolo de tratamiento de la dislipidemia. 2017 , 12, 2521-2525	
930	Tratamiento de las dislipidemias en situaciones especiales: diabetes mellitus, cardiopatía isquémica e insuficiencia renal. 2017 , 12, 2526-2533	
929	Clinical Predictors for Lack of Favorable Vascular Response to Statin Therapy in Patients With Coronary Artery Disease: A Serial Optical Coherence Tomography Study. 2017 , 6,	12
928	Time to change the SCORE?. 2017 , 38, 595-597	4
927	Pleiotropic effects of metformin to rescue statin-induced muscle injury and insulin resistance: A proposed mechanism and potential clinical implications. 2017 , 107, 39-44	7
926	Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study). 2017 , 49, 737-747	4
925	Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis. 2017 , 318, 156-166	192
924	Improving secondary cardiovascular risk prediction: taking a few steps along the long path from probability toward certainty. 2017 , 38, 3219-3221	3
923	Association between spicy food consumption and lipid profiles in adults: a nationwide population-based study. 2017 , 118, 144-153	11
922	Implications of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers. 2017 , 6,	6
921	Symptomatic Carotid Artery Stenosis: Surgery, Stenting, or Medical Therapy?. 2017 , 19, 62	23
920	Utility of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-Infected Adults With Carotid Atherosclerosis. 2017 , 10,	17
919	Lipid-Lowering and Anti-Inflammatory Benefits of Statin Therapy: More Than Meets the Plaque. 2017 , 10,	9
918	Are the PCSK9 inhibitors the panacea of atherosclerosis treatment?. 2017 , 15, 491-494	4
917	Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype. 2017 , 19, 61	9
916	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data. 2017 , 19, 58	12
915	An update on type 2 diabetes management in primary care. 2017 , 42, 20-29	6
914	Secondary prevention strategies after an acute ST-segment elevation myocardial infarction in the AMI code era: beyond myocardial mechanical reperfusion. 2017 , 17, 54	12

913	A pilot study of brisk walking in sedentary combination antiretroviral treatment (cART)- treated patients: benefit on soluble and cell inflammatory markers. 2017 , 17, 61	27
912	Cardiovascular disease risk among Chinese antiretroviral-naïve adults with advanced HIV disease. 2017 , 17, 287	18
911	Accuracy of low-density lipoprotein cholesterol estimation at very low levels. 2017 , 15, 83	26
910	Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. 2017 , 16, 4	32
909	Effect of two lipid-lowering strategies on high-density lipoprotein function and some HDL-related proteins: a randomized clinical trial. 2017 , 16, 49	4
908	Efficacy of low- and moderate-intensity statins for achieving low- density lipoprotein cholesterol targets in Thai type 2 diabetic patients. 2017 , 16, 6	5
907	Relationship between simple markers of insulin resistance and coronary artery calcification. 2017 , 11, 1007-1012	7
906	Preventive effect of pravastatin on the development of hypertension in patients with hypercholesterolemia: A post-hoc analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. 2017 , 11, 998-1006	5
905	Use of Statins and Outcomes in Intracerebral Hemorrhage Patients. 2017 , 48, 2098-2104	25
904	Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy. 2017 , 248, 355-360	5
903	The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention: from clinical trials to real-world experience. 2017 , 32, 633-641	1
902	Role of Niacin in Current Clinical Practice: A Systematic Review. 2017 , 130, 173-187	48
901	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). 2017 , 24, 4-40	43
900	Cardiovascular Disease. 2017 , 243-267	
899	2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2017 , 135, e726-e779	16.7 396
898	The Dubious Value of Coronary Calcium Scoring on Lung Cancer Screening CT. 2017 , 14, 343-344	7
897	Comparing Strategies for Lipid Lowering in Argentina: An Analysis from the CVD Policy Model-Argentina. 2017 , 32, 524-533	2
896	Intensive LDL-cholesterol lowering therapy and neurocognitive function. 2017 , 170, 181-191	46

895	Comparison of cardiovascular risk assessment tools and their guidelines in evaluation of 10-year CVD risk and preventive recommendations: A population based study. 2017 , 228, 52-57	13
894	Effective Management of Cardiovascular Risk Factors-Are We Doing Enough?. 2017 , 33, 300-302	1
893	Short-term changes in arterial inflammation predict long-term changes in atherosclerosis progression. 2017 , 44, 141-150	16
892	Observational Prospective study to esTIMAtE the rates of outcomes in patients undergoing PCI with drug-eluting stent implantation who take statins -follow-up (OPTIMA II). 2017 , 33, 253-259	
891	Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology. 2017 , 69, 1617-1636	36
890	Dyslipidemias. 2017 , 1637-1647	
889	Impact of combined lipid lowering and blood pressure control on coronary plaque: myocardial ischemia treated by percutaneous coronary intervention and plaque regression by lipid lowering and blood pressure controlling assessed by intravascular ultrasonography (MILLION) study. 2017 , 32, 539-548	2
888	Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. 2017 , 119, 388-396	11
887	Acute myocardial infarction. 2017 , 389, 197-210	486
886	Impact of a national collaborative care initiative for patients with depression and diabetes or cardiovascular disease. 2017 , 44, 77-85	48
885	Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. 2017 , 106, 58-68	17
884	Criteria for assigning laboratory measurands to models for analytical performance specifications defined in the 1st EFLM Strategic Conference. 2017 , 55, 189-194	87
883	Perioperative Optimization of Geriatric Lower Extremity Bypass in the Era of Increased Performance Accountability. 2017 , 38, 248-254	2
882	PCSK9 inhibitors: A new era in stroke prevention?. 2017 , 37, e44	3
881	Correlation of compliance to statin therapy with lipid profile and serum HMGCoA reductase levels in dyslipidemic patients. 2017 , 69, 6-10	12
880	The decreased achievement of therapeutic goal in lipid lowering therapy in obese and diabetic patients in Poland. 2017 , 69, 6-12	3
879	Cardiovascular Risk Factor Management Performance in Canada and the United States: A Systematic Review. 2017 , 33, 393-404	18
878	Shared decision making and the internist. 2017 , 37, 1-6	12

877	Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology. <i>Circulation</i> , 2017 , 135, e793-e813	16.7	43
876	Guideline-based statin/lipid-lowering therapy eligibility for primary prevention and accuracy of coronary artery calcium and clinical cardiovascular events: The Multi-Ethnic Study of Atherosclerosis (MESA). 2017 , 40, 163-169		6
875	Effects of statins on the kidneys in patients with type 2 diabetes. 2017 , 21, 633-642		3
874	The benefits of β supplementation depend on adiponectin basal level and adiponectin increase after the supplementation: A randomized clinical trial. 2017 , 34, 7-13		18
873	Stability of physical activity, fitness components and diet quality indices. 2017 , 71, 519-524		12
872	Hyperlipidemia is associated with lower risk of poststroke mortality independent of statin use: A population-based study. 2017 , 12, 152-160		25
871	Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms?. 2017 , 22, 85-96		48
870	Prevention of Cardiovascular Disease Among Cancer Survivors: the Role of Pre-existing Risk Factors and Cancer Treatments. 2017 , 4, 239-247		6
869	Integrating CHWs as Part of the Team Leading Diabetes Group Visits: A Randomized Controlled Feasibility Study. 2017 , 43, 589-599		9
868	Using Machine Learning to Define the Association between Cardiorespiratory Fitness and All-Cause Mortality (from the Henry Ford Exercise Testing Project). 2017 , 120, 2078-2084		14
867	Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years. 2017 , 5, 1412753		5
866	Women and Heart Disease: An Evidence-Based Update. 2017 , 13, 610-616		1
865	Overview of Some Risk Factors in Cardiovascular Disease. 2017 ,		
864	Efficacy and Safety of Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib Administered as Monotherapy in Japanese Patients With Primary Hypercholesterolemia. 2017 , 81, 1686-1692		1
863	Statin Therapy Negatively Impacts Skeletal Muscle Regeneration and Cutaneous Wound Repair in Type 1 Diabetic Mice. 2017 , 8, 1088		3
862	Incidence, Predictors, and Clinical Outcomes of New-Onset Diabetes Mellitus after Percutaneous Coronary Intervention with Drug-Eluting Stent. 2017 , 32, 1603-1609		5
861	Combining Potent Statin Therapy with Other Drugs to Optimize Simultaneous Cardiovascular and Metabolic Benefits while Minimizing Adverse Events. 2017 , 47, 432-439		15
860	Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Association of Interventional Cardiology (SICI-GISE) and Italian Society of Cardiac Surgery (SICCH): clinical approach to pharmacologic pre-treatment for patients undergoing myocardial revascularization procedures. 2017 , 19, D151-D162		0

859	Identification of Patients with Statin Intolerance in a Managed Care Plan: A Comparison of 2 Claims-Based Algorithms. 2017 , 23, 926-934	1
858	Glycemic Response to Black Beans and Chickpeas as Part of a Rice Meal: A Randomized Cross-Over Trial. 2017 , 9,	27
857	Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus. 2017 , 41, 23-30	7
856	Impact of a Genetic Risk Score for Coronary Artery Disease on Reducing Cardiovascular Risk: A Pilot Randomized Controlled Study. 2017 , 4, 53	29
855	Cardiovascular Screening for the Asymptomatic Patient with Diabetes: More Cons Than Pros. 2017 , 2017, 8927473	11
854	Pravastatin-Induced Eczematous Eruption Mimicking Psoriasis. 2017 , 2017, 3418204	5
853	Low Levels of Sex Hormone-Binding Globulin Constitute an Independent Risk Factor for Arterial Stiffness in Korean Women. 2017 , 2017, 6956495	4
852	Clinical workup of fatty liver for the primary care provider. 2019 , 131, 19-30	2
851	Safety and tolerability of high-intensity statin therapy in heart transplant patients receiving immunosuppression with tacrolimus. 2019 , 33, e13454	7
850	Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. 2019 , 108, 520-538	18
849	The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events trial: To continue or not? How to answer the question. 2019 , 157, 164-165	
848	Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom. 2019 , 35, 829-835	8
847	Unfolding the pleiotropic facades of rosuvastatin in therapeutic intervention of myriads of neurodegenerative disorders. 2019 , 46, 283-291	4
846	Statin Use and Gastrointestinal Hemorrhage: A Large Retrospective Cohort Study. 2019 , 19, 65-74	10
845	Association of endogenous sex hormone levels with coronary artery calcium progression among post-menopausal women in the Multi-Ethnic Study of Atherosclerosis (MESA). 2019 , 13, 41-47	36
844	Does Nonenhanced CT-based Quantification of Abdominal Aortic Calcification Outperform the Framingham Risk Score in Predicting Cardiovascular Events in Asymptomatic Adults?. 2019 , 290, 108-115	39
843	Real-world use of PCSK9 inhibitors: A single-center experience. 2019 , 47, 265-270	4
842	Dietary polyphenols for atherosclerosis: A comprehensive review and future perspectives. 2019 , 59, 114-132	35

841	Effect of pistachio on brachial artery diameter and flow-mediated dilatation: A systematic review and meta-analysis of randomized, controlled-feeding clinical studies. 2019 , 59, 328-335	9
840	Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease. 2019 , 34, 1-10	6
839	Health benefits of pistachios consumption. 2019 , 33, 715-726	18
838	Lipid-modifying activity of curcuminoids: A systematic review and meta-analysis of randomized controlled trials. 2019 , 59, 1178-1187	41
837	Critical review of 2016 ACC guidelines on therapies for cholesterol lowering with reference to laboratory testing. 2019 , 489, 189-195	3
836	A nationwide cohort study of the role of CHADS score in predicting lower extremity amputation and death among patients with peripheral arterial occlusive disease. 2019 , 22, 39-44	2
835	Pharmacists' Impact on Secondary Stroke Prevention. 2019 , 32, 503-508	2
834	Can the ESC/EAS LDL-cholesterol target in patients with diabetes and high cardiovascular risk be achieved in clinical practice? Results from an ambulatory multidisciplinary diabetes center cohort. 2019 , 45, 592-595	
833	Association of pre-admission statin therapy and the inflammatory response in ST elevation myocardial infarction patients. 2019 , 24, 17-22	1
832	Physical Activity and Heart Failure: Taking Steps to Control a Major Public Health Burden. 2020 , 14, 555-570	1
831	Markers of Atherosclerosis, Clinical Characteristics, and Treatment Patterns in Heart Failure: A Case-Control Study of Middle-Aged Adult Heart Failure Patients in Rural Kenya. 2016 , 11, 97-107	8
830	Racial/ethnic differences in treatment recommendations: lifestyle changes and medication prescriptions for high cholesterol. 2020 , 25, 273-288	1
829	Tolerance of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Inhibitors in Patients With Self-Reported Statin Intolerance. 2020 , 33, 276-282	5
828	Cardiovascular risk assessment models: Have we found the perfect solution yet?. 2020 , 27, 2375-2385	3
827	Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?. 2020 , 30, 151-157	2
826	Association of Non-LDL Indices with Recurrent Stroke Risk while on Lipid-Modifying Therapy. 2020 , 27, 144-154	2
825	Characteristics of metabolic factors related to arterial stiffness in young and old adults. 2020 , 42, 225-232	5
824	Treatment practices and lipid profile of patients with acute coronary syndrome: results from a tertiary care hospital. 2020 , 75, 527-534	4

823	High-intensity lipid-lowering regimens in patients with stable coronary artery disease: the intriguing question of all-cause mortality. 2020 , 6, 328-330	3
822	Within subject variability of HDL-cholesterol in HIV-infected patients. 2020 , 132, 162-166	0
821	Suicide prediction models: a critical review of recent research with recommendations for the way forward. 2020 , 25, 168-179	41
820	Safety Outcomes of Atorvastatin 80 mg Versus Atorvastatin 40 mg in a Veteran Population. 2020 , 54, 151-156	2
819	The Critically Ill Cirrhotic Patient. 2020 ,	
818	Early-life exposures and cardiovascular disease risk among Ghanaian migrant and home populations: the RODAM study. 2020 , 11, 250-263	1
817	Residual inflammatory risk after contemporary lipid lowering therapy. 2020 , 6, 105-111	1
816	PCSK9 inhibitors and cardiovascular outcomes. 2020 , 20, 35-47	6
815	Key Articles and Guidelines in the Management of Dyslipidemia: 2019 Update. 2020 , 33, 882-894	2
814	Percutaneous coronary intervention versus coronary arterial bypass grafting in patients with multi-vessel coronary revascularization (from the CREDO-Kyoto PCI/CABG registry/cohort-2). 2020 , 96, 42-51	4
813	Disease Prevention in Heart Failure. 2020 , 487-500.e4	
812	Short-term safety and long-term benefits of stent postdilation after primary percutaneous coronary intervention: Results of a cohort study. 2020 , 95, 1249-1256	3
811	23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9. 2020 , 41, 327-335	5
810	Statin-based therapy for primary and secondary prevention of ischemic stroke: A meta-analysis and critical overview. 2020 , 15, 377-384	15
809	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. 2020 , 41, 111-188	2236
808	Safety of High-Intensity Statins in the Veteran Population: Atorvastatin 40 to 80 mg Compared With Rosuvastatin 20 to 40 mg. 2020 , 54, 405-413	5
807	Method development for quantitative determination of seven statins including four active metabolites by means of high-resolution tandem mass spectrometry applicable for adherence testing and therapeutic drug monitoring. 2020 , 58, 664-672	5
806	Statin Use and Risk of Cognitive Decline in the ADNI Cohort. 2020 , 28, 507-517	4

805	Treatment patterns of lipid-lowering therapies and possible statin intolerance among statin users with clinical atherosclerotic cardiovascular disease (ASCVD) or diabetes mellitus (DM) in Taiwan. 2020 , 26, 1171-1180	3
804	Characteristics and management of stroke in Korea: 2014-2018 data from Korean Stroke Registry. 2020 , 15, 619-626	10
803	Multiple imputation for systematically missing confounders within a distributed data drug safety network: A simulation study and real-world example. 2020 , 29 Suppl 1, 35-44	3
802	PCSK9 inhibitors: Ratification of the role of LDL cholesterol in cardiovascular prevention. Towards a convergence of European and North American prevention guidelines?. 2020 , 220, 374-382	
801	Non-High-Density Lipoprotein Cholesterol and Guidelines for Cholesterol Lowering in Recent History. 2020 , 51, 14-23	3
800	Hypertriglyceridemia triggered acute pancreatitis in pregnancy - diagnostic approach, management and follow-up care. 2020 , 19, 2	16
799	Post-Coronary Artery Bypass Medications in Dialysis Patients: Do We Need to Change Strategies?. 2020 , 68, 706-713	1
798	Computerized Advisory Decision Support for Cardiovascular Diseases in Primary Care: A Cluster Randomized Trial. 2020 , 133, 750-756.e2	4
797	Clinical Impact of Routine Cardiology Consultation Prior to Elective Carotid Endarterectomy in Neurologically Asymptomatic Patients. 2020 , 59, 536-544	2
796	No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up. 2020 , 52, 249-256	1
795	Association of Serum Uric Acid with Metabolic Syndrome and Its Components: A Cross-Sectional Study in Chinese Coastal Population. 2020 , 18, 103-109	2
794	Rationale and design of the Greek registry for familial hypercholesterolemia (GRegistry-FH) of the hellenic college of treatment of atherosclerosis (HCTA). 2020 , 61, 284-287	1
793	Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS. 2020 , 220, 82-88	2
792	Effect of Androgen Deprivation Therapy on Metabolic Complications and Cardiovascular Risk. 2020 , 13, 451-462	3
791	Genetic disorders of lipoprotein metabolism. 2020 , 245-265	
790	Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. 2020 , 7, 64-77	229
789	Have the Government's prescription algorithm and the 2013 American College of Cardiology/American Heart Association guidelines for managing dyslipidemia influenced the management of dyslipidemia? The MEJORALO-CV Project. 2020 , 220, 282-289	
788	Pragmatic Trials in Genomic Medicine: The Integrating Pharmacogenetics In Clinical Care (I-PICC) Study. 2020 , 13, 381-390	7

787	Advanced glycation end products and chronic inflammation in adult survivors of childhood leukemia treated with hematopoietic stem cell transplantation. 2020 , 67, e28106	6
786	Increased risk of developing peripheral artery disease in hemodialysis patients receiving statin treatments: a population-based cohort study in Taiwan. 2020 , 35, 1753-1760	2
785	Unmet needs in the management of cardiovascular risk in inflammatory joint diseases. 2020 , 16, 23-36	7
784	Impact of new lipid management guidelines on the treatment of extreme and very high-risk patients: AACE/ACE and AHA/ACC guidelines. 2020 , 12, 105-109	1
783	Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review. 2020 , 43, 222-234	9
782	Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE. 2020 , 22, 2248-2256	2
781	Effect of Statins on the Risk of Poststroke Pneumonia: National Population-Based Cohort Study. 2020 , 13, 2689-2698	2
780	Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study. 2020 , 19, 167	6
779	Effect of Passive Choice and Active Choice Interventions in the Electronic Health Record to Cardiologists on Statin Prescribing: A Cluster Randomized Clinical Trial. 2021 , 6, 40-48	10
778	Abcsic Acid Treatment in Patients with Prediabetes. 2020 , 12,	2
777	J-shaped relationship between cardiovascular risk and efficacy of intensive blood pressure reduction: A post-hoc analysis of the SPRINT trial. 2020 , 15, e0240102	1
776	Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and both. 2020 , 36, 1927-1938	0
775	Impact of lipid levels and high-intensity statins on vein graft patency after CABG: Midterm results of the ACTIVE trial. 2020 , 35, 3286-3293	4
774	Challenges and Opportunities for the Prevention and Treatment of Cardiovascular Disease Among Young Adults: Report From a National Heart, Lung, and Blood Institute Working Group. 2020 , 9, e016115	28
773	The Enhanced Pharmacological Effects of Modified Traditional Chinese Medicine in Attenuation of Atherosclerosis Is Driven by Modulation of Gut Microbiota. 2020 , 11, 546589	4
772	Ambulatory Blood Pressure Monitoring in HIV-Infected Patients: Usefulness for Cardiovascular Risk Assessment. 2020 , 19, 2325958220935693	0
771	Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias. 2020 , 32, 209-218	1
770	Epidemiological Evidence: Use at Your Own Risk. 2020 , 87, 1119-1129	2

- 769 Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives. **2020**, 2020, 9815016 7
- 768 Effect of 3-Hydroxy-3-Methyl-Glutaryl-Coenzyme A Reductase Inhibitors on the Meibomian Gland Morphology in Patients with Dyslipidemia. **2020**, 219, 240-252 3
- 767 The evaluation and management of patients with LDL-C ≥ 90 mg/dL in a large health care system. **2020**, 1, 100002 0
- 766 The Role of Sex-Specific Risk Factors in the Risk Assessment of Atherosclerotic Cardiovascular Disease for Primary Prevention in Women. **2020**, 22, 46 8
- 765 The associations between neutrophil-to-lymphocyte ratio and the Chinese Visceral Adiposity Index, and carotid atherosclerosis and atherosclerotic cardiovascular disease risk. **2020**, 139, 111019 8
- 764 Non-HDL or LDL cholesterol in heterozygous familial hypercholesterolaemia: findings of the Simon Broome Register. **2020**, 31, 167-175 2
- 763 Subclinical atherosclerosis: how and when to treat it?. **2020**, 22, E87-E90 11
- 762 Prolonged hyperlipidemia exposure increases the risk of arterial stiffness in young adults: a cross-sectional study in a cohort of Chinese. **2020**, 20, 1091 2
- 761 The cholesterol-lowering effect of unripe *Rubus coreanus* is associated with decreased oxidized LDL and apolipoprotein B levels in subjects with borderline-high cholesterol levels: a randomized controlled trial. **2020**, 19, 166 5
- 760 Statin use in patients with non-HMGCR idiopathic inflammatory myopathies: A retrospective study. **2020**, 43, 732-742 7
- 759 Lipids and lipoproteins. **2020**, 487-506 1
- 758 Rates and Correlates of Incident Type 2 Diabetes Mellitus Among Persons Living With HIV-1 Infection. **2020**, 11, 555401 1
- 757 Outcomes of coronary artery bypass grafting in patients with human immunodeficiency virus infection. **2020**, 35, 2543-2549 1
- 756 Molecular and Cellular Mechanisms of Electronegative Lipoproteins in Cardiovascular Diseases. **2020**, 8, 8
- 755 Real-World Effectiveness of Therapy With Rosuvastatin Combined With Fenofibric Acid in a Sample of Colombian Patients With Mixed Dyslipidemia. **2020**, 11, 2150132720977733
- 754 Effects of Urate-Lowering Therapy on Risk of Hyperlipidemia in Gout by a Population-Based Cohort Study and on Hepatic Lipogenesis-Related Gene Expression. **2020**, 2020, 8890300 3
- 753 Dyslipidemias and stroke prevention: recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology. **2020**, 2
- 752 A bibliometric analysis of multimorbidity from 2005 to 2019. **2020**, 10, 2235042X20965283 1

751	The conundrum of asymptomatic carotid stenosis-determinants of decision and evidence. 2020 , 8, 1279	1
750	First national registry on the effectiveness and safety of evolocumab in clinical practice in patients attended in cardiology in Spain. The RETOSS-CARDIO study. 2020 , 32, 231-241	1
749	At the intersection of precision medicine and population health: an implementation-effectiveness study of family health history based systematic risk assessment in primary care. 2020 , 20, 1015	6
748	Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects. 2020 , 16, 837-851	2
747	Prediction models for cardiovascular disease risk in the hypertensive population: a systematic review. 2020 , 38, 1632-1639	5
746	Markers of Myocardial Stress, Myocardial Injury, and Subclinical Inflammation and the Risk of Sudden Death. <i>Circulation</i> , 2020 , 142, 1148-1158	16.7 6
745	Association of in-hospital intensive statins dosage and death in arteriosclerotic cardiovascular disease with percutaneous coronary intervention: insights of multicentre cohort from China. 2020 , 76, 1755-1763	
744	Trends in LDL-C and Non-HDL-C Levels with Age. 2020 , 11, 1046-1057	10
743	Efficacy and Tolerability of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Compared with a Fixed-Dose Combination of Simvastatin and Ezetimibe in Brazilian Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia: A Multicenter, Randomized Trial. 2020 , 93, 100595	4
742	Cardiovascular prevention guidelines of the scientific societies and healthcare administrations: The need for convergence. 2020 , 220, 294-296	
741	Predictors of Statin Intolerance in Patients With a New Diagnosis of Atherosclerotic Cardiovascular Disease Within a Large Integrated Health Care Institution: The IMPRES Study. 2020 , 75, 426-431	3
740	Exercise-Pharmacology Interactions: Metformin, Statins, and Healthspan. 2020 , 35, 338-347	6
739	Relation of Low-Density Lipoprotein Cholesterol Level to Plaque Rupture. 2020 , 134, 48-54	3
738	Is race or ethnicity associated with under-utilization of statins among women in the United States: The study of women's health across the nation. 2020 , 43, 1388-1397	3
737	Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type. 2020 , 17,	
736	Predicting Risk of Atherosclerotic Cardiovascular Disease Using Pooled Cohort Equations in Older Adults With Frailty, Multimorbidity, and Competing Risks. 2020 , 9, e016003	5
735	Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial. 2020 , 51, 2960-2971	8
734	Maternal cardiovascular disease risk factors as predictors of preterm birth in California: a case-control study. 2020 , 10, e034145	2

733	Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. 2020 , 105,	26
732	High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients. 2020 , 19, 194	5
731	Prediction of Coronary Artery Calcium Score Using Machine Learning in a Healthy Population. 2020 , 10,	3
730	Lipid-lowering Therapies in Myositis. 2020 , 22, 70	
729	Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet. 2020 , 8, e00637	5
728	Risks of Incident Cardiovascular Disease Associated With Concomitant Elevations in Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-The Framingham Heart Study. 2020 , 9, e014711	10
727	Efficacy and safety of Zhibitai in treating coronary heart disease patients with hyperlipemia: A protocol for systematic review and meta-analysis. 2020 , 99, e21991	
726	Assessing the effectiveness of statin therapy for alleviating cerebral small vessel disease progression in people \geq 5 years of age. 2020 , 20, 292	10
725	Plaque Regression and Endothelial Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER). 2020 , 13, e008933	1
724	Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape. 2020 , 15, 1177271920974652	14
723	Can Blood-Circulating Factors Unveil and Delay Your Biological Aging?. 2020 , 8,	10
722	Prevalence, treatment, and control of severe hyperlipidemia. 2020 , 3, 100079	1
721	[Prudential approach to subclinical hypothyroidism]. 2020 , 162, 76-83	
720	Statin Use for Atherosclerotic Cardiovascular Disease Prevention Among Sexual Minority Adults. 2020 , 9, e018233	2
719	Classification of drug use patterns. 2020 , 8, e00687	1
718	De-Ritis Ratio Is Associated with Mortality after Cardiac Arrest. 2020 , 2020, 8826318	1
717	Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias. 2020 , 32, 209-218	2
716	A controlled trial of dissemination and implementation of a cardiovascular risk reduction strategy in small primary care practices. 2020 , 55, 944-953	4

7 ¹⁵	The Haiti cardiovascular disease cohort: study protocol for a population-based longitudinal cohort. 2020 , 20, 1633	4
7 ¹⁴	Performance of the Pooled Cohort Equations to Estimate Atherosclerotic Cardiovascular Disease Risk by Body Mass Index. 2020 , 3, e2023242	9
7 ¹³	Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial. 2020 , 5, 787-793	11
7 ¹²	Tight versus standard blood pressure control on the incidence of myocardial infarction and stroke: an observational retrospective cohort study in the general ambulatory setting. 2020 , 21, 91	1
7 ¹¹	Statin dose titration patterns and subsequent major cardiovascular events in very high-risk patients: estimates from Swedish population-based registry data. 2020 , 6, 323-331	4
7 ¹⁰	Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India. 2020 , 15, e0233230	5
7 ⁰⁹	Hemodynamic Change of Coronary Atherosclerotic Plaque After Statin Treatment: A Serial Follow-Up Study by Computed Tomography-Derived Fractional Flow Reserve. 2020 , 9, e015772	4
7 ⁰⁸	Consumption of Goat Cheese Naturally Rich in Omega-3 and Conjugated Linoleic Acid Improves the Cardiovascular and Inflammatory Biomarkers of Overweight and Obese Subjects: A Randomized Controlled Trial. 2020 , 12,	6
7 ⁰⁷	Disparities in Biomarkers for Patients With Diabetes After the Affordable Care Act. 2020 , 58 Suppl 6 Suppl 1, S31-S39	1
7 ⁰⁶	Underuse of statins for secondary prevention of atherosclerotic cardiovascular disease events among ambulatory surgical patients. 2020 , 18, 101085	2
7 ⁰⁵	Treatment Patterns of Lipid-Lowering Therapy in Patients with Coronary Artery Disease Aged Above and Below 75 Years: A Retrospective Cross-Sectional Study of 1500 Patients in a Tertiary Care Referral Center in Germany. 2020 , 37, 521-527	0
7 ⁰⁴	Deep learning-enabled point-of-care sensing using multiplexed paper-based sensors. 2020 , 3, 66	38
7 ⁰³	Combined effects of carotid plaques and hypertension on the risk of cardiovascular disease and all-cause mortality. 2020 , 43, 715-722	5
7 ⁰²	Risk factors of white matter hyperintensities in South Asian patients with transient ischemic attack and minor stroke. 2020 , 62, 1279-1284	3
7 ⁰¹	Citrus reticulata peel oil as an antiatherogenic agent: Hypolipogenic effect in hepatic cells, lipid storage decrease in foam cells, and prevention of LDL oxidation. 2020 , 30, 1590-1599	3
7 ⁰⁰	Hyperlipidemias in elderly patients: results from the Berlin Aging Study II (BASEII), a cross-sectional study. 2020 , 19, 92	11
6 ⁹⁹	Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals. 2020 , 5, 871-880	10
6 ⁹⁸	External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Anti-Inflammatory Drug Users: Real-World Application. 2020 , 2, 269-275	

697	Association of Dry Eye Disease With Dyslipidemia and Statin Use. 2020 , 218, 54-58	1
696	Association of hyperlipidaemia with 5-year survival after hospitalisation for acute myocardial infarction: a propensity score matched analysis. 2020 , 7, e001163	2
695	Commentary: Yin and Yang: Antiplatelet and lipid-lowering therapies to prevent vein graft thrombosis and atherosclerosis after coronary artery bypass graft surgery. 2020 ,	1
694	Using Administrative Data to Predict Suicide After Psychiatric Hospitalization in the Veterans Health Administration System. 2020 , 11, 390	18
693	Impact of Plasma Exposure of Statins and Their Metabolites With Major Adverse Cardiovascular Events in Chinese Patients With Coronary Artery Disease. 2020 , 11, 675	1
692	Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus. 2020 , 9,	
691	Efficacy of statin treatment based on cardiovascular outcomes in elderly patients: a standard meta-analysis and Bayesian network analysis. 2020 , 48, 300060520926349	3
690	Valorization of pomelo (<i>Citrus grandis</i> Osbeck) peel: A review of current utilization, phytochemistry, bioactivities, and mechanisms of action. 2020 , 19, 1969-2012	38
689	Nicotinamide Riboside-The Current State of Research and Therapeutic Uses. 2020 , 12,	44
688	Cardiovascular prevention guidelines of the scientific societies and healthcare administrations: The need for convergence. 2020 , 220, 294-296	
687	Reorganizing the treatment of cardiovascular disease in response to coronavirus disease 2019; time for the polypill?. 2020 , 35, 428-433	5
686	Statins Alone or in Combination with Ezetimibe or PCSK9 Inhibitors in Atherosclerotic Cardiovascular Disease Protection. 2020 ,	0
685	Long-term nitric oxide synthase inhibition prevents 17 β -estradiol-induced suppression of cyclooxygenase-dependent contractions and enhancement of endothelium-dependent hyperpolarization-like relaxation in mesenteric arteries of ovariectomized rats. 2020 , 882, 173275	
684	The South Asian Healthy Lifestyle Intervention (SAHELI) trial: Protocol for a mixed-methods, hybrid effectiveness implementation trial for reducing cardiovascular risk in South Asians in the United States. 2020 , 92, 105995	2
683	High manganese exposure decreased the risk of high triglycerides in workers: a cross-sectional study. 2020 , 20, 874	1
682	An Empirical Comparison of Statistical Methods for Missing Data in Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Trials for Chronic Pain and Lipid-Lowering Products. 2020 , 54, 1416-1427	
681	Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002-2016. 2020 , 14, 305-314	2
680	Effect of a Comprehensive Cardiovascular Risk Reduction Intervention in Persons With Serious Mental Illness: A Randomized Clinical Trial. 2020 , 3, e207247	26

679	Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets : Lipid-lowering combination therapy. 2020 , 22, 66	6
678	Trends in cardiovascular risk factor prevalence among Lithuanian middle-aged adults between 2009 and 2018. 2020 , 299, 9-14	3
677	ANGPTL3 deficiency alters the lipid profile and metabolism of cultured hepatocytes and human lipoproteins. 2020 , 1865, 158679	4
676	Pleiotropic Effects of Simvastatin on the Regulation of Potassium Channels in Monocytes. 2020 , 11, 101	4
675	Cumulative Adherence to Secondary Prevention Guidelines and Mortality After Acute Myocardial Infarction. 2020 , 9, e014415	16
674	Statin use is associated with improved survival in multiple myeloma: A Swedish population-based study of 4315 patients. 2020 , 95, 652-661	11
673	Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A in the ADVANCE Trial. 2020 , 43, 1293-1299	8
672	The predictive study of the relation between elevated low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and mortality in peritoneal dialysis. 2020 , 19, 51	3
671	PCSK9 Protein and rs562556 Polymorphism Are Associated With Arterial Plaques in Healthy Middle-Aged Population: The STANISLAS Cohort. 2020 , 9, e014758	9
670	Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine. 2020 , 10,	30
669	Diabetes mellitus: an important risk factor for peripheral vascular disease. 2020 , 18, 131-137	7
668	Correlations between Direct and Calculated Low-Density Lipoprotein Cholesterol Measurements in Children and Adolescents. 2020 , 34, e23236	1
667	Impact of team-based care on appropriate statin therapy prescribing in ***HIV-infected patients. 2020 , 3, 615-622	2
666	Prevalence of Coronary Artery Calcification on Pre-Atrial Fibrillation Ablation CT Pulmonary Venograms and its Impact on Selection for Statin Therapy. 2020 , 9,	4
665	Statin intensity and risk for cardiovascular events after heart transplantation. 2020 , 7, 2074-2081	5
664	116? How much should LDL-C be lowered in the «low risk» population?. 2020 , 73, 690-691	
663	Comparison of calculated LDL-cholesterol using the Friedewald formula and de Cordova formula with a directly measured LDL-cholesterol in Nepalese population. 2020 , 20, e00165	1
662	Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights. 2020 , 21,	16

661	The institutionalisation and deinstitutionalisation of the cholesterol theory. 2020 , 12, 173-192	0
660	Prevalence and Correlates of Statin Underuse for Secondary Prevention of Cardiovascular Disease in Older Adults 65-79 Years of Age: The Italian Health Examination Survey 2008-2012. 2020 , 23, 394-400	3
659	Statins and All-Cause Mortality in Patients Undergoing Hemodialysis. 2020 , 9, e014840	9
658	Hsa-miR-140-5p down-regulates LDL receptor and attenuates LDL-C uptake in human hepatocytes. 2020 , 297, 111-119	13
657	Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics. 2020 , 72, 320-342	67
656	Environmentally responsive hydrogels for repair of cardiovascular tissue. 2021 , 26, 1273-1285	3
655	Nonlinear optical responses of oxidized low-density lipoprotein: Cutoff point for z-scan peak-valley distance. 2020 , 30, 101689	0
654	Reducing cardiovascular risk among people living with HIV: Rationale and design of the INcreasing Statin Prescribing in HIV Behavioral Economics REsearch (INSPIRE) randomized controlled trial. 2020 , 63, 109-117	3
653	Hyperlipidemia and Statins Use for the Risk of New Diagnosed Sarcopenia in Patients with Chronic Kidney: A Population-Based Study. 2020 , 17,	8
652	Effectiveness of a pharmacist-led population health approach to implementing statin therapy in primary prevention patients with type 2 diabetes mellitus. 2020 , 3, 723-728	1
651	Case report of one month and 15 days old baby with type V hyperlipoproteinemia (HLP). 2020 , 20, 22	
650	Primary Prevention Statins in Older Adults: Personalized Care for a Heterogeneous Population. 2020 , 68, 467-473	3
649	Personal Health Practices and Perceptions of Lifestyle Counseling and Preventive Services Among Residents.. 2022 , 16, 203-213	0
648	Incidence and Predictors of Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Disease or Multiple Risk Factors. 2020 , 9, e014402	26
647	Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. <i>Circulation</i> , 2020 , 141, e139-e596	16.7 2824
646	Lipoprotein-associated phospholipase A2 predicted cardiovascular disease in obstructive sleep apnea syndrome. 2020 , 163, 105881	4
645	Statins Disrupt Macrophage Rac1 Regulation Leading to Increased Atherosclerotic Plaque Calcification. 2020 , 40, 714-732	27
644	Low-density lipoprotein cholesterol goal attainment rates in high-risk patients with cardiovascular diseases and diabetes mellitus in Korea: a retrospective cohort study. 2020 , 19, 5	5

643	Concordance and prevalence of subclinical atherosclerosis in different vascular territories. 2020 , 28, 285-294	4
642	Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries. 2020 , 2020, 3856242	5
641	Development of a 3-Dimensional Prognostic Score for Patients With Symptomatic Peripheral Artery Disease: PAD Score. 2020 , 71, 658-665	1
640	Pharmacists' Utilization of Non-HDL-C Levels in Managing Patients With Lipid Disorders. 2021 , 56, 378-383	0
639	Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry. 2020 , 225, 88-96	3
638	Association of blood lipid profile with incident chronic kidney disease: A Mendelian randomization study. 2020 , 300, 19-25	12
637	Cardiovascular risk factors and cardiovascular disease in patients with type 1 diabetes and end-stage renal disease candidates for kidney-pancreas transplantation: Trends from 1999 to 2017. 2020 , 163, 108135	7
636	Target Doses of Secondary Prevention Medications Are Not Being Achieved in Patients With Reduced Left Ventricular Ejection Fraction After Acute Coronary Syndrome (ANZACS-QI 34). 2020 , 29, 1386-1396	1
635	Improving statin prescription through the involvement of nurses in the provision of ASCVD score: a quality improvement initiative in primary care. 2020 , 132, 479-484	1
634	Time trends analysis of statin prescription prevalence, therapy initiation, dose intensity, and utilization from the hospital information system of Jinshan Hospital, Shanghai (2012-2018). 2020 , 20, 201	6
633	ImPlementation REsearCh to DEvelop Interventions for People Living with HIV (the PRECLuDE consortium): Combatting chronic disease comorbidities in HIV populations through implementation research. 2020 , 63, 79-91	5
632	Effects of ABCA1 gene polymorphisms on risk factors, susceptibility and severity of coronary artery disease. 2020 , 96, 666-673	2
631	Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?. 2020 , 4, 4	1
630	Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. 2020 , 51, 1546-1554	35
629	Assessment of the Efficacy of Lowering LDL Cholesterol with Rosuvastatin 10 mg in Four Korean Statin Benefit Groups as per ACC/AHA Guidelines (NewStaR4G). 2020 , 9,	1
628	Vascular ultrasound imaging for screening patients at risk for cardiovascular events: application from the west to the East. 2014 , 9, 379-80	1
627	Risk scoring for the primary prevention of cardiovascular disease. 2017 , 3, CD006887	45
626	Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease. 2021 , 36, 1-8	1

625	Effect of Probucol and/or Cilostazol on Carotid Intima Media Thickness in Patients with Coronary Heart Disease: A Randomized, Multicenter, Multinational Study. 2021 , 28, 124-136	3
624	Traditional Mexican foods as functional agents in the treatment of cardiometabolic risk factors. 2021 , 61, 1353-1364	5
623	Physicochemical and dissolution properties of ezetimibe–rosuvastatin binary system in development of fixed-dose combinations. 2021 , 144, 1219-1227	3
622	PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks. 2021 , 21, 83-92	10
621	Estimation of the increased risk associated with recurrent events or polyvascular atherosclerotic cardiovascular disease in the United Kingdom. 2020 , 2047487319899212	5
620	Low adherence to statin treatment during the 1st year after an acute myocardial infarction is associated with increased 2nd-year mortality risk-an inverse probability of treatment weighted study on 54 872 patients. 2021 , 7, 141-147	9
619	A systematic review of the effect of dietary interventions on cardiovascular disease risk in adults with spinal cord injury. 2021 , 44, 184-203	4
618	Practical Guidance for Food Consumption to Prevent Cardiovascular Disease. 2021 , 30, 163-179	8
617	Cortisol level after dexamethasone suppression test in patients with non-functioning adrenal incidentaloma is positively associated with the duration of reactive hyperemia response on microvascular bed. 2021 , 44, 609-619	1
616	Association Between the Atherosclerotic Disease Risk Score and Carotid Artery Stenosis. 2021 , 257, 189-194	1
615	Association between statin use and second cancer risk in breast cancer patients: a nationwide population-based cohort study. 2021 , 185, 773-783	0
614	Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia. 2021 , 30, 324-349	20
613	The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. 2021 , 15, 33-60	33
612	Dyslipemias and pregnancy, an update. 2021 , 33, 41-52	5
611	Optical Coherence Tomography Predictors for a Favorable Vascular Response to Statin Therapy. 2021 , 10, e018205	1
610	Development of a Novel Clinical Decision Support System for Exercise Prescription Among Patients With Multiple Cardiovascular Disease Risk Factors. 2021 , 5, 193-203	5
609	Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society. 2021 , 12, 1-51	5
608	Evaluation of physician's knowledge in Jordan about the ACC/AHA blood cholesterol guidelines. 2021 , 75, e13784	1

607	Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease. 2021 , 36, 1-8	
606	National Trends in Statin Medication Prescribing in Patients With a History of Stroke or Transient Ischemic Attack. 2021 , 34, 216-223	0
605	Is multiple sclerosis a risk factor for atherosclerosis?. 2021 , 48, 99-103	6
604	How low is safe? The frontier of very low (. 2021 , 42, 2154-2169	6
603	Atorvastatin impairs liver mitochondrial function in obese Göttingen Minipigs but heart and skeletal muscle are not affected. 2021 , 11, 2167	2
602	Provider Adherence to Prescribing Guidelines for Statin Therapy. 2021 ,	
601	Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. 2021 ,	4
600	Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes. 2021 , 21, 19	1
599	Effect of gene DNA methylations on the lipid-lowering efficacy of simvastatin. 2021 , 22, 27-39	0
598	Cardiovascular Disease. 2021 , 239-260	
597	Kawasaki Disease. 2021 , 179-199	
596	Statin Use in Older Adults with Stable Atherosclerotic Cardiovascular Disease. 2021 , 69, 979-985	2
595	Schlaganfall (Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung. 2021 , 751-762	
594	Investigation of Factors of Anti-aging Medical Checkups Affecting HDL Subfractions. 2021 , 48,	
593	Cardiovascular Diseases and Rheumatology. 2021 , 353-381	
592	Racionalidad científica para la evolución de las metas de LDL-c. 2021 , 32, 182-191	
591	Five-Year Risk of Acute Myocardial Infarction After Acute Ischemic Stroke in Korea. 2021 , 10, e018807	5
590	Bempedoic acid: Review of a novel therapy in lipid management. 2021 , 78, 95-104	1

589	Dyslipidemia and Cardiometabolic Syndrome. 2021 , 1, 18	1
588	Biomarkers. 2021 ,	0
587	The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study. 2021 , 19, 25	0
586	Patient-Perceived Versus Actual Risk of Cardiovascular Disease and Associated Willingness to Consider and Use Prevention Therapy. 2021 , 14, e006548	2
585	Effect of diet on neurological disorders and regenerative processes in the brain. 2021 , 41-79	
584	Reassessment of Inclusion Criteria in the 2013 the American College of Cardiology and the American Heart Association Cholesterol Guidelines for Cardiovascular Disease Prevention. 2021 , 17, 86-95	1
583	Improved Lipid Target Level Attainment in Patients with Peripheral Artery Disease. 2021 , 19, 634-642	
582	Prevalence of Guideline-Directed Medical Therapy for Cardiovascular Disease Among Baltimore City Adults in the Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS) Study. 2021 , 1	0
581	Interactions Between Enhanced Polygenic Risk Scores and Lifestyle for Cardiovascular Disease, Diabetes, and Lipid Levels. 2021 , 14, e003128	23
580	Comparing different types of statins for secondary prevention of cardio-cerebrovascular disease from a national cohort study. 2021 , 16, e0247419	
579	Anthropometric measures of obesity and associated cardiovascular disease risk in the Eastern Caribbean Health Outcomes Research Network (ECHORN) Cohort Study. 2021 , 21, 399	2
578	A reappraisal of the prevalence of pediatric hypertension through a nationwide database in Taiwan. 2021 , 11, 4475	0
577	Lipid Profile and IL-17A in Allergic Rhinitis: Correlation With Disease Severity and Quality of Life. 2021 , 14, 109-117	3
576	Validaci3n externa de las ecuaciones europea y americana para el c3lculo del riesgo cardiovascular en poblaci3n laboral espa3ola. 2021 ,	0
575	Late effects post-autologous hematopoietic stem cell transplantation. 2021 , 47-57	
574	Cost-effectiveness of Statin Use Guidelines. 2021 , 6, 363-364	
573	Effects of vitamin D supplementation on apolipoprotein A1 and B100 levels in adults: Systematic review and meta-analysis of controlled clinical trials. 2021 , 13, 190-197	1
572	Preventive Cardiovascular Care in Patients With HIV Infection in an Outpatient Clinic. 2021 , 8971900211000700	

571	Antihyperlipidemic and Antiobesity potential of Aquilaria agallocha & Borago officinalis in Fixed Dose Combination; A Contingent Probe with Atorvastatin & Orlistat. 2021 , 17,	
570	The Relationship between Cardiovascular Risk Scores and Several Markers of Subclinical Atherosclerosis in an Asymptomatic Population. 2021 , 10,	5
569	Dyslipidemia among allergic rhinitis patients: Frequency and risk factors. 2021 , 14, 100523	0
568	Association of Accelerometer-Measured Physical Activity and Cardiovascular Health in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). 2021 , 1540415320985581	0
567	Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks. 2021 , 11, 6697	
566	Compatibility between an overnight fasting and random cholesterol tests in Asians. 2021 , 11, 6478	1
565	Personalized medicine in lipid-modifying therapy. 2021 , 18, 185-203	0
564	Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy. 2021 , 65, 103250	2
563	Statin Use and Benefits of Thyroid Function: A Retrospective Cohort Study. 2021 , 12, 578909	2
562	Regulation of endoplasmic reticulum stress and trophectoderm lineage specification by the mevalonate pathway in the mouse preimplantation embryo. 2021 , 27,	0
561	Sex differences in coronary artery calcium progression: The Korea Initiatives on Coronary Artery Calcification (KOICA) registry. 2021 , 16, e0248884	1
560	Non-HDL-C Is More Stable Than LDL-C in Assessing the Percent Attainment of Non-fasting Lipid for Coronary Heart Disease Patients. 2021 , 8, 649181	3
559	Prescription of statins and pharmacokinetic interactions in Colombian patients. 2021 , 17, 627-634	1
558	Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study. 2021 , 10, e016947	10
557	New Drugs and Interventional Strategies for the Management of Hypertension. 2021 , 27, 1396-1406	0
556	Escalation of lipid-lowering therapy in patients with vascular disease receiving HIGH-intensity statins: the retrospective POST-HIGH study. 2021 , 11, 8884	1
555	Association of Treatment Intensity and Adherence to Lipid-Lowering Therapy with Major Adverse Cardiovascular Events Among Post-MI Patients in Germany. 2021 , 38, 2532-2541	2
554	Very High Coronary Artery Calcium (≥ 1000) and Association With Cardiovascular Disease Events, Non-Cardiovascular Disease Outcomes, and Mortality: Results From MESA. <i>Circulation</i> , 2021 , 143, 1571-1583	13

553	Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. 2021 , 271, 119220	11
552	Essentials of a new clinical practice guidance on familial hypercholesterolaemia for physicians. 2021 , 51, 769-779	0
551	Qualitative Exploration of Barriers to Statin Adherence and Lipid Control: A Secondary Analysis of a Randomized Clinical Trial. 2021 , 4, e219211	2
550	Effect of a dietary intervention with functional foods on LDL-C concentrations and lipoprotein subclasses in overweight subjects with hypercholesterolemia: Results of a controlled trial. 2021 , 40, 2527-2534 ¹	
549	Prevention of atherosclerotic cardiovascular disease in South Asians in the US: A clinical perspective from the National Lipid Association. 2021 , 15, 402-422	3
548	Low LDL-C levels are associated with risk of mortality in a Chinese cohort study. 2021 , 73, 563-572	3
547	Statin Utilization among Patients with Acute Coronary Syndrome: Systematic Review. 2021 , 9, 267-278	
546	Cardiovascular disease prevention and therapy in women with Type 2 diabetes. 2021 , 17, 487-496	4
545	Nursing workload. Calculation of cardiovascular risk and therapeutic objectives. 2021 , 33 Suppl 1, 10-17	
544	Inferior control of low-density lipoprotein cholesterol in women is the primary sex difference in modifiable cardiovascular risk: A large-scale, cross-sectional study in primary care. 2021 , 324, 141-147	6
543	Effects of double-dose statin therapy for the prevention of post-stroke epilepsy: A prospective clinical study. 2021 , 88, 138-142	2
542	Patient perceptions and use of non-statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry. 2021 , 44, 863-870	1
541	Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives. 2021 , 21, 815-834	4
540	Attenuating the Variability of Lipids Is Beneficial for the Hypertension Management to Reduce the Cardiovascular Morbidity and Mortality in Older Adults. 2021 , 8, 692773	0
539	Effect of competing mortality risks on predictive performance of the QRISK3 cardiovascular risk prediction tool in older people and those with comorbidity: external validation population cohort study. 2021 , 2, e352-e361	5
538	Switching, Persistence and Adherence to Statin Therapy: a Retrospective Cohort Study Using the Australian National Pharmacy Data. 2021 , 1	3
537	Impact of the 2016 Canadian Lipid Guidelines on Daily Practice at a Community Hospital. 2021 ,	
536	Interhospital and interindividual variability in secondary prevention: a comparison of outpatients with a history of chronic coronary syndrome versus outpatients with a history of acute coronary syndrome (the iASPIRE Study). 2021 , 8,	1

535	A systematic review of the correlation between serum asymmetric dimethylarginine, carotid atherosclerosis and ischaemic stroke. 2021 , 51, e13558	2
534	Changes in Cardiovascular Risk Factors and Cardiovascular Events in the Elderly Population. 2021 , 10, e019482	3
533	Trends in optimal medical therapy at discharge and clinical outcomes in patients with acute coronary syndrome in Thailand. 2021 , 77, 669-676	1
532	Statin Therapy and the Incidence of Thromboembolism and Vascular Events Following Liver Transplantation. 2021 , 27, 1432-1442	1
531	External validation of the European and American equations for calculating cardiovascular risk in a Spanish working population. 2021 , 221, 561-568	
530	Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States. 2021 , 6, 100177	2
529	A Clinical Debate: Subclinical Hypothyroidism. 2021 , 19, e115948	1
528	The U-Shaped Association of Non-High-Density Lipoprotein Cholesterol Levels With All-Cause and Cardiovascular Mortality Among Patients With Hypertension. 2021 , 8, 707701	2
527	Real-world analyses of patients with elevated atherosclerotic cardiovascular disease risk from the Optum Research Database. 2021 , 17, 743-755	2
526	Association of monocyte-to-high density lipoprotein ratio with arterial stiffness in patients with diabetes. 2021 , 21, 362	0
525	Association Between Vitamin D and Statin-Related Myopathy: A Meta-analysis. 2021 , 1	1
524	Assessing Cardiovascular Risk in People Living with HIV: Current Tools and Limitations. 2021 , 18, 271-279	4
523	The clinical role of combined serum C1q and hsCRP in predicting coronary artery disease. 2021 , 93, 50-58	0
522	Lipids Abnormality and Type 2 Diabetes Mellitus: Causes and Consequences.	
521	Nutritional Approach to Prevention and Treatment of Cardiovascular Disease in Childhood. 2021 , 13,	3
520	Assessment of Coronary Artery Calcium Scoring to Guide Statin Therapy Allocation According to Risk-Enhancing Factors: The Multi-Ethnic Study of Atherosclerosis. 2021 , 6, 1161-1170	10
519	Could Flozins Be the Statins for Risk-Based Primary Prevention of Heart Failure?. 2021 , 6, 741-742	6
518	Fewer patients receive recommendations for pharmacotherapy in primary prevention using the 2018 atherosclerotic cardiovascular disease risk estimator. 2021 , 148, 106555	1

517	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. 2021 , 27, 363-401	21
516	MEDI6012: Recombinant Human Lecithin Cholesterol Acyltransferase, High-Density Lipoprotein, and Low-Density Lipoprotein Receptor-Mediated Reverse Cholesterol Transport. 2021 , 10, e014572	4
515	Lipoprotein (a): When to Measure and How to Treat?. 2021 , 23, 51	2
514	Comparative efficacy of fixed-dose statin and antihypertensive agent combinations: A network meta-analysis of randomized controlled trials. 2021 , 141, 106900	0
513	Protective Effects of Flavonoids Against Mitochondriopathies and Associated Pathologies: Focus on the Predictive Approach and Personalized Prevention. 2021 , 22,	11
512	Cholesterol Control for Subclinical Coronary Atherosclerosis in Subjects Without Indication for Statin Therapy. 2021 , 153, 51-57	0
511	Physical Activity as a Critical Component of First-Line Treatment for Elevated Blood Pressure or Cholesterol: Who, What, and How?: A Scientific Statement From the American Heart Association. 2021 , 78, e26-e37	10
510	Low-Density Lipoprotein Cholesterol and Risk of Recurrent Vascular Events in Chinese Patients With Ischemic Stroke With and Without Significant Atherosclerosis. 2021 , 10, e021855	1
509	Study on the Effect of Macrophages on Vascular Endothelium in Mice With Different TCM Syndromes of Dyslipidemia and its Biological Basis Based on RNA-Seq Technology. 2021 , 12, 665635	1
508	Statin gap in patients living with HIV: assessing dose appropriateness. 2021 , 22, 917-923	0
507	Prioritizing the Role of Major Lipoproteins and Subfractions as Risk Factors for Peripheral Artery Disease. <i>Circulation</i> , 2021 , 144, 353-364	16.7 6
506	Inhibits PCSK9 and Lowers Cholesterol Levels in Rats. 2021 , 26,	0
505	Deintensification or No Statin Treatment Is Associated With Higher Mortality in Patients With Ischemic Stroke or Transient Ischemic Attack. 2021 , 52, 2521-2529	2
504	A Propensity-Matched Analysis of Endovascular Intervention versus Open Nonautologous Bypass as Initial Therapy in Patients with Chronic Limb-Threatening Ischemia. 2021 , 75, 194-204	
503	Peroxisome Proliferator-Activated Receptor Alpha Mediates the Beneficial Effects of Atorvastatin in Experimental Colitis. 2021 , 12, 618365	1
502	What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. 2021 , 10, e020893	0
501	The determinants of lipid profiles in early adolescence in a Ugandan birth cohort. 2021 , 11, 16503	1
500	Diabetic dyslipidaemia. 2021 , 26, e00248	1

499	Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter Variant. 2021 , 5, 1755-1766	0
498	The Relationship Between Serum Uric Acid at Different Concentrations of Lipid Indices and the Risk of Myocardial Revascularization in Patients With Acute Coronary Syndrome: A Retrospective Analysis. 2021 , 8, 732715	1
497	The Protective Effects of Statins Towards Vessel Wall Injury Caused by a Stent Retrieving Mechanical Thrombectomy Device : A Histological Analysis of the Rabbit Carotid Artery Model. 2021 , 64, 693-704	0
496	Coronary Artery Calcium: Where Do We Stand After Over 3 Decades?. 2021 , 134, 1091-1095	1
495	The Impact of American College of Cardiology Chest Pain Center Accreditation on Guideline Recommended Acute Myocardial Infarction Management. 2021 , 20, 173-178	
494	Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia. 2021 , 1	0
493	A Multicenter Prospective Hospital-based Cohort Study on the Efficacy and Safety of Pitavastatin. 2021 , 17, e122820189541	2
492	Colchicine Use and Risks of Stroke Recurrence in Acute Non-Cardiogenic Ischemic Stroke Patients: A Population-Based Cohort Study. 2021 , 11,	0
491	Effect of pravastatin on erythrocyte membrane fatty acid contents in patients with chronic kidney disease. 2021 , 40, 392-400	
490	Premature Menopause and 10-Year Risk Prediction of Atherosclerotic Cardiovascular Disease. 2021 , ,	1
489	Prediction of brain age from routine T2-weighted spin-echo brain magnetic resonance images with a deep convolutional neural network. 2021 , 105, 78-85	4
488	Cost-Effectiveness of Posthospital Management of Acute Coronary Syndrome: A Real-World Investigation From Italy.. 2022 , 25, 185-193	2
487	Euphornin L promotes lipid clearance by dual regulation of LDLR and PCSK9. 2021 , 22, 1381	
486	Adherence and persistence in the use of statins and ezetimibe over 8 years in a real-life study. 2021 , 37, 2061-2066	0
485	Predictors of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitor Prescriptions for Secondary Prevention of Clinical Atherosclerotic Cardiovascular Disease. 2021 , 14, e007237	1
484	Familial Hypercholesterolaemia in the Malaysian Community: Prevalence, Under-Detection and Under-Treatment. 2021 , 28, 1095-1107	3
483	Dyslipidemia. 2022 , 387-393	
482	An Application of Deep Belief Networks in Early Warning for Cerebrovascular Disease Risk. 2022 , 34, 1-14	2

481	The Molecular Basis of Predicting Atherosclerotic Cardiovascular Disease Risk. 2021 , 128, 287-303	9
480	Total cholesterol, arterial stiffness, and systolic blood pressure: a mediation analysis. 2021 , 11, 1330	2
479	Dyslipemias and pregnancy, an update. 2021 , 33, 41-52	3
478	Dislipidemia diabética. 2021 , 32, 168-172	1
477	Uptake of Statin Guidelines to Prevent and Treat Cardiovascular Disease. 2021 , 34, 113-122	1
476	Brown Algae Potential as a Functional Food against Hypercholesterolemia: Review. 2021 , 10,	7
475	Optimal cholesterol treatment plans and genetic testing strategies for cardiovascular diseases. 2021 , 24, 1-25	3
474	Association of Coronary Artery Calcium Score vs Age With Cardiovascular Risk in Older Adults: An Analysis of Pooled Population-Based Studies. 2017 , 2, 986-994	49
473	Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol: A Randomized Clinical Trial. 2020 , 3, e2027092	8
472	Natural products: The role and mechanism in low-density lipoprotein oxidation and atherosclerosis. 2021 , 35, 2945-2967	12
471	Pathophysiology and Management of Dyslipidemias Associated with Insulin-Resistant States. 2021 , 307-322	2
470	Risk Assessment Approach to Management. 2015 , 305-313	1
469	Vulnerable Plaques Versus Patients-How to Reduce Acute Coronary Events in the Future. 2015 , 33-42	1
468	Use of Combination Statin and Bile Acid Sequestrant Therapy to Treat Dyslipidemia. 2015 , 1-10	2
467	Stable Ischemic Heart Disease. 2015 , 2109-2172	1
466	Stable Ischemic Heart Disease. 2014 , 1-70	1
465	A potent risk model for predicting new-onset acute coronary syndrome in patients with type 2 diabetes mellitus in Northwest China. 2020 , 57, 705-713	5
464	First national registry on the effectiveness and safety of evolocumab in clinical practice in patients attended in cardiology in Spain. The RETOSS-CARDIO study. 2020 , 32, 231-241	1

463	Update of therapeutic planning tables oriented towards obtaining therapeutic objectives. 2019 , 31, 271-277	6
462	Prevalence and factors associated with statin use in high-risk patients with type 1 diabetes from a specialized diabetes unit. 2019 , 66, 512-519	7
461	Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol. 2017 , 11, 1065-1072	29
460	PCSK9 inhibitors: Ratification of the role of LDL cholesterol in cardiovascular prevention. Towards a convergence of European and North American prevention guidelines?. 2020 , 220, 374-382	1
459	Have the Government's prescription algorithm and the 2013 American College of Cardiology/American Heart Association guidelines for managing dyslipidaemia influenced the management of dyslipidaemia? The MEJORALO-CV Project. 2020 , 220, 282-289	0
458	Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: comparing and contrasting guidance across the Atlantic. 2017 , 38, 2256-2258	14
457	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy. 2017 , 19, D3-D54	11
456	Moving Beyond Clinical Risk Scores with a Mobile App for the Genomic Risk of Coronary Artery Disease.	5
455	Polygenic Risk Score Modifies Risk of Coronary Artery Disease Conferred by Low-Density Lipoprotein Cholesterol.	2
454	Lifestyle Changes in Relation to Initiation of Antihypertensive and Lipid-Lowering Medication: A Cohort Study. 2020 , 9, e014168	11
453	Gaps in Dyslipidemia Care Among Working-Aged Individuals With Employer-Sponsored Health Care. 2020 , 9, e015807	2
452	Statin-centric versus low-density lipoprotein-centric approach for atherosclerotic cardiovascular disease prevention: a Singapore perspective. 2016 , 57, 360-7	5
451	Improving prescribing for older patients - 'Yes S-I-R-E!'. 2019 , 60, 298-302	2
450	Coronary disease is not associated with robust alterations in inflammatory gene expression in human epicardial fat. 2019 , 4,	7
449	Pressure overload leads to coronary plaque formation, progression, and myocardial events in ApoE ^{-/-} mice. 2019 , 4,	16
448	Impact of environmental factors on alloimmunity and transplant fate. 2017 , 127, 2482-2491	4
447	Secondary cardiovascular prevention in older adults: an evidence based review. 2015 , 12, 459-64	12
446	Health Benefits of Orange Juice and Citrus Flavonoids. 2017 , 299-324	3

445	Glycemic Index and Diabetes Mellitus. 2016 , 45-77	1
444	Large Artery Atherosclerotic Occlusive Disease. 2017 , 23, 133-157	8
443	Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetes - A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society. 2020 , 85, 82-125	7
442	Improved Cardiovascular Disease Outcomes in Older Adults. 2016 , 5,	15
441	Cardiovascular disease risk profile among young Saudi women of Al-Qassim, Saudi Arabia: A cross-sectional study. 2016 , 10, 29-37	9
440	The Potential Role of Biomarkers Associated with ASCVD Risk: Risk-Enhancing Biomarkers. 2019 , 8, 173-182	8
439	Evaluation of the Effectiveness of a Patient-Centered Educational Mailer Designed to Improve Statin Adherence: A Pragmatic Trial. 2016 , 4, 1256	2
438	Predictive network modeling in human induced pluripotent stem cells identifies key driver genes for insulin responsiveness. 2020 , 16, e1008491	7
437	Primary prevention of cardiovascular disease: The past, present, and future of blood pressure- and cholesterol-lowering treatments. 2018 , 15, e1002539	7
436	Modified treatment approach using cardiovascular disease risk calculator for primary prevention. 2014 , 9, e104478	1
435	Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe. 2015 , 10, e0115270	21
434	Quantifying the contribution of statins to the decline in population mean cholesterol by socioeconomic group in England 1991 - 2012: a modelling study. 2015 , 10, e0123112	8
433	Statin Treatment and Mortality in Community-Dwelling Frail Older Patients with Diabetes Mellitus: A Retrospective Observational Study. 2015 , 10, e0130946	28
432	2013 ACC/AHA versus 2004 NECP ATP III Guidelines in the Assignment of Statin Treatment in a Korean Population with Subclinical Coronary Atherosclerosis. 2015 , 10, e0137478	6
431	Effects of Statin Therapy on Clinical Outcomes of Survivors of Acute Myocardial Infarction with Severe Systolic Heart Failure. 2015 , 10, e0144602	2
430	Anatomical and Physiological Changes after Paclitaxel-Coated Balloon for Atherosclerotic De Novo Coronary Lesions: Serial IVUS-VH and FFR Study. 2016 , 11, e0147057	42
429	Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. 2016 , 11, e0153502	5
428	Young Adult Exposure to Cardiovascular Risk Factors and Risk of Events Later in Life: The Framingham Offspring Study. 2016 , 11, e0154288	43

427	Drivers of the Sex Disparity in Statin Therapy in Patients with Coronary Artery Disease: A Cohort Study. 2016 , 11, e0155228	27
426	Independent Prognostic Value of Single and Multiple Non-Specific 12-Lead Electrocardiographic Findings for Long-Term Cardiovascular Outcomes: A Prospective Cohort Study. 2016 , 11, e0157563	3
425	Statin Intensity and Clinical Outcome in Patients with Stable Coronary Artery Disease and Very Low LDL-Cholesterol. 2016 , 11, e0166246	7
424	Efficacy of Statin Treatment in Early-Stage Chronic Kidney Disease. 2017 , 12, e0170017	6
423	Low cholesterol level associated with severity and outcome of spontaneous intracerebral hemorrhage: Results from Taiwan Stroke Registry. 2017 , 12, e0171379	15
422	Fatty liver disease determines the progression of coronary artery calcification in a metabolically healthy obese population. 2017 , 12, e0175762	7
421	Prediction of atherosclerotic cardiovascular disease mortality in a nationally representative cohort using a set of risk factors from pooled cohort risk equations. 2017 , 12, e0175822	4
420	Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge. 2017 , 12, e0181308	19
419	Xuezhikang contributes to greater triglyceride reduction than simvastatin in hypertriglyceridemia rats by up-regulating apolipoprotein A5 via the PPAR δ signaling pathway. 2017 , 12, e0184949	11
418	An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD ⁺ levels in healthy volunteers. 2017 , 12, e0186459	123
417	An electronic health record based model predicts statin adherence, LDL cholesterol, and cardiovascular disease in the United States Military Health System. 2017 , 12, e0187809	6
416	Trends in lipid profiles and descriptive characteristics of U.S. adults with and without diabetes and cholesterol-lowering medication use-National Health and Nutrition Examination Survey, 2003-2012, United States. 2018 , 13, e0193756	5
415	Modeling statin myopathy in a human skeletal muscle microphysiological system. 2020 , 15, e0242422	3
414	Statins: Then and Now. 2019 , 15, 23-31	30
413	Latest Advances in Cardiac CT. 2020 , 15, 1-7	4
412	Effects of cholesterol levels on outcomes of out-of-hospital cardiac arrest: a cross-sectional study. 2019 , 6, 242-249	2
411	Surveillance for Certain Health Behaviors and Conditions Among States and Selected Local Areas - Behavioral Risk Factor Surveillance System, United States, 2015. 2018 , 67, 1-90	39
410	Experiencia en la utilizaci3n de hipolipemiantes en una cohorte de pacientes en 12 ciudades colombianas. 2020 , 32, 13-20	1

409	Statin-Associated Muscle Adverse Events: Update for clinicians. 2016 , 16, e406-e415	8
408	VPO1 mediates oxidation of LDL and formation of foam cells. 2016 , 7, 35500-35511	8
407	Using Cluster Analysis to Identify Subgroups of College Students at Increased Risk for Cardiovascular Disease. 2018 , 26, 470-482	2
406	Benefits of Rosuvastatin in Cardiovascular Protection Remain Unclear After HOPE-3. 2016 , 13, 212-214	2
405	STATIN ADVERSE EFFECTS: MECHANISMS, DIAGNOSIS, PREVENTION AND MANAGEMENT. 2018 , 8, 266-276	3
404	Re-assessing the role of non-fasting lipids; a change in perspective. 2016 , 4, 431	14
403	Clinical outcomes of PCSK9Is: a meta-analysis of randomized clinical trials. 2017 , 7, 598-606	3
402	Accelerated Atherosclerosis in Rheumatoid Arthritis: Mechanisms and Treatment. 2019 , 25, 969-986	8
401	Should Cushing's Syndrome be Considered as a Disease with High Cardiovascular Risk in Relevant Guidelines?. 2020 , 18, 12-24	2
400	Primary Hypertriglyceridemia: A Look Back on the Clinical Classification and Genetics of the Disease. 2020 , 16, 521-531	7
399	Fasting-Evoked En Route Hypoglycemia in Diabetes (FEEHD): From Guidelines to Clinical Practice. 2020 , 16, 949-956	2
398	Hypertriglyceridemia - Common Causes, Prevention and Treatment Strategies. 2018 , 14, 67-76	22
397	Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview. 2020 , 20, 2150-2168	32
396	American Heart Association's Cholesterol CarePlan as a Smartphone-Delivered Web App for Patients Prescribed Cholesterol-Lowering Medication: Protocol for an Observational Feasibility Study. 2019 , 8, e9017	2
395	Recent updates in dyslipidemia management: perspectives in stroke-specific situation. 2020 , 4, 9-20	2
394	Trends and Disparities in Quality of Diabetes Care in the US: The National Health and Nutrition Examination Survey, 1999-2016. 2019 , 10,	2
393	Russian clinical guidelines Coronary artery bypass grafting in patients with ischemic heart disease: rehabilitation and secondary prevention. 2016 , 7, 5-71	35
392	Impact of training primary care physicians in behavioral counseling to reduce cardiovascular disease risk factors in Ecuador. 2018 , 42, e139	0

391	Sprouted and Non-Sprouted Chickpea Flours: Effects on Sensory Traits in Pasta and Antioxidant Capacity. 2019 , 69, 203-209	3
390	Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning?. 2014 , 20, 14219-29	29
389	Role of Statins and Ascorbic Acid in the Natural History of Diabetic Retinopathy: A New, Affordable Therapy?. 2019 , 50, S23-S27	4
388	The use of statins in patients with heart failure: more questions than answers. 2015 , 7, 1687-90	6
387	The Association between 10-Year Atherosclerotic Cardiovascular Diseases Risk Score Calculated Using 2013 American College of Cardiology/American Heart Association Guidelines and Serum 25-Hydroxyvitamin D Level among Aged 40-79 Years in Korea: The Sixth Korea National Health and Nutrition Examination Surveys. 2018 , 39, 174-179	5
386	Longitudinal study of low serum LDL cholesterol and depressive symptom onset in postmenopause. 2016 , 77, 212-20	10
385	Validation of Risk Prediction Models for Atherosclerotic Cardiovascular Disease in a Prospective Korean Community-Based Cohort. 2020 , 44, 458-469	5
384	Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians. 2016 , 32, 440-445	5
383	Control of type 2 diabetes in King Abdulaziz Housing City (Iskan) population, Saudi Arabia. 2016 , 23, 1-5	13
382	Safety and efficacy of alirocumab: A meta analysis of 12 randomized controlled trials. 2019 , 8, 2249-2257	1
381	SIMVASTATIN DECREASES SEX HORMONE LEVELS IN MALE RATS. 2017 , 23, 175-181	9
380	Origin and therapy for hypertriglyceridaemia in type 2 diabetes. 2014 , 5, 165-75	11
379	Temporal Trends and Patient Characteristics Associated With Drug Utilisation After First-Ever Stroke: Insights From Chronic Disease Registry Data in Singapore. 2020 , 49, 137-154	2
378	Utilization and adherence to guideline-recommended lipid-lowering therapy at an academic medical center. 2017 , 37, 276-281	2
377	Free-Living Humans Cross Cardiovascular Disease Risk Categories Due to Daily Rhythms in Cholesterol and Triglycerides. 2019 , 17, 3	4
376	Impact of Different Types of Statins on Clinical Outcomes in Patients Hospitalized for Ischemic Heart Failure. 2018 , 72, 401-405	5
375	Innovative Approaches to Teaching Dyslipidemia Management in a Required Pharmacy Therapeutics Sequence. 2018 , 82, 6317	1
374	Sarcopenia and Sarcopenic Obesity and Their Association with Cardiovascular Disease Risk in Postmenopausal Women: Results for the 2008-2011 Korea National Health and Nutrition Examination Survey. 2016 , 21, 378	3

373	Endovascular Management of Atherosclerotic Renal Artery Stenosis: Post-Cardiovascular Outcomes in Renal Atherosclerotic Lesions Era Winner or False Alarm?. 2017 , 33, 1-15	5
372	[Practicality of cardiovascular risk functions]. 2016 , 16, e6792	2
371	Assessment of Carotid Intima-Media Thickness as an Early Marker Of Vascular Damage In Hypertensive Children. 2017 , 108, 452-457	12
370	Four Statin Benefit Groups Defined by The 2013 ACC/AHA New Cholesterol Guideline are Characterized by Increased Plasma Level of Electronegative Low-Density Lipoprotein. 2016 , 32, 667-675	6
369	Statin Therapy: Review of Safety and Potential Side Effects. 2016 , 32, 631-639	134
368	Autoimmune-like Drug-induced Liver Injury Caused by Atorvastatin and Demonstration of the Safety Profile of Pravastatin: A Case Report and Literature Review. 2020 , 12, e7299	3
367	A Pilot Study on the Effects of Nut Consumption on Cardiovascular Biomarkers. 2020 , 12, e8798	1
366	Behavioral Treatment Development. 2021 , 27-68	0
365	FH ALERT: efficacy of a novel approach to identify patients with familial hypercholesterolemia. 2021 , 11, 20421	0
364	Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial. 2021 , 10, e021412	0
363	Abnormal Paraoxonase-1 (PON1) enzyme activity in idiopathic inflammatory myopathies. 2021 ,	1
362	Efficacy and Safety of Lipid-Lowering Drugs of Different Intensity on Clinical Outcomes: A Systematic Review and Network Meta-Analysis. 2021 , 12, 713007	1
361	Association between high systolic blood pressure and objective hearing impairment among Japanese adults: a facility-based retrospective cohort study. 2021 ,	0
360	Optimizing treatment goals for long-term health outcomes among patients with type 2 diabetes mellitus. 2021 , 9,	0
359	Response by Peng et al to Letter Regarding Article, "Very High Coronary Artery Calcium (≥1000) and Association With Cardiovascular Disease Events, Non-Cardiovascular Disease Outcomes, and Mortality: Results From MESA". <i>Circulation</i> , 2021 , 144, e275-e276	16.7
358	Stratification Analysis of Statin Effect on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients on Hemodialysis. 2021 ,	0
357	The Projected Impact of Population-Wide Achievement of LDL Cholesterol . 2021 , 1	0
356	Assessment of the Obese Patient. 2014 , 167-187	

355 Fettstoffwechsel und Hypertonie bei Diabetes. **2014**, 217-237

354 Lipidsenkende Mittel. **2014**, 733-746

353 Dyslipidemias. **2014**, 1-11

352 The ideal management of blood cholesterol: a review of the updated 2013 ACC/AHA cholesterol guideline for reducing cardiovascular risk. **2014**, 57, 857

351 The impact of a new cholesterol guideline issued from the USA. **2014**, 23, 79-88

1

350 Relevance of target-organ lesions as predictors of mortality in patients with diabetes mellitus. **2014**, 103, 272-81

0

349 Recent Guidelines on the Management of Blood Cholesterol: 2013 ACC/AHA Guidelines and 2014 NICE Draft Guidelines. **2014**, 87, 142

1

348 Comprehensive Guideline for Care of Patients With Heart Failure. **2014**, 25, 151-162

347 Familial hypercholesterolemia--screening to facilitate early prevention. **2014**, 111, 521-2

346 Evaluation and Use of Registry Data in a GIS Analysis of Diabetes. **2015**, 2, 318-331

1

345 Increased Estimated 10-Year Risk for Cardiovascular Disease Assessed Using the Pooled Cohort Equation in Non-Diabetic Subjects According to Increasing HbA1c Levels. **2015**, 4, 123

344 Cardiovascular Disease in Patient-Centered Medical Homes: The Trident Approach. **2015**, 201-225

343 Prevention of Cardiovascular Disease: The Polypill Concept. **2015**, 613-632

342 Statins and Fibrates: Should They Be Recommended?. **2015**, 11-23

1

341 The Role of Preventive Nutrition in Clinical Practice. **2015**, 843-863

340 Appendix C. Case Study Answer Keys. **2015**,

339 Statins and PCSK9 Inhibitors: Defining the Correct Patients. **2015**, 99-117

1

338 Changes in Medical Management after Coronary CT Angiography. **2015**, 105, 410-7

- 337 Familial Hypercholesterolemia?. **2015**,
- 336 Review on Cardiovascular Disease Prediction Model in Diabetes Patients. **2015**, 16, 6
- 335 Participants with Treated Hyperlipidemia may be More Health Conscious. **2015**, 22, 1025-6
- 334 Update on the Pharmacologic Agents for Dyslipidemia. **2015**, 16, 269
- 333 Cardiovascular Disease in Women: An Update. **2015**, 129-141
- 332 The Impact of Statin Intolerance in Lipid Clinic Patients. **2015**, 06, 314-321
- 331 6. Benefits of high cholesterol levels for all-cause mortality: biochemical bases. **2015**, 93-108
- 330 Medical Screening/Assessment in the Dental Office. 465-484
- 329 Management of Dyslipidemia according to the 2015 Treatment Guideline for Diabetes: Controversies and Issues to Resolve. **2016**, 17, 96
- 328 Alcohol Consumption and Cardiovascular Disease in Aging Populations. **2016**, 57-64
- 327 Of statins and low-density lipoprotein cholesterol, "fats" and fiction. **2016**, 20, 151-3
- 326 Quantitative Measurement of Effect of Short-term Life Style Modification on Lipid Profiles in Korean Patients with Hyperlipidemia. **2016**, 5, 79
- 325 Lipidsenkende Mittel. **2016**, 523-530
- 324 Stable Ischemic Heart Disease. **2016**, 1-70
- 323 Management of Risks Factors for Older Women: Osteoporosis and Cardiovascular Disease. **2016**, 1-15
- 322 Clinical Applications of Cardiac CT. **2016**, 51-54
- 321 14. Dyslipidemia. **2016**,
- 320 S.A.M. and Breast Cancer Focus on Statins, Red Yeast Rice, Sterols, and Other Integrative Cholesterol Medicines: The Real Natural Options. **2016**, 141-171

- 319 Statin therapy for elderly patients should be assessed for each individual. **2016**, 2,
- 318 Changes in the practice of cardiology: therapies at the forefront of science. **2016**, 57, 344-6 ○
- 317 In Reply. **2016**, 113, 643-644
- 316 Fixed-dose Strategy Is Lacking. **2016**, 113, 642
- 315 [Are therapeutic LDL goals justified? Controversies between the European and American guidelines]. **2016**, 16, e6825 ○
- 314 Management of Risks Factors for Older Women: Osteoporosis and Cardiovascular Disease. **2017**, 517-530
- 313 Importancia de la medicina traslacional: mecanismos del beneficio del tratamiento de las dislipemias y su implicaci3n en la reducci3n de la placa. **2017**, 17, 16-23
- 312 Cardiovascular Disease Risk in Women: What Makes It Different from Men. **2017**, 1-31 ○
- 311 Lipidsenkende Mittel. **2017**, 529-538
- 310 Stable Ischemic Heart Disease. **2017**,
- 309 Peripheral Arterial Disease. **2017**,
- 308 Hyperlipidemia. **2017**,
- 307 Dyslipidemia. **2017**,
- 306 Tailoring cardiovascular risk assessment and prevention for women: One size does not fit all. **2017**, 2017, e201701 5
- 305 The year in cardiology 2016: imaging. **2017**, 12, 175-190
- 304 . **2017**, 106, 921-926 ○
- 303 The Effect of Monthly Medication on Mortality After a Coronary Event. **2018**, 23, 192-199
- 302 Influence of APOA5 locus on the treatment efficacy of three statins: evidence from a randomized pilot study in Chinese subjects.

- 301 Chapter 16: Dyslipidemia. **2017**,
- 300 Impact of Drugs on Diabetes Risk and Glycemic Control. **2018**, 541-573 0
- 299 Therapeutic approach to dyslipidemias, the main cause of atherosclerosis. **2018**, 4, 9
- 298 Obstacles to Optimal Lipid-Lowering Therapy - Any Solution?. **2018**, 82, 948-950
- 297 Lipids. **2018**, 137-151
- 296 Ischemic Stroke. **2018**, 827-918
- 295 Angina and Ischemia in Women with No Obstructive Coronary Artery Disease. **2018**, 101-133
- 294 Guidelines that are just for guidance. 031-037
- 293 New clinical and pharmacological aspects of the use of atorvastatin for primary and secondary prevention of complications of cardiovascular diseases. **2018**, 110-117
- 292 Chapter 27: Health Promotion, Disease Prevention, and Population Health. **2018**,
- 291 Combined lipid-lowering therapy. **2018**, 64, 1177-1184
- 290 Legacy Effect of Statin Should Not Be Discontinued. **2018**, 10, 106-107
- 289 ACUTE MYOCARDIAL INFARCTION ATYPICAL COURSE DIAGNOSTICS IN THE PATIENT OF YOUNG AGE. **2019**, 2, 176
- 288 Schlaganfall [Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung. **2019**, 1-12
- 287 Lipids and Renal Disease. **2019**, 15, 88-89 2
- 286 Identifying Smoking-Related Disease on Lung Cancer Screening CT Scans: Increasing the Value. **2019**, 6, 233-245 6
- 285 Impact of Drugs on Diabetes Risk and Glycemic Control. **2019**, 1-33 0
- 284 How Much Do Lipid Guidelines Help the Clinician? Reading Between the (Guide)lines. **2019**, 15, 16-22 1

283	PCSK9 inhibitors: Add-on therapy to reduce stroke risk. 2019 , 14, 42-48	
282	LipoGlo: A sensitive and specific reporter of atherogenic lipoproteins.	
281	Stable Ischemic Heart Disease in the Older Adult. 2019 , 3, 291-296	
280	FEATURES OF MANAGEMENT OF PATIENTS WITH LATE DIAGNOSTED CONGENITAL HEART DISEASE. 2019 , 15, 111	3
279	Statins and the Kidney. 2019 , 1330-1333.e2	
278	Pressure overload leads to coronary plaque formation, progression and myocardial events in ApoE ^{-/-} mice.	
277	Association between occurrence of urinary bladder cancer and treatment with statin medication. 2019 , 45, 97-102	1
276	RISK FACTORS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: RISK STRATIFICATION AND TREATMENT TACTICS. 2019 , 4, 20-25	
275	Current Medical and Surgical Stroke Prevention Therapies for Patients with Carotid Artery Stenosis. 2019 , 16, 96-103	1
274	Treating dyslipidemia: something more than giving statins. 2019 , 31, 119-120	1
273	[Statin-associated muscle symptoms: epidemiology, risk factors, mechanisms and treatment]. 2019 , 59, 4-12	1
272	Inflammation of adipose tissue. Is there a place for statins to correct adiposopathy?. 2019 , 16, 12-19	
271	To Whom Thrombus Aspiration May Concern?. 2019 , 7, 1774-1781	1
270	Optimized cardiovascular risk in peripheral arterial disease - does intensified statin therapy matter?. 2019 , 48, 371-372	
269	[Own and Parental Predictors of Hypertriglyceridemia in Children of Persons with Early Ischemic Heart Disease]. 2019 , 59, 11-18	1
268	Performance of cardiovascular risk scores in mortality prediction ten years after Acute Coronary Syndromes. 2019 , 65, 1074-1079	
267	Anticoagulation in the Hospitalized Patient with Decompensated Cirrhosis: Management of a Delicate Balance. 2020 , 219-236	
266	Fixeddose combination of rosuvastatin + ezetimibe: ease of use, safety and efficacy. 2019 , 21-26	1

- 265 A Pharmacist and Health Coach Delivered Mobile Health Intervention for Type 2 Diabetes: Protocol for a Randomized Controlled Crossover Study (Preprint).
- 264 Population Health Management during Student Pharmacist Introductory Experiential Education to Expand Clinical Pharmacist Impact. **2019**, 10, 0
- 263 Analysis of Safety Issues of Using Statins in Patients with Diabetes and Hypothyroidism. **2019**, 7, 163-175 1
- 262 Assessment and Utilization of Patient-Reported Outcomes Measures to Improve Cardiovascular Disease Prevention.
- 261 LDL as a therapeutic objective. **2019**, 31 Suppl 2, 1-15 2
- 260 Non-HDL cholesterol as a therapeutic goal. **2019**, 31 Suppl 2, 28-33 1
- 259 Factors Associated with County-Level Variation in the Prescription of Statins. **2019**, 25, 1358-1365 3
- 258 Association of Cardiovascular Events and Blood Pressure and Serum Lipoprotein Indicators Based on Functional Data Analysis as a Personalized Approach to the Diagnosis. **2020**, 278-293 1
- 257 Acute Statin Administration Reduces Levels of Steroid Hormone Precursors. **2020**, 52, 742-746
- 256 Hyperlipidemia: An Evidence-based Review of Current Guidelines. **2020**, 12, e7326 2
- 255 Hyperlipidaemia.
- 254 Tight versus standard blood pressure control on the incidence of myocardial infarction and stroke: An observational retrospective cohort study in the general ambulatory setting.
- 253 Differences in Cardiovascular Care Between Adults With and Without Opioid Prescriptions in the United States. **2020**, 9, e015961 1
- 252 ¿116? ¿Hasta cuánto hay que bajar el cLDL de la población catalogada como en «bajo riesgo»? **2020**, 73, 690-691 1
- 251 Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study. **2021**, 10, 0
- 250 Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy. **2021**, 22, 5
- 249 A Cost-Consequence Analysis of Preemptive Testing for Statin Myopathy Risk Compared to Usual Care. **2021**, 11, 1
- 248 High-Intensity Statin vs. Low-Density Lipoprotein Cholesterol Target for Patients Undergoing Percutaneous Coronary Intervention: Insights From a Territory-Wide Cohort Study in Hong Kong. **2021**, 8, 760926 1

247	Statin-Related New-Onset Diabetes Appears Driven by Increased Insulin Resistance: Are There Clinical Implications?. 2021 , 41, 2798-2801	1
246	Prediction of primary venous thromboembolism based on clinical and genetic factors within the U.K. Biobank. 2021 , 11, 21340	0
245	Risk Assessment in CVD. 2020 , 33-60	
244	Cognitive Function Assessment in Patients on Moderate- or High-Intensity Statin Therapy. 2020 , 12, 255-265	1
243	Primary care physicians' awareness and perceptions on adherence to primary cardiovascular disease prevention guidelines in Lebanon: A cross-sectional study. 2020 , 1742395320983879	0
242	Ion Mobility Lipoprotein Analysis. 2021 , 537-544	
241	HIV and Dyslipidemia. 2021 , 431-466	
240	Comparison of seven different reagents of peroxidase method for small and dense low density lipoprotein cholesterol (sdLDL-C) measurement. 2021 , 35, e23660	2
239	Challenges involved in establishing a web-based clinical decision support tool in community health centers. 2020 , 8, 100488	1
238	Determinants of Statin Initiation Among Adult Diabetic Patients in Bonga, Ethiopia. 2020 , 13, 4839-4847	0
237	Comparison of 2018 AHA-ACC Multi-Society Cholesterol Guidelines with 2013 ACC-AHA Cholesterol Guidelines. 2021 , 107-120	
236	When evidence is lacking: a mixed-methods approach for the development of practice guidance in liver transplantation. 2021 , 9, 22-30	0
235	Cardiovascular Disease in Women: Focus on Lipid Management. 2021 , 467-487	
234	Atherogenesis and Vascular Biology. 2021 , 11-34	
233	Impact of Drugs on Diabetes Risk and Glycemic Control. 2020 , 541-573	
232	Reactive Hyperemia Index Associated With Atherosclerotic Cardiovascular Disease Under Treatment for Lifestyle Diseases. 2020 , 12, 293-299	4
231	Impact of a Multidisciplinary, Endocrinologist-Led Shared Medical Appointment Model on Diabetes-Related Outcomes in an Underserved Population. 2020 , 33, 74-81	1
230	Chapter 7: Cardiology: Clopidogrel/CYP2C19 Case. 2020 ,	

- 229 Progress in the Treatment of Coronary Microvascular Dysfunction. **2020**, 10, 103-110
- 228 Self-reported Morisky Eight-item Medication Adherence Scale for Statins Concorde with the Pill Count Method and Correlates with Serum Lipid Profile Parameters and Serum HMGCoA Reductase Levels. **2020**, 12, e6542 4
- 227 Changes in cardiovascular risk factors in patients with acromegaly after trans-sphenoidal adenomectomy. **2020**, 67, 1169-1177
- 226 RISK FACTORS IN ETIOPATHOGENESIS OF CARDIOVASCULAR DISEASES. **2020**, 1, 76
- 225 Tight blood pressure control versus standard blood pressure control on the incidence of myocardial infarction and stroke: An observational retrospective cohort study.
- 224 Tight versus standard blood pressure control on the incidence of myocardial infarction and stroke: An observational retrospective cohort study in the general ambulatory setting.
- 223 Exploring the role of adiponectin in statin-induced glucose intolerance: a prospective open label study. **2020**, 35,
- 222 The 50 Most Highly Cited Reviews of 2013-2017. **2021**, 48, 168-184 1
- 221 Rice bran oil could favorably ameliorate atherogenicity and insulin resistance indices among men with coronary artery disease: post hoc analysis of a randomized controlled trial. **2021**, 20, 153 0
- 220 Statin Therapy in Patients Undergoing Thoracic Aorta Replacement for Aortic Aneurysms. **2021**, 9, 147-154 1
- 219 Strategies to Improve Immune Suppression Post-Liver Transplantation: A Review. **2021**, 2, 441-454 0
- 218 Chapter 27: Health Promotion, Disease Prevention, and Population Health. **2020**,
- 217 Assessment of the Obese Patient. **2014**, 167-187 0
- 216 Approach to Primary Care of the Male Patient. **2021**, 13-34
- 215 **Ök Akter ve Alt Ekstremitte Periferik Arter Hastalıklarında Endovasküler Tedavi.**
- 214 Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl. **2020**, 15, e0240166 1
- 213 Impact of a Digital Diabetes Prevention Program on Risk Factors for Chronic Disease in a Workforce Cohort. **2020**, 62, 1040-1045 0
- 212 Impact of changing reimbursement criteria on statin treatment patterns among patients with atherosclerotic cardiovascular disease or cardiovascular risk factors. **2021**, 46, 415-423 1

211	Primary Prevention of Coronary Artery Disease. 2021 , 81-123	
210	[Statin treatment as primary prevention in dyslipidaemic patients older than 75 years]. 2020 , 46, 464-471	
209	Response. 2014 , 60, 40	
208	[Not Available]. 2014 , 67, 186-7	
207	Evolution of lipid management guidelines: evidence might set you free. 2014 , 60, 612-7, e333-9	
206	Adiponectin & inflammatory biomarkers in coronary artery disease. 2014 , 139, 799-801	
205	Familial hypercholesterolemia. 2014 , 14, 669-72	8
204	Impact of 3'UTR genetic variants in PCSK9 and LDLR genes on plasma lipid traits and response to atorvastatin in Brazilian subjects: a pilot study. 2015 , 8, 5978-88	8
203	Simplified lipid guidelines: Prevention and management of cardiovascular disease in primary care. 2015 , 61, 857-67, e439-50	29
202	Statin therapy for heart failure: to prescribe or not?. 2015 , 7, 1702-3	
201	Carotid artery evaluation and coronary calcium score: which is better for the diagnosis and prevention of atherosclerotic cardiovascular disease?. 2015 , 8, 18591-600	4
200	Using drug sales data to evaluate the epidemiology of cardiometabolic risk factors and their inequality: an ecological study on atorvastatin and total cholesterol in Iran. 2015 , 29, 260	2
199	The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice. 2015 , 8, 483-9	14
198	Cardiovascular Risk and Level of Statin Use Among Women With Breast Cancer in a Cardio-Oncology Clinic. 2016 , 16, 217-24	5
197	A Metaanalysis of Interventions to Improve Adherence to Lipid-Lowering Medication. 2016 , 16, 230-7	3
196	Clinical Characteristics and Unmet Need Among Patients with Atherosclerotic Cardiovascular Disease Stratified by Statin Use. 2016 , 9, 434-444	8
195	The Cost-Benefit Balance of Statins in Hawai'i: A Moving Target. 2017 , 76, 99-102	2
194	The Association between CHADS-VASc Score and Mortality in Patients with Heart Failure with Reduced Ejection Fraction. 2017 , 33, 429-435	4

193	Statin-prescribing trends for primary and secondary prevention of cardiovascular disease. 2017 , 63, e495-e503	16
192	Associations between four types of single-nucleotide polymorphisms in PLA2G7 gene and clinical atherosclerosis: a meta-analysis. 2017 , 7, 122-133	5
191	Million hearts: prevalence of leading cardiovascular disease risk factors--United States, 2005-2012. 2014 , 63, 462-7	30
190	Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c. 2018 , 43, 214-227	2
189	Free triiodothyronine level correlates with statin responsiveness in acute myocardial infarction. 2018 , 15, 290-297	
188	Management of Lipid Levels and Cardiovascular Disease in HIV-Infected Individuals: Just Give Them a Statin?. 2016 , 23, 169-73	3
187	Achieving triple treatment goals in multi-ethnic Asian patients with type 2 diabetes mellitus in primary care. 2018 , 13, 10-18	4
186	Contemporary Prescription Patterns of Adenosine Diphosphate Receptor Inhibitors in Acute Coronary Syndrome. 2018 , 43, 667-674	1
185	Employer-Sponsored Wellness Programs for Hypertension and Dyslipidemia in a 2-Hospital Health System. 2019 , 12, 287-293	
184	The association between the rs10248618 SNP and serum lipid traits, the risk of coronary artery disease, and ischemic stroke. 2018 , 11, 4585-4594	0
183	Significant reduction in the LDL cholesterol increases the risk of intracerebral hemorrhage: a systematic review and meta-analysis of 33 randomized controlled trials. 2020 , 12, 463-477	6
182	Analysis of Pharmacist Interventions Used to Resolve Safety Target of Polypharmacy (STOP) Drug Interactions. 2020 , 37, 268-275	
181	Consumption and market share of cholesterol-lowering drugs in high-risk patients before and after the release of the 2013 ACC/AHA cholesterol guidelines: a retrospective observational study. 2020 , 10, e036769	1
180	Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol. 2021 , 8, 789931	2
179	Cardiovascular risk factors are associated with augmented thrombogenicity in healthy individuals: analysis using the Total Thrombus-formation Analysis System. 2021 , 19, 88	0
178	Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis. 2021 , 37, 110056	3
177	Easy Diet Screener: A quick and easy tool for determining dietary patterns associated with lipid profile and body adiposity. 2021 ,	1
176	Evaluation of the Effectiveness and Safety of Alirocumab Use in Statin-Intolerant Veterans.. 2021 , 38, e67-e71	

175	Clinical utility of polygenic risk scores for coronary artery disease. 2021 ,	7
174	Statin and dual antiplatelet therapy for the prevention of early neurological deterioration and recurrent stroke in branch atheromatous disease: a protocol for a prospective single-arm study using a historical control for comparison. 2021 , 11, e054381	1
173	LDL-cholesterol trajectories and statin treatment in Finnish type 2 diabetes patients: a growth mixture model. 2021 , 11, 22603	
172	Risk factors for carotid plaque progression after optimising the risk factor treatment: substudy results of the Atherosclerotic Plaque Characteristics Associated with a Progression Rate of the Plaque and a Risk of Stroke in Patients with the carotid Bifurcation Plaque Study (ANTIQUE). 2021 ,	
171	Determining propensity for sub-optimal low-density lipoprotein cholesterol response to statins and future risk of cardiovascular disease. 2021 , 16, e0260839	0
170	Fettstoffwechselstörungen: Therapie. 2016 , 1-8	
169	Health Care Professional's Knowledge of Pregnancy Complications and Women's Cardiovascular Health: An International Study Utilizing Social Media.. 2022 ,	0
168	Effects of meat and processed meat consumption on the lipid profile in the population with cardiovascular diseases. 14, 828-835	
167	Optical Fiber SPR Sensor for Highly-Sensitive Detection of Cholesterol Concentration. 2020 ,	
166	Quantifying the burden of cardiovascular diseases among people living with HIV in sub-Saharan Africa: findings from a modeling study for Uganda.	
165	Consumption and market share of cholesterol-lowering drugs in high-risk patients before and after the release of the 2013 ACC/AHA cholesterol guidelines: a retrospective observational study. 2020 , 10, e036769	1
164	50 10 2013-2017 10 2021 , 22-36	
163	Pharmacist-Led Programs to Increase Statin Prescribing: A Narrative Review of the Literature.. 2022 , 10,	0
162	Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology.. 2022 , 37, 61-72	
161	Stability Indicating RP-HPLC Method Development And Validation For The Simultaneous And Rapid Estimation Of Rosuvastatin And Fenofibrate In Pharmaceutical Dosage Form. 2022 , 13, 23-36	
160	Effects of Lactobacillus paracasei N1115 on dyslipidaemia: A randomized controlled study. 2022 , 89, 104956	
159	Comparison of a Machine Learning Method and Various Equations for Estimating Low-Density Lipoprotein Cholesterol in Korean Populations.. 2022 , 9, 824574	2
158	Digital Health in Primordial and Primary Stroke Prevention: A Systematic Review.. 2022 , STROKEAHA121036400	

- 157 Prognostic significance of visit-to-visit variability, and maximum and minimum LDL cholesterol in diabetes mellitus.. **2022**, 21, 19 2
- 156 Heart Transplant, Kawasaki Disease, and Bone Marrow Transplant: Are There Consequences?. **2022**, 1
- 155 Coronary computed tomographic angiography derived findings and risk score improves the allocation of lipid lowering therapy compared to clinical score.. **2022**, 101, e28801
- 154 Diet quality scores associated with improved cardiometabolic measures among African American adolescents.. **2021**, 0
- 153 Race/Ethnicity, Spirometry Reference Equations and Prediction of Incident Clinical Events: The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study.. **2021**, 5
- 152 Impact of Statin Treatment Intensity after Endovascular Revascularization on Lower Extremity Peripheral Artery Disease.. **2022**, 63, 333-341
- 151 USE OF INDICATORS OF DYSLIPIDEMIA IN THE DIAGNOSIS OF MASKED FORMS OF ARTERIAL HYPERTENSION. **2022**, 18, 39
- 150 Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.. **2022**, 5, e2148030 3
- 149 Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study.. **2022**, 21, 28 1
- 148 Relationships Between Bronchodilators, Steroids, Antiarrhythmic Drugs, Antidepressants, and Benzodiazepines and Heart Disease and Ischemic Stroke in Patients With Predominant Bronchiectasis and Asthma.. **2022**, 9, 797623 0
- 147 Potential of four definitions of metabolic syndrome to discriminate individuals with different 10-year cardiovascular disease risk scores: a cross-sectional analysis of an Iranian cohort.. **2022**, 12, e058333 0
- 146 Contemporary Management of Dyslipidemia.. **2022**, 1 1
- 145 Management of atherosclerotic extracranial carotid artery stenosis.. **2022**, 21, 273-283 0
- 144 Associations between Genetically Proxied Inhibition of Lipid-lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.. **2022**,
- 143 Race and Modifiable Factors Influencing Cardiovascular Disease.. **2022**, 106, 401-409
- 142 Homozygous familial hypercholesterolemia in China: Genetic and clinical characteristics from a real-world, multi-center, cohort study.. **2022**, 0
- 141 [Advantages of Universal Early Childhood Screening for Familial Hypercholesterolaemia in Germany].. **2022**, 0
- 140 Real-world Insights into Evolocumab Use in Patients with Hyperlipidemia: Canadian Analysis from the ZERBINI Study. **2022**, 0

139 Combining familial hypercholesterolemia and statin genetic studies as a strategy for the implementation of pharmacogenomics. A multidisciplinary approach.. **2022**,

138 Associations of glycemia and lipid levels in pregnancy with dyslipidemia 10-14 years later: The HAPO follow-up study.. **2022**, 185, 109790

137 Ten-year atherosclerosis cardiovascular disease (ASCVD) risk score and its components among an Iranian population: a cohort-based cross-sectional study.. **2022**, 22, 162 1

136 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. *Circulation*, **2022**, 101161CIR0000000000001063 16.7 35

135 Targeting PCSK9 inhibitors to those who will benefit most.. **2022**, 1

134 Cardiotoxicity in pediatric lymphoma survivors.. **2021**, 19, 957-974 0

133 Persistent Cardiometabolic Health Gaps: Can Therapeutic Care Gaps Be Precisely Identified from Electronic Health Records.. **2021**, 10, 0

132 Comparison of High-Statin Therapy vs Moderate-Statin Therapy in Achieving Positive Low-Density Lipoprotein Change in Patients After Acute Coronary Syndrome: A Randomized-Control Trial.. **2021**, 13, e20710

131 Kawasaki Disease Undiagnosed in Childhood, Myocardial Infarction in Adulthood - Case Report. **2021**, 26, 43-46

130 Anterior Circulation Acute Ischemic Stroke in the Plateau of China: Risk Factors and Clinical Characteristics.. **2022**, 13, 859616

129 Development of a clinical polygenic risk score assay and reporting workflow.. **2022**, 0

128 Presentation_1.pdf. **2020**,

127 Data_Sheet_1.PDF. **2019**,

126 Table_1.docx. **2020**,

125 Table_2.docx. **2020**,

124 Image_1.PDF. **2018**,

123 Image_2.PDF. **2018**,

122 Table_1.PDF. **2018**,

- 121 Table_2.PDF. **2018**,
- 120 Image1.tiff. **2017**,
- 119 DataSheet_1.pdf. **2020**,
- 118 Statin discontinuation in persons with and without Alzheimer's disease.. **2022**, 1
- 117 Correlation Between Atherosclerotic Cardiovascular Disease Risk Factors and Statin Prescribing Patterns.. **2021**, 14, 140-146
- 116 Cholesterin und Arteriosklerose. **2022**, 37-38
- 115 Association between Indoor Temperature in Winter and Serum Cholesterol: A Cross-Sectional Analysis of the Smart Wellness Housing Survey in Japan.. **2022**, ○
- 114 Selective effect of laparoscopic Roux-en-Y gastric bypass on lipid metabolism. **2022**, 34, 68-74
- 113 Longitudinal evaluation of treatment patterns, risk factors and outcomes in patients with cardiovascular disease treated with lipid-lowering therapy in the UK.. **2022**, 12, e055015
- 112 Targeted Strategy in Lipid-Lowering Therapy. **2022**, 10, 1090 2
- 111 Effectiveness of Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy on Lipid Levels in Type 2 Diabetes: a Meta-analysis.. **2022**, 1 ○
- 110 Predictive performance of a competing risk cardiovascular prediction tool CRISK compared to QRISK3 in older people and those with comorbidity: population cohort study.. **2022**, 20, 152 ○
- 109 Serum Lipid Profiles and All-Cause Mortality: A Retrospective Single Center Study on Chinese Inpatient Centenarians. **2022**, 10,
- 108 Efficacy of oats for dyslipidaemia: protocol for a systematic review and meta-analysis.. **2022**, 12, e058291
- 107 Yoga for Dyslipidemia. **2022**, 223-241
- 106 Dyslipidemia in Renal Transplant Recipients. **2022**, 3, 188-199 ○
- 105 Framingham and American College of Cardiology/American Heart Association Pooled Cohort Equations, High-Sensitivity Troponin T, and N-Terminal ProBrain-Type Natriuretic Peptide for Predicting Atherosclerotic Cardiovascular Events Across the Spectrum of Kidney Dysfunction.
- 104 Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada. ○

103	Long-term outcomes of primary cardiovascular prevention: A retrospective study at a referral center in Portugal. 2022,	0
102	Workers' Activity Profiles Associated With Predicted 10-Year Cardiovascular Disease Risk.	
101	Medical Management of Peripheral Arterial Disease. 2022, 100837	
100	Trends and Risk Factors Associated With Stroke Recurrence in China, 2007-2018. 2022, 5, e2216341	0
99	Using a deep learning algorithm to score coronary artery calcium in myocardial perfusion imaging: A real opportunity or just a new hype?.	
98	Would You Recommend a Statin to This Patient for Primary Prevention of Cardiovascular Disease?. 2022, 175, 862-872	1
97	IMPROVING CHOLESTEROL SCREENING IN CHILDREN ¶S EDUCATING PRIMARY CARE PROVIDERS ENOUGH?. 2022,	
96	Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia. 2022,	1
95	Coronary artery calcium and atherosclerotic cardiovascular disease risk in women with early menopause: The Multi-Ethnic Study of Atherosclerosis (MESA). 2022, 11, 100362	0
94	Coronary Artery Calcium Data and Reporting System (CAC-DRS): A Primer. 30,	
93	Vascular Pathobiology: Atherosclerosis and Large Vessel Disease. 2022, 265-306	
92	Associations of Socioeconomic Status and Healthy Lifestyle With Incidence of Dyslipidemia: A Prospective Chinese Governmental Employee Cohort Study. 10,	1
91	Intensity of and Adherence to Lipid-Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease.	1
90	Revisiting the Time Needed to Provide Adult Primary Care.	3
89	U-Shaped Relationship of Non-HDL Cholesterol With All-Cause and Cardiovascular Mortality in Men Without Statin Therapy. 9,	1
88	Health Technology Disinvestment in Singapore. 2018, 47, 338-344	2
87	Long-term mortality rates of young stroke in Taiwan: A decade-long epidemiology population-based study. 239698732211152	
86	Combination therapy in the guidelines: from high-intensity statins to high-intensity lipid-lowering therapies: Combination therapy in the guideline. 2022, 1, 25-29	0

- 85 Cardiovascular Disease. **2021**, 435-451
- 84 Efficacy and safety of hybutimibe on primary hypercholesterolemia: a randomized, double-blinded, placebo and positive-controlled, parallel phase II study. **2022**, 7, 77-84
- 83 Hypertension and diabetes including their earlier stage are associated with increased risk of sudden cardiac arrest. **2022**, 12, 1
- 82 Statin Prescription Patterns and Associations with Subclinical Inflammation. **2022**, 58, 1096
- 81 A score to predict the stroke recurrence of patients with embolic stroke of undetermined source.
- 80 Associations between statins and adverse events in secondary prevention of cardiovascular disease: Pairwise, network, and dose-response meta-analyses of 47 randomized controlled trials. 9,
- 79 Trends in Lipid Concentrations and Lipid Control Among US Adults, 2007-2018. **2022**, 328, 737 1
- 78 Underprescribing of statin therapy in people with HIV at risk for atherosclerotic cardiovascular disease.
- 77 Reducing Disparities in Cholesterol Control. **2022**, 328, 714
- 76 Effects of APOE gene ϵ allele on serum lipid profiles and risk of cardiovascular disease and tumorigenesis in southern Chinese population. **2022**, 20, 0
- 75 Cholesterol and Arteriosclerosis. **2022**, 37-38 0
- 74 Novel biomarkers of inflammation for endothelial dysfunction in chronic kidney disease patients. **2022**, 42, 177-180 0
- 73 Factors predicting statin initiation during childhood in familial hypercholesterolemia: importance of genetic diagnosis.. **2022**, 0
- 72 Resolution of apolipoprotein A1 and A2 proteoforms: their cardiometabolic correlates and implications for future research. **2022**, 33, 264-269 0
- 71 Community pharmacist intervention to close statin gaps in diabetes care: The GuIDE-S study. **2022**, 0
- 70 Chapter 7: Cardiology: Clopidogrel/CYP2C19 Case. **2022**, 0
- 69 Low-Density Lipoprotein Cholesterol Levels on Statins and Cardiovascular Event Risk in Stable Coronary Artery Disease [An Observation From the REAL-CAD Study] **2022**, 0
- 68 Postoperative statin therapy is not associated with reduced incidence of venous thromboembolic events following kidney transplantation. 0

67	Morbid liver manifestations are intrinsically bound to metabolic syndrome and nutrient intake based on a machine-learning cluster analysis. 13,	0
66	The effect of statins exposure during pregnancy on congenital anomalies and spontaneous abortions: A systematic review and meta-analysis. 13,	0
65	Physical Function and Subsequent Risk of Cardiovascular Events in Older Adults: The Atherosclerosis Risk in Communities Study. 2022, 11,	0
64	Bolstering the Business Case for Adoption of Shared Decision-Making Systems in Primary Care: Randomized Controlled Trial. 2022, 6, e32666	0
63	Relaci3n entre el signo del lbulo hendido y enfermedad cardiovascular en pacientes del Hospital Universitario de los Andes, diciembre de 2017 a julio de 2018. 2021, 8, 18-31	0
62	The quality of websites regarding statins (Preprint).	0
61	The Effect of Atorvastatin on Lipid Profile and Inflammatory Marker in patient with Diabetes Dyslipidemia. 2022, 4105-4110	0
60	Association between Statin Use and Diabetes Risk in Patients with Transient Ischemic Attack. 2022, 19, 13770	0
59	Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins.	0
58	Assessment of the Effective Management of Patients With Severe Primary Hypercholesterolemia Under Care in Family Medicine Clinics at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. 2022,	0
57	Heterogeneity in the Association Between the Presence of Coronary Artery Calcium and Cardiovascular Events: A Machine Learning Approach in the MESA Study.	0
56	The Potential Role of Artificial Intelligence in Lung Cancer Screening Using Low-Dose Computed Tomography. 2022, 12, 2435	2
55	Neurocognitive Impairment in Cardiovascular Disease Patients Taking Statins Versus Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: A Systematic Review. 2022,	0
54	Red Cell Distribution Width and Absolute Lymphocyte Count Associate with Biomarkers of Inflammation and Subsequent Mortality in Rheumatoid Arthritis. jrheum.211411	0
53	Glycaemic, Blood Pressure and Low Density Lipoprotein Cholesterol Control in Adult Patients with Diabetes in Singapore: A Review of Singapore Literature Over Two Decades. 2017, 46, 374-391	4
52	Thoughts on secondary prevention after percutaneous coronary intervention in Japan. 2018, 4, 67-70	0
51	Hyperlipidemia in the Setting of Primary Biliary Cholangitis: A Case Report and Review of Management Strategies. 2022,	0
50	Real-World Clinical Experience of Rosuvastatin as a Lipid-Lowering Therapy for Primary and Secondary Prevention of Cardiovascular Events (REAL ROSE). 2022,	0

49	Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care Network.	3
48	Machine learning outperforms traditional logistic regression and offers new possibilities for cardiovascular risk prediction: A study involving 143,043 Chinese patients with hypertension. 9,	0
47	Initial statin dose after myocardial infarction and long-term cardiovascular outcomes.	0
46	Pravastatin and placental insufficiency associated disorders: A systematic review and meta-analysis. 13,	0
45	Dyslipidemia in Chronic Kidney Disease. 2022 , 549-572	0
44	Lack of association between metabolic phenotype and food consumption by degree of food processing: results from the Study of Workers' Health (ESAT). 2022 ,	0
43	Ten-Year Evolution of Statin Eligibility and Use in a Population-Based Cohort. 2023 , 187, 138-147	0
42	Effectiveness of statins for the primary prevention of cardiovascular disease in the Asian elderly population. 2022 ,	0
41	Adherence to Statin Treatment in Patients with Familial Hypercholesterolemia: a Dynamic Prediction Model. 2022 ,	0
40	Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia.	0
39	Can the use of photobiomodulation for localized fat reduction induce changes in lipid profile? A critical integrative review. 2023 , 38,	0
38	Accuracy and Clinical Impact of Estimating Low-Density Lipoprotein-Cholesterol at High and Low Levels by Different Equations. 2022 , 10, 3156	0
37	High prevalence of dyslipidaemia among persons with diabetes mellitus and hypertension at a tertiary hospital in Blantyre, Malawi. 2022 , 22,	0
36	Evaluation of a Model to Target High-risk Psychiatric Inpatients for an Intensive Postdischarge Suicide Prevention Intervention.	1
35	Association between dietary inflammatory index and atherosclerosis cardiovascular disease in U.S. adults. 9,	0
34	Oxidized low-density lipoprotein associates with cardiovascular disease by a vicious cycle of atherosclerosis and inflammation: A systematic review and meta-analysis. 9,	0
33	Rhabdomyolysis Related to Red Yeast Rice Ingestion. 2023 ,	0
32	Protective effects of lovastatin in a population-based ALS study and mouse model.	0

31	US Trends in Cholesterol Screening, Lipid Levels, and Lipid-Lowering Medication Use in US Adults, 1999 to 2018.	1
30	Dyslipidemia and the preventive potential in the Greenlandic population. 2023 , 51, 22-27	0
29	INFLUENCE OF ROSUVASTATIN ON VASCULAR ENDOTHELIUM FUNCTIONAL STATE AND SYSTEMIC INFLAMMATION IN PATIENTS WITH ISCHEMIC HEART DISEASE AND DIABETES MELLITUS. 2022 , 4-8	0
28	Regional deprivation and risk of developing cardiovascular diseases (Framingham Risk Score): data from ESSE-RF. 2023 , 26, 49	0
27	Trends in Provision of Medications and Lifestyle Counseling in Ambulatory Settings by Gender and Race for Patients With Atherosclerotic Cardiovascular Disease, 2006-2016. 2023 , 6, e2251156	1
26	Management of Risks Factors for Older Women: Osteoporosis and Cardiovascular Disease (CVD). 2023 , 1-16	0
25	Development and Validation of the HIV-CARDIO-PREDICT Score to Estimate the Risk of Cardiovascular Events in HIV-Infected Patients. 2023 , 12, 523	0
24	Correlates of Myopathy in Diabetic Patients Taking Statins. 2023 ,	0
23	Brazilian green propolis extracts modulate cholesterol homeostasis in a preclinical guinea pig model: an in vitro and in vivo study. 2023 , 14, 2022-2033	0
22	Joint effects of paraoxonase 1 rs662 polymorphism and vitamins C/E intake on coronary artery disease severity (Gensini and SYNTAX scores) and lipid profile in patients undergoing coronary angiography. 9,	0
21	Prevalencia de factores de riesgo cardiovascular en indígenas embera-chamúe de Cristianópolis (Jardín), Antioquia. 2015 , 28, 5-16	0
20	Efficacy and safety of bempedoic acid in women with hypercholesterolemia: Pooled analyses from phase 3 trials.	0
19	The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review. 2023 , 2, 122-164	0
18	CD40-targeting magnetic nanoparticles for MRI/optical dual-modality molecular imaging of vulnerable atherosclerotic plaques. 2023 , 369, 17-26	0
17	Trends in Prevalence, Risk-Factors Controls and Medications in ASCVD Among US Adults, 1999-2018.	0
16	The effects of obesity and metabolic abnormalities on severe COVID-19-related outcomes after vaccination: A population-based study. 2023 , 35, 585-600.e5	0
15	Cardiovascular Risk Factor Prevalence, Treatment, and Control in US Adults Aged 20 to 44 Years, 2009 to March 2020. 2023 , 329, 899	2
14	Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease. 2023 , 329, 1078	0

- 13 Tissue Engineering and Targeted Drug Delivery in Cardiovascular Disease: The Role of Polymer Nanocarrier for Statin Therapy. **2023**, 11, 798 ○
- 12 Genetics, Safety, Cost-Effectiveness, and Accessibility of Injectable Lipid-Lowering Agents: A Narrative Review. **2023**, 2023, 1-9 ○
- 11 Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation. 10, ○
- 10 Effect of Urinary Albumin Creatinine Ratio on Cardiovascular Morbidity and Mortality in Diabetes Patients with Atherosclerotic Disease. Volume 16, 819-828 ○
- 9 Comorbidity Patterns in Patients at Cardiovascular Hospital Admission. **2023**, 10, 26 ○
- 8 Long-Chain Polyunsaturated Fatty Acids Effects on Cardiovascular Risk in Childhood: A Narrative Review. **2023**, 15, 1661 ○
- 7 Endothelial KCa channels: Novel targets to reduce atherosclerosis-driven vascular dysfunction. 14, ○
- 6 Untargeted Lipidomic Profiling Reveals Lysophosphatidylcholine and Ceramide as Atherosclerotic Risk Factors in apolipoprotein E Knockout Mice. **2023**, 24, 6956 ○
- 5 Statins Utilization Trends and Expenditures in the US Before and After the Implementation of the 2013 ACC/AHA Guidelines. **2023**, ○
- 4 A bibliometric analysis and visualization of literature on non-fasting lipid research from 2012 to 2022. 14, ○
- 3 Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale. ○
- 2 A comparison of safety and efficacy between long-term DAPT and intensive statins combined with short-term DAPT for acute ischemic stroke. **2023**, 28, ○
- 1 A Virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in Non-Human Primates. ○